U.S. patent application number 10/519388 was filed with the patent office on 2005-08-18 for morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof.
Invention is credited to Greiner, Elisabeth, Sailer, Bettina, Schmidhammer, Helmut, Schullner, Falko, Schutz, Johannes, Spetea, Mariana, Stubegger, Kurt.
Application Number | 20050182258 10/519388 |
Document ID | / |
Family ID | 30009787 |
Filed Date | 2005-08-18 |
United States Patent
Application |
20050182258 |
Kind Code |
A1 |
Schmidhammer, Helmut ; et
al. |
August 18, 2005 |
Morphinan derivatives the quaternary ammonium salts thereof
substituted in position 14, method for production and use
thereof
Abstract
The present invention relates to a class of morphinan compounds
and quaternary ammonium salts thereof, substituted in Position 14,
which may be used as highly active analgesics or also as opioid
antagonists. The present invention also relates to the
pharmaceutically acceptable salts and easily produced derivatives
thereof, a process for the production thereof and use thereof in
the production of pharmaceutical specialities.
Inventors: |
Schmidhammer, Helmut;
(Innsbruck, AT) ; Spetea, Mariana; (Innsbruck,
AT) ; Schutz, Johannes; (Innsbruck, AT) ;
Greiner, Elisabeth; (Patsch, AT) ; Schullner,
Falko; (Mils, AT) ; Sailer, Bettina;
(Innsbruck, AT) ; Stubegger, Kurt; (Innsbruck,
AT) |
Correspondence
Address: |
COHEN, PONTANI, LIEBERMAN & PAVANE
551 FIFTH AVENUE
SUITE 1210
NEW YORK
NY
10176
US
|
Family ID: |
30009787 |
Appl. No.: |
10/519388 |
Filed: |
March 17, 2005 |
PCT Filed: |
June 27, 2003 |
PCT NO: |
PCT/EP03/06866 |
Current U.S.
Class: |
546/45 ;
546/72 |
Current CPC
Class: |
A61P 3/04 20180101; A61P
25/36 20180101; C07D 489/08 20130101; A61P 25/04 20180101; A61P
1/00 20180101; A61P 25/00 20180101; A61P 25/20 20180101; A61P 1/10
20180101; A61P 19/02 20180101; C07D 489/00 20130101; A61P 29/00
20180101; A61P 25/32 20180101; A61P 39/02 20180101 |
Class at
Publication: |
546/045 ;
546/072 |
International
Class: |
C07D 498/02; C07D
489/02 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 3, 2002 |
DE |
102 29 842.4 |
Claims
1. Compounds of the formula (I) or (Ia), 73in which the
substituents have the following significance: R.sub.1:
C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.3-C.sub.16-(cycli- cal saturated
group)alkyl, where alkyl is C.sub.1-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkenyl, where alkenyl
is C.sub.2-C.sub.6; C.sub.4-C.sub.16-(cyclical saturated
group)alkinyl, where alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where
aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.8-C.sub.16-arylalkinyl, where aryl
is C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
R.sub.2: C.sub.4-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.3-C.sub.16-(cyclical saturated
group)alkyl, where alkyl is C.sub.1-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkenyl, where alkenyl
is C.sub.2-C.sub.6; C.sub.4-C.sub.16-(cyclical saturated
group)alkinyl, where alkinyl is C.sub.2-C.sub.6;
C.sub.8-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where
aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.8-C.sub.16-arylalkinyl, where aryl
is C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-aklinyl;
C.sub.3-C.sub.6-alkenoyl; C.sub.3-C.sub.6alkinoyl;
C.sub.9-C.sub.16-arylalkenoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenoyl is C.sub.3-C.sub.6-alkenoyl;
C.sub.9-C.sub.16-arylalkinoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinoyl is C.sub.3-C.sub.6-alkinoyl; R.sub.3: hydrogen,
C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where
aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; alkoxyalkyl, where alkoxy is
C.sub.1-C.sub.6-alkoxy and alkyl is C.sub.1-C.sub.6-alkyl;
CO.sub.2(C.sub.1-C.sub.6-alkyl); CO.sub.2H; CH.sub.2OH. R.sub.4:
hydrogen; hydroxy; C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.10-alkyloxyalk- oxy, where alkyloxy is
C.sub.1-C.sub.4 and alkoxy is C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.3-C.sub.16-(cyclical saturated group)alkyloxy, where alkyl is
C.sub.1-C.sub.6; C.sub.4-C.sub.16-(cyclica- l saturated
group)alkenyloxy, where alkenyl is C.sub.2-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkinyloxy where alkinyl
is C.sub.2-C.sub.6; C.sub.7-C.sub.16-arylalkyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.1-C.sub.6-alkanoyloxy; C.sub.3-C.sub.6-alkenoyloxy;
C.sub.3-C.sub.6-alkinoyloxy; C.sub.7-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.2-C.sub.6-alkanoyloxy; C.sub.9-C.sub.16-arylalkenoyl- oxy,
where aryl is C.sub.6-C.sub.10-aryl and alkenoyloxy is
C.sub.3-C.sub.6-alkenoyloxy; C.sub.9-C.sub.16-arylalkinoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkinoyloxy is
C.sub.3-C.sub.6-aikinoyloxy; R.sub.5: hydrogen; hydroxy;
C.sub.1-C.sub.6-alkyloxy; C.sub.2-C.sub.10-alkyloxyalkoxy, where
alkyloxy is C.sub.1-C.sub.4 and alkoxy is C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.3-C.sub.16-(cyclical saturated group)alkyloxy, where alkyl is
C.sub.1-C.sub.6; C.sub.4-C.sub.16-(cyclica- l saturated
group)alkenyloxy, where alkenyl is C.sub.2-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkinyloxy, where
alkinyl is C.sub.2-C.sub.6; C.sub.7-C.sub.16-arylalkyloxy, where
aryl is C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.2-C.sub.6-alkanoyloxy; C.sub.7-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.2-C.sub.6-alkanoyloxy; X is oxygen; wherein a single or
double bond can be present between the carbon atoms of numbers 7
and 8, wherein alkyl, alkenyl and alkinyl can each be branched or
unbranched, aryl can be unsubstituted or mono-, di- or
trisubstituted, independently in each case, with hydroxy, halogen,
nitro, cyano, thiocyanato, trifluoromethyl, C.sub.1-C.sub.3-alkyl,
C.sub.1-C.sub.3-alkoxy, CO.sub.2H, CONH.sub.2,
CO.sub.2(C.sub.1-C.sub.3-alkyl), CONH(C.sub.1-C.sub.3-alkyl),
CON(C.sub.1-C.sub.3-alkyl).sub.2, CO(C.sub.1-C.sub.3-alkyl); amino;
(C.sub.1-C.sub.3-monoalkyl)amino, (C.sub.1-C.sub.3-dialkyl)amino;
C.sub.5-C.sub.6-cycloalkylamino, (C.sub.1-C.sub.3-alkanoyl)amido,
SH, SO.sub.3H, SO.sub.3(C.sub.1-C.sub.3-- alkyl),
SO.sub.2(C.sub.1-C.sub.3-alkyl), SO(C.sub.1-C.sub.3-alkyl),
C.sub.1-C.sub.3-alkylthio or C.sub.1-C.sub.3-alkanoylthio, wherein
-(cyclical saturated group) is either preferably
C.sub.3-C.sub.10-cycloal- kyl or a heterocyclical group with 2 to 9
carbon atoms, containing further one or more heteroatoms, with the
exception of compounds where R.sub.1 is methyl, R.sub.2 is
C.sub.4-C.sub.6-alkyl, R.sub.3 is hydrogen or methyl, R.sub.4 is
hydroxy or methoxy and R.sub.5 is hydroxy, methoxy or an oxygen
atom bound to the carbon atom in the 5.sup.th position, when X is
oxygen; with the further exception of compounds where R.sub.1 is
cyclopropylmethyl and XR.sub.2 is benzyloxy, when R.sub.4 is oxygen
or benzyloxy and R.sub.5 is an oxygen atom bound to the carbon atom
in the 5.sup.th position; with the further exception of compounds
where R.sub.1 is cyclopropylmethyl and XR.sub.2 is benzyloxy, when
R.sub.4 is oxygen, hydroxy or benzyloxy and R.sub.5 is hydroxy or
methoxy.
2. Compounds of the formula (IA) or (IAa), 74where the substituents
have the following significance: R.sub.1: C.sub.1-C.sub.6-alkyl;
C.sub.2-C.sub.6-alkenyl; C.sub.2-C.sub.6-alkinyl;
C.sub.3-C.sub.16-(cycli- cal saturated group)alkyl, where alkyl is
C.sub.1-C.sub.6; C.sub.4-C.sub.16-(cyclical saturated
group)alkenyl, where alkenyl is C.sub.2-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkinyl, where alkinyl
is C.sub.2-C.sub.6; C.sub.7-C.sub.16-arylalkyl, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinyl is C.sub.2-C.sub.8-alkinyl; wherein the two
substituents R.sub.1 can be the same or different; R.sub.2:
C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.3-C.sub.16-(cyclical saturated
group)alkyl, where alkyl is C.sub.1-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkenyl, where alkenyl
is C.sub.2-C.sub.6; C.sub.4-C.sub.16-(cyclical saturated
group)alkinyl, where alkinyl is C.sub.2-C.sub.6;
C.sub.8-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where
aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.8-C.sub.16-arylalkinyl, where aryl
is C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.3-C.sub.6-alkenoyl; C.sub.3-C.sub.6-alkinoyl;
C.sub.9-C.sub.16-arylalkenoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenoyl is C.sub.3-C.sub.6-alkenoyl;
C.sub.9-C.sub.16-arylalkinoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinoyl is C.sub.3-C.sub.6-alkinoyl; R.sub.3: hydrogen,
C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where
aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; alkoxyalkyl, where alkoxy is
C.sub.1-C.sub.6-alkoxy and alkyl is C.sub.1-C.sub.6-alkyl;
CO.sub.2(C.sub.1-C.sub.6-alkyl); CO.sub.2H; CH.sub.2OH. R.sub.4:
hydrogen; hydroxy; C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.10-alkyloxyalk- oxy, where alkyloxy is
C.sub.1-C.sub.4 and alkoxy is C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.3-C.sub.16-(cyclical saturated group)alkyloxy, where alkyl is
C.sub.1-C.sub.6; C.sub.4-C.sub.16-(cyclica- l saturated
group)alkenyloxy, where alkenyl is C.sub.2-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkinyloxy where alkinyl
is C.sub.2-C.sub.6; C.sub.7-C.sub.16-arylalkyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.2-C.sub.6-alkanoyloxy; C.sub.3-C.sub.6-alkenoyloxy;
C.sub.3-C.sub.6-alkinoyloxy; C.sub.8-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.2-C.sub.6-alkanoyloxy; C.sub.9-C.sub.16-arylalkenoyl- oxy,
where aryl is C.sub.6-C.sub.10-aryl and alkenoyloxy is
C.sub.3-C.sub.6-alkenoyloxy; C.sub.9-C.sub.16-arylalkinoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkinoyloxy is
C.sub.3-C.sub.6-alkinoyloxy; R.sub.5: hydrogen; hydroxy;
C.sub.1-C.sub.6-alkyloxy; C.sub.2-C.sub.10-alkyloxyalkoxy, where
alkyloxy is C.sub.1-C.sub.4 and alkoxy is C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.3-C.sub.16-(cyclical saturated group)alkyloxy, where alkyl is
C.sub.1-C.sub.6; C.sub.4-C.sub.16-(cyclica- l saturated
group)alkenyloxy, where alkenyl is C.sub.2-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkinyloxy, where
alkinyl is C.sub.2-C.sub.6; C.sub.7-C.sub.16-arylalkyloxy, where
aryl is C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.2-C.sub.6-alkanoyloxy; C.sub.7-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.2-C.sub.6-alkanoyloxy; X is oxygen; Y.sup.- is I.sup.-,
Br.sup.-, Cl.sup.-, OH.sup.- or another pharmacologically
acceptable counterion; wherein a single or double bond can be
present between the carbon atoms of numbers 7 and 8, wherein alkyl,
alkenyl and alkinyl can each be branched or unbranched, aryl can be
unsubstituted or mono-, di- or trisubstituted, independently in
each case, with hydroxy, halogen, nitro, cyano, thiocyanato,
trifluoromethyl, C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy,
CO.sub.2H, CONH.sub.2, CO.sub.2(C.sub.1-C.sub.3-alkyl),
CONH(C.sub.1-C.sub.3-alkyl), CON(C.sub.1-C.sub.3-alkyl).sub.2,
CO(C.sub.1-C.sub.3-alkyl); amino; (C.sub.1-C.sub.3-monoalkyl)amino,
(C.sub.1-C.sub.3-dialkyl)amino; C.sub.5-C.sub.6-cycloalkylamino,
(C.sub.1-C.sub.3-alkanoyl)amido, SH, SO.sub.3H,
SO.sub.3(C.sub.1-C.sub.3-alkyl), SO.sub.2(C.sub.1-C.sub.3-alky- l),
SO(C.sub.1-C.sub.3-alkyl), C.sub.1-C.sub.3-alkylthio or
C.sub.1-C.sub.3-alkanoylthio, wherein -(cyclical saturated group)
is either preferably C.sub.3-C.sub.10-cycloalkyl or a
heterocyclical group with 2 to 9 carbon atoms, containing
furthermore one or more heteroatoms.
3. Compounds of the formulae (I) or (IA) of claims 1 or 2, in which
X is oxygen; R.sub.1 is C.sub.1-C.sub.6-alkyl;
C.sub.2-C.sub.6-alkenyl; C.sub.4-C.sub.16-cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; R.sub.2 is
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where
aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; R.sub.3 is hydrogen or methyl; R.sub.4 is
hydroxy, methoxy or acetoxy.
4. Compounds of the formula (IA) of claim 2, in which X is oxygen;
R.sub.1 is C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.4-C.sub.16-cycloalkylalkyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; R.sub.2 is C.sub.1-C.sub.6-alkyl or
C.sub.2-C.sub.6-alkenyl, R.sub.3 is hydrogen or methyl; R.sub.4 is
hydroxy, methoxy or acetoxy.
5. Compounds of claims 1 or 2, selected from:
17-allyl-4,5.alpha.-epoxy-3--
methoxy-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-allyl-4,5.alpha.-epoxy-3-hydroxy-1
40-(3-phenylpropyloxy)morphinan-6-o- ne,
17-allyl-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-1
4.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-allyl-4,5.alpha.-epoxy-3-h- ydroxy-5.beta.-methyl-1
4.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3phenylpropyloxy-
)morphinan-6-one,
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.--
(3-phenylpropyloxy)morphinan-6-one,
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-
-methoxy-50-methyl-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.beta.-(3-
-phenylpropyloxy)morphinan-6-one,
17-cyclopropylmethyl-4,5.alpha.-epoxy-3--
methoxy-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenylpropylo-
xy)morphinan-6-one,
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-methoxy-5.beta-
.-methyl-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.beta.-(-
3-phenylpropyloxy)morphinan-6-one,
4,5.alpha.-epoxy-3-methoxy-5.beta.,17-d-
imethyl-14.beta.-[(3-phenylpropyl)oxy]morphinan-6-one,
4,5.alpha.-epoxy-3-hydroxy-5.beta.,17-dimethyl-14.beta.-[(3-phenylpropyl)-
oxy]morphinan-6-one,
17-propyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phen-
ylpropyloxy)morphinan-6-one,
17-propyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-
-(3-phenylpropyloxy)morphinan-6-one,
17-propyl-4,5.alpha.-epoxy-3-methoxy--
5.beta.-methyl-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-propyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.beta.-(3-phenylpro-
pyloxy)morphinan-6-one,
17-tetrahydrofurfuryl-4,5.alpha.-epoxy-3-methoxy-1-
4.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-tetrahydrofurfuryl-4,5.alph-
a.-epoxy-3-hydroxy-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-tetrahydrofurfuryl-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-14.beta.--
(3-phenylpropyloxy)morphinan-6-one,
17-tetrahydrofurfuryl-4,5.alpha.-epoxy-
-3-hydroxy-5-methyl-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-(2-phenylethyl)-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy-
)morphinan-6-one,
17-(2-phenylethyl)-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(-
3-phenylpropyloxy)morphinan-6-one,
17-(2-phenylethyl)-4,5.alpha.-epoxy-3-m-
ethoxy-5.beta.-methyl-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-(2-phenylethyl)-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.beta.-(3--
phenylpropyloxy)morphinan-6-one,
17-ethyl-4,5.alpha.-epoxy-3-methoxy-14.be-
ta.-(3phenylpropyloxy)morphinan-6-one,
17-ethyl-4,5.alpha.-epoxy-3-hydroxy- -1
40-(3-phenylpropyloxy)morphinan-6-one,
17-ethyl-4,5.alpha.-epoxy-3-meth-
oxy-5.beta.-methyl-14.beta.-(3-phenylpropyloxy)morphinan-6-one,
17-ethyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.beta.-(3-phenylprop-
yloxy)morphinan-6-one,
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.-
beta.-[(2-methylbenzyl)oxy]morphinan-6-one,
14.beta.-[(2-chlorobenzyl)oxy]-
-17-(cyclopropylmethyl)-4,5.alpha.-epoxy-3-hydroxymorphinan-6-one,
14.beta.-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxymorphin-
an-6-one, 1
4.beta.-butoxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-
morphinan-6-one,
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.--
[(3-methylbutyl)oxy]morphinan-6-one, 4,5.alpha.-epoxy-5 .beta., 1
7-dimethyl-14.beta.-[(3-phenylpropyl)oxy]-3-[(prop-2-inyl)oxy]morphinan-6-
-one, 1
4.beta.-[(3-chlorobenzyl)oxy]-4,5.alpha.-epoxy-17-methyl-3-[(prop--
2-inyl)oxy]morphinan-6-one, 4,5.alpha.-epoxy-17-ethyl-3-methoxy-1
4.beta.-[(3-phenylpropyl)oxy]morphinan-6-one,
4,5.alpha.-epoxy-17-ethyl-3-
-hydroxy-14.beta.-[(3-phenylpropyl)oxy]morphinan-6-one,
4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3-methylbutyl)oxy]-17-propylmorphin-
an-6-one, 5.beta.-benzyl-14-methoxycodeinone
(=5-benzyl-7,8-didehydro-4,5.- alpha.-epoxy-3,1
4.beta.-dimethoxy-17-methyl-morphinan-6-one),
5.beta.-benzyl-4,5.alpha.-epoxy-3,1
4.beta.-dimethoxy-17-methylmorphinan-- 6-one,
5.beta.-benzyl-4,5.alpha.-epoxy-3-hydoxy-1 4.beta.-methoxy-1
7-methylmorphinan-6-one,
4-hydroxy-3-methoxy-17-methyl-14-[(3-phenylpropy-
l)oxy]-morphinan-6-one,
3,4-dimethoxy-17-methyl-14-[(3-phenylpropyl)oxy]-m- orphinan-6-one,
14.beta.-benzyloxy-4-hydroxy-3-methoxy-17-methylmorphinan-- 6-one,
1 4.beta.-benzyloxy-3,4-dimethoxy-1 7-methylmorphinan-6-one,
4-hydroxy-3-methoxy-17-methyl-1
4.beta.-[(2-naphthylmethyl)oxy]morphinan-- 6-one,
3,4-dimethoxy-17-methyl-14.beta.-[(2-naphthylmethyl)oxy]morphinan-6-
-one, 4-hydroxy-3-methoxy-5.beta., 1
7-dimethyl-14.beta.-[(3-phenylpropyl)- oxy]-morphinan-6-one,
3,4-dimethoxy-5,17-dimethyl-1
4.beta.-[(3phenylpropyl)oxy]-morphinan-6-one,
14.beta.-ethoxy-4-hydroxy-3-
-methoxy-5.beta.,17-dimethylmorphinan-6-one,
14.beta.-ethoxy-3,4-dimethoxy- -5,17-dimethylmorphinan-6-one,
14.beta.-benzyloxy-3,4-dimethoxy-5.beta.,17-
-dimethylmorphinan-6-one,
4,5.alpha.-epoxy-3-hydroxy-17,17-dimethyl-6-oxo--
14.beta.-[(3-phenylpropyl)oxy]morphinanium-iodide,
(17S)-4,5.alpha.-epoxy--
17-ethyl-3-hydroxy-17-methyl-6-oxo-14.beta.-[(3-phenylpropyl)oxy]morphinan-
ium-iodide,
(17R)-4,5.alpha.-epoxy-3-hydroxy-17-methyl-6-oxo-14.beta.-[(3--
phenylpropyl)oxy]-17-[(2(R,S)-tetrahydrofurfuran-2-yl)methyl]morphinanium--
iodide,
(17R)-17-allyl-4,5.alpha.-epoxy-14.beta.-ethoxy-3-hydroxy-17-methy-
l-6-oxomorphinanium-iodide, (17R)-17-allyl-4,5.alpha.-epoxy
3-hydroxy-14.beta.-methoxy-17-methyl-6-oxomorphinanium-iodide,
(17S)-17-allyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17-methyl-6-ox-
omorphinanium-iodide,
4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17,17-di-
methyl-6-oxo-morphinanium-iodide,
5.beta.-benzyl-14.beta.-(butyloxy)-4,5-e-
poxy-3-hydroxy-17,17-dimethyl-6-oxomorphinanium-iodide,
(17S)-17-allyl-5.beta.-benzyl-14.beta.-butoxy-4,5.alpha.-epoxy-3-hydroxy--
17-methyl-6-oxomorphinanium-iodide,
14.beta.-butoxy-4,5.alpha.-epoxy-3-hyd-
roxy-17,17-dimethyl-6-oxomorphinanium-iodide,
(17R)-17-cyclopropylmethyl-4-
,5.alpha.-epoxy-3-hydroxy-17-methyl-6-oxo-14.beta.-[(3-phenylpropyl)oxy]mo-
rphinanium-iodide,
(17R)-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-methoxy-1-
7-methyl-6-oxo-140-[(3-phenylpropyl)oxy]morphinanium-iodide,
(17R)-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-17-methyl-6-oxo-14.-
beta.-[(2-phenylbenzyl)oxy]morphinanium-iodide,
(17R)-14.beta.-[(4-chlorob-
enzyl)oxy]-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-17-methyl-6-oxo-
morphinanium-iodide,
17(R)-4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17--
methyl-6-oxo-17-(2-phenylethyl)morphinanium-iodide,
4,5.alpha.-expoxy-3-methoxy-17-methyl-14.beta.-[(3-phenylpropyl)oxy]morph-
inan-6-one,
4,5.alpha.-expoxy-3-methoxy-14.beta.-[(3-phenylpropyl)oxy]morp-
hinan-6-one,
4,5.alpha.-expoxy-3-hydroxy-17-methyl-14.beta.-[(3-phenylprop-
yl)oxy]morphinan-6-one,
4,5.alpha.-expoxy-17-methyl-14.beta.-[(3-phenylpro-
pyl)oxy]morphinan-6-one,
17-(cyclopropylmethyl)-4,5.alpha.-epoxy-14.beta.--
[(3-phenylpropyl)oxy]morphinan-6-one, 4,5.alpha.-epoxy-1
40-[(3-phenylpropyl)oxy]morphinan-6-one,
17-(cyclopropylmethyl)-4-hydroxy- -1
40-[(3-phenylpropyl)oxy]morphinan-6-one,
17-(cyclopropylmethyl)-4-metho- xy-1
40-[(3-phenylpropyl)oxy]morphinan-6-one,
4-(n-butyloxy)-17-(cycloprop- ylmethyl)-1
40-[(3-phenylpropyl)oxy]morphinan-6-one, or any pharmaceutically
acceptable salt or easily accessible derivative of it.
6. A pharmaceutical composition, comprising a compound of claims 1
or 2 and/or a pharmaceutically acceptable acid addition salt
thereof, together with a pharmaceutically acceptable carrier
substance.
7. (canceled)
8. A method of using a compound of claims 1 or 2 for the treatment
of pain, including chronic and acute pain, post-operative pain,
rheumatic diseases (e.g. arthritis), ileus, obstipation,
overweight, addiction, including opioid, cocaine and alcohol
addiction as well as for the manufacture of a narcotic.
9. Compounds according to claim 1 or 2, wherein R.sub.5 is OH or
alkoxy.
10. Compounds according to claim 1 or 2, wherein R.sub.3 is
hydrogen, alkyl or aralkyl, preferably hydrogen or alkyl.
11. Compounds according to claim 1 or 2, wherein R.sub.4 is OH,
alkoxy or alkenyloxy or alkinyloxy.
12. Compounds according to claim 1 or 2, wherein a single bond is
present between the carbon atoms of the numbers 7 and 8.
13. Compounds according to claim 1 or 2, wherein R.sub.2 is alkyl
or aralkyl, preferably aralkyl.
14. Compounds according to claim 1 or 2, wherein R.sub.1 is alkyl,
(cyclical saturated group)alkyl, aralkyl or alkenyl.
15. Compounds according to claim 1 or 2, wherein R.sub.1 is
C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.3-C.sub.16-(cyclical saturated
group)alkyl, where alkyl is C.sub.1-C.sub.6;
C.sub.4-C.sub.16-(cyclical saturated group)alkenyl, where alkenyl
is C.sub.2-C.sub.6; C.sub.4-C.sub.16-(cyclical saturated
group)alkinyl, where alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalk- yl, where aryl is C.sub.6-C.sub.10-aryl
and alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl,
where aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.8-C.sub.16-arylalkinyl, where aryl
is C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl.
Description
[0001] The present invention relates to a class of morphinan
compounds and the quaternary salts thereof substituted in Position
14, which may be used as highly active analgesics or also as opioid
antagonists. The present invention further relates to
pharmaceutically acceptable salts and easily-produced derivatives
thereof, a process of production thereof and use thereof in the
production of pharmaceutical specialities.
[0002] The existence of opioid receptors as receptors of the
central nervous system (CNS), which impart analgesic effects, has
been clearly proven. These receptors are subdivided into three
subtypes, .mu., .kappa. and .delta.. Activation of these receptors
by opioid agonists leads to an analgesic effect. The activation of
the .mu.-receptors causes the highest analgesic effect, whereby
particularly N-methyl substituted morphinans with an oxygen
function in Position 6 (morphine, oxymorphone, hydromorphone, etc.)
are particularly active opioid agonists and are used as effective
analgesics. In the past a great deal of work has been invested in
structure-activity relationship studies of this class of
substance.
[0003] In the Journal of Medicinal Chemistry 1984, 27, pp.
1575-1579 various 14-methoxy-N-methylmorphinan-6-ones are described
with various substituents in Position 3. These derivatives show
higher analgesic activity than their 14-hydroxy analogues.
[0004] A detailed study of 5-methyloxymorphone
(=14-hydroxy-5-methyldihydr- omorphinone) is described in Helvetica
Chimica Acta (1988, 71, pp. 1801-1804), which arrives at the result
that the introduction of a 5-methyl group reduces the opioid
agonistic properties of oxymorphone.
[0005] A further study of 14-alkoxy-N-methylmorphinan-6-ones is
described in Helvetica Chimica Acta 1989, 7 2, p p. 1233-1239, in
which the influence of various substituents in Position 3 and of
the amino nitrogen have been evaluated.
[0006] The German published patent application DE 34 12 727
describes 14-alkoxy-N-methylmorphinan-6-ones
(14-O-alkyloxymorphones) with higher activity than their 14-hydroxy
analogues.
[0007] If instead of the N-methyl group, e.g. an
N-cyclopropylmethyl group, an N-allyl group or an
N-tetrahydrofurfuryl group is introduced, then normally compounds
result which cause antagonistic effects on opioid receptors (see
Prog. Med. Chem. 1998, 35, 83-132). Such opioid antagonists cancel
both the analgesic effect as well as the side effects of opioid
agonists (e.g. respiratory depression or obstipation).
[0008] Surprisingly, it has now been found that e.g.
N-cyclopropylmethyl, N-allyl or N-tetrahydrofurfuryl substituted
morphinan-6-ones with arylalkyl substituents or longer chained
alkyl substituents in Position 14 are highly active opioid agonists
with excellent analgesic activity. The very high analgesic activity
enables low dosing, which leads to a lower rate of side
effects.
[0009] Furthermore, its has been surprisingly found that a
quatemisation of morphinan-6-ones, which exhibit arylalkyl
substituents or alkyl substituents in Position 14, on one hand
leads to substances with higher analgesic activity, but on the
other hand to substances with excellent opioid antagonism. The
previously described quatemisation of 14-hydroxymorphinan-6-ones
(e.g. oxymorphone or naloxone) led to a significant weakening of
the effectiveness (see M. A. Iorio et al., Eur. J. Med. Chem.-
Chim. Ther. 1984, 19, 301-303). Furthermore, it has been found that
these new substances develop their effect primarily in the
periphery, because they cannot, or can only to a slight extent,
overcome the blood-brain barrier.
[0010] The present invention provides highly active compounds of
the formulae (I), (Ia), (IA) and (IAa) as defined in the claims 1
and 2. Preferred embodiments are given in the subclaims, along with
further aspects of this invention, such as compositions and uses.
The statements made, in particular in conjunction with the
compounds, about preferred embodiments apply analogously also to
the other aspects of the invention, such as the compositions and
uses.
[0011] Additional preferred embodiments are defined in the
following.
[0012] Compounds of the formulae (I) and (Ia), in which the
substituents have the following significance:
[0013] R.sub.1: C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.4-C.sub.16-Cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkenyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkinyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and alkyl
is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where aryl
is C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinyl is C.sub.2-C.sub.6-alkinyl;
[0014] R.sub.2: subject to the following definition of X,
C.sub.4-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.4-C.sub.16-cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkenyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkinyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl,
[0015] where aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.8-C.sub.16-arylalkinyl, where aryl
is C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-aklinyl;
C.sub.3-C.sub.6-alkenoyl; C.sub.3-C.sub.6-alkinoyl:
C.sub.9-C.sub.16-arylalkenoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenoyl is C.sub.3-C.sub.6-alkenoyl;
C.sub.9-C.sub.16-arylalkinoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinoyl is C.sub.3-C.sub.6-alkinoyl;
[0016] R.sub.3: hydrogen; C.sub.1-C.sub.6-alkyl;
C.sub.2-C.sub.6-alkenyl; C.sub.7-C.sub.16-arylalkyl, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl; alkoxyalkyl, where alkoxy
is C.sub.1-C.sub.6-alkoxy and alkyl is C.sub.1-C.sub.6-alkyl;
CO.sub.2(C.sub.1-C.sub.6-alkyl); CO.sub.2H; CH.sub.2OH.
[0017] R.sub.4: hydrogen; hydroxy; C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.10-alkyloxyalkoxy, where alkyloxy is C.sub.1-C.sub.4
and alkoxy is C.sub.1-C.sub.6-alkyloxy C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.4-C.sub.16-cycloalkylalkyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkenyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkinyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7C.sub.16-arylalky- loxy, where aryl is C.sub.6-C.sub.10-aryl
and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.1-C.sub.6-alkanoyloxy; C.sub.1-C.sub.6-alkenoyloxy;
C.sub.1-C.sub.6-alkinoyloxy; C.sub.7C.sub.16-arylalkanoyloxy, where
aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.1-C.sub.6-alkylanoyloxy; C.sub.9-C.sub.16-arylalkeno- yloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkenoyloxy is
C.sub.3-C.sub.6-alkenoyloxy; C.sub.7-C.sub.16-arylalkinoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkinoyloxy is
C.sub.3-C.sub.6-alkinoyloxy;
[0018] R.sub.5: hydrogen; hydroxy; C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.10-alkyloxyalkoxy, where alkyloxy is C.sub.1-C.sub.4
and alkoxy is C.sub.1-C.sub.6-alkyloxy C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.4-C.sub.16-cycloalkylalkyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkenyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-Cycloalkylalkinyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalk- yloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.1-C.sub.6-alkanoyloxy; C.sub.7-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.1-C.sub.6-alkylanoyloxy;
[0019] X is oxygen, sulphur or methylene.
[0020] In the present invention alkyl, alkenyl and alkinyl consist
of branched or unbranched alkyl, alkenyl and alkinyl.
[0021] Aryl can be unsubstituted or mono-, di- or trisubstituted
independently with hydroxy, halogen, nitro, cyano, thiocyanato,
trifluoromethyl, C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy,
CO.sub.2H, CONH.sub.2, CO.sub.2(C.sub.1-C.sub.3-alkyl),
CONH(C.sub.1-C.sub.3-alkyl), CON(C.sub.1-C.sub.3-alkyl).sub.2,
CO(C.sub.1-C.sub.3-alkyl); amino; (C.sub.1-C.sub.3-monoalkyl)amino,
(C.sub.1-C.sub.3-dialkyl)amino; C.sub.5-C.sub.6-Cycloalkylamino,
(C.sub.1-C.sub.3-alkanoyl)amido, SH, SO.sub.3H,
SO.sub.3(C.sub.1-C.sub.3-- alkyl), SO.sub.2(C.sub.1-C.sub.3-alkyl),
SO(C.sub.1-C.sub.3-alkyl), C.sub.1-C.sub.3-alkylthio or
C.sub.1-C.sub.3-alkanoylthio.
[0022] The above stated definitions for alkyl, alkenyl, alkinyl and
aryl apply to all substituents of this application.
[0023] If the (cyclical saturated group) contains heteroatoms, then
there are preferably 1 to 3 heteroatoms, in particular 1 or 2 and
most preferably one heteroatom, preferably selected from O, S, N, P
and B and more preferably from O, S and N.
[0024] In the formulae (IA) and (IAa) the substituents preferably
have the following significance:
[0025] R.sub.1: C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.4-C.sub.16-cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-Cycloalkylalkenyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkinyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where
aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.8-C.sub.16-arylalkinyl, where aryl
is C.sub.6-C.sub.10-aryl and alkinyl is
C.sub.2-C.sub.6-alkinyl;
[0026] The two substituents R.sub.1 can be the same or
different;
[0027] R.sub.2: subject to the following definition of X,
C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.4-C.sub.16-cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkenyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkinyl, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-C.sub.10-aryl and
alkyl is C.sub.1-C.sub.6-alkyl; C.sub.8-C.sub.16-arylalkenyl, where
aryl is C.sub.6-C.sub.10-aryl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.8-C.sub.16-arylalkinyl, where aryl
is C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.1-C.sub.6-alkanoyl; C.sub.3-C.sub.6-alkenoyl:
C.sub.3-C.sub.6-alkinoyl; C.sub.7-C.sub.16-arylalkanoyl, where aryl
is C.sub.6-C.sub.10-aryl and alkanoyl is C.sub.1-C.sub.6-alkyl;
C.sub.9-C.sub.16-arylalkenoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenoyl is C.sub.3-C.sub.6-alkenoyl;
C.sub.9-C.sub.16-arylalkinoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinoyl is C.sub.3-C.sub.6-alkinoyl;
[0028] R.sub.3: hydrogen; C.sub.1-C.sub.6-alkyl;
C.sub.2-C.sub.6-alkenyl; C.sub.7-C.sub.16-arylalkyl, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl; alkoxyalkyl, where alkoxy
is C.sub.1-C.sub.6-alkoxy and alkyl is C.sub.1-C.sub.6-alkyl;
CO.sub.2(C.sub.1-C.sub.6-alkyl); CO.sub.2H; CH.sub.2OH.
[0029] R.sub.4: hydrogen; hydroxy; C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.10-alkyloxyalkoxy, where alkyloxy is C.sub.1-C.sub.4
and alkoxy is C.sub.1-C.sub.6-alkyloxy C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.4-C.sub.16-Cycloalkylalkyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-Cycloalkylalkenyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-Cycloalkylalkinyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalk- yloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is. C.sub.2-C.sub.6-alkinyl;
C.sub.1-C.sub.6-alkanoyloxy; C.sub.1-C.sub.6-alkenoyloxy;
C.sub.1-C.sub.6-alkinoyloxy; C.sub.7-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.1-C.sub.6-alkylanoyloxy; C.sub.9-C.sub.16-arylalkeno- yloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkenoyloxy is
C.sub.3-C.sub.6-alkenoyloxy; C.sub.7-C.sub.16-arylalkinoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkinoyloxy is
C.sub.3-C.sub.6-alkinoyloxy;
[0030] R.sub.5: hydrogen; hydroxy; C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.10-alkyloxyalkoxy, where alkyloxy is C.sub.1-C.sub.4
and alkoxy is C.sub.1-C.sub.6-alkyloxy C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.4-C.sub.16-cycloalkylalkyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkenyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkinyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalk- yloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.1-C.sub.6-alkanoyloxy; C.sub.7-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.1-C.sub.6-alkylanoyloxy;
[0031] X is oxygen, sulphur or methylene.
[0032] In this invention alkyl, alkenyl and alkinyl consist of
branched or unbranched alkyl, alkenyl and alkinyl.
[0033] Aryl can be unsubstituted or mono-, di- or trisubstituted
independently with hydroxy, halogen, nitro, cyano, thiocyanato,
trifluoromethyl, C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-alkoxy,
CO.sub.2H, CONH.sub.2, CO.sub.2(C.sub.1-C.sub.3-alkyl),
CONH(C.sub.1-C.sub.3-alkyl), CON(C.sub.1-C.sub.3-alkyl).sub.2,
CO(C.sub.1-C.sub.3-alkyl); amino; (C.sub.1-C.sub.3-monoalkyl)amino,
(C.sub.1-C.sub.3-dialkyl)amino; C.sub.5-C.sub.6-cycloalkylamino;
(C.sub.1-C.sub.3-alkanoyl)amido, SH, SO.sub.3H,
SO.sub.3(C.sub.1-C.sub.3-- alkyl), SO.sub.2(C.sub.1-C.sub.3-alkyl),
SO(C.sub.1-C.sub.3-alkyl), C.sub.1-C.sub.3-alkylthio or
C.sub.1-C.sub.3-alkanoylthio.
[0034] The above stated definitions for alkyl, alkenyl, alkinyl and
aryl apply to all substituents of this application.
[0035] If the (cyclical saturated group) contains heteroatoms, then
there are preferably 1 to 3 heteroatoms, in particular 1 or 2 and
most preferably one heteroatom, preferably selected from O, S, N, P
and B and more preferably from O, S and N.
[0036] The compounds of this invention comprise also
pharmaceutically and pharmacologically acceptable salts of the
compounds of the formula (I). According to this invention both
inorganic and also organic salts are suitable. Examples of suitable
inorganic salts for this invention are hydrochlorides,
hydrobromides, sulphates and phosphates. Possible organic salts are
for example methane sulphonates, salicylates, fumarates,
maleinates, succinates, aspartates, citrates, oxalates and
orotates.
[0037] In a preferred representation of the formula (I) or (Ia),
when X is oxygen, R.sub.1 is C.sub.1-C.sub.6-alkyl;
C.sub.2-C.sub.6-alkenyl; C.sub.4-C.sub.16-cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.7C.sub.16-arylalkyl, where aryl is C.sub.6-aryl and alkyl is
C.sub.1-C.sub.3-alkyl; R.sub.2 is C.sub.7-C.sub.16-arylalkyl, where
aryl is C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl; R.sub.3 is hydrogen or
methyl; R.sub.4 is hydroxy, methoxy or acetoxy.
[0038] Strongly preferred compounds, in which X is oxygen, are
those in which R.sub.1 to R.sub.4 are as follows (wherein these
compounds can be present as free bases/acids or as acceptable
salt):
[0039] R.sub.1: methyl, ethyl, propyl, butyl, pentyl, hexyl, in
particular methyl, ethyl, propyl and most preferred methyl
[0040] R.sub.2: phenylmethylene (in the examples the notation
phenylmethyl is used), phenylethylene, phenylpropylene,
phenylbutylene, phenylpentylene, phenylhexylene, whereby the phenyl
core can be optionally substituted, in particular phenylpropylene
(in the examples this radical is also termed phenylpropyl)
[0041] R.sub.3: methyl, ethyl, propyl, butyl, pentyl, hexyl, in
particular methyl, ethyl, propyl and most preferred methyl
[0042] R.sub.4: OH, methoxy, acetoxy, in particular OH
[0043] One example of a particularly preferred compound is
4,5.alpha.-epoxy-3-hydroxy-5.beta.,17-dimethyl-14.beta.-[(3-phenylpropyl)-
oxy]morphinan-6-one, in particular the hydrochloride and the
hydrobromide.
[0044] In a particularly preferred representation of this invention
the compound is selected from:
[0045]
17-allyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy)mor-
phinan-6-one
[0046]
17-allyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenylpropyloxy)mor-
phinan-6-one
[0047]
17-allyl-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-14.beta.-(3-phen-
ylpropyloxy)morphinan-6-one
[0048]
17-allyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.beta.-(3-phen-
ylpropyloxy)morphinan-6-one
[0049]
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpr-
opyloxy)morphinan-6-one
[0050]
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenylpr-
opyloxy)morphinan-6-one
[0051]
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-14.be-
ta.-(3-phenylpropyloxy)morphinan-6-one
[0052]
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.be-
ta.-(3-phenylpropyloxy)morphinan-6-one
[0053]
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylp-
ropyloxy)morphinan-6-one
[0054]
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenylp-
ropyloxy)morphinan-6-one
[0055]
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-14.b-
eta.-(3-phenylpropyloxy)morphinan-6-one
[0056]
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.b-
eta.-(3-phenylpropyloxy)morphinan-6-one
[0057] 4,5.alpha.-epoxy-3-methoxy-5.beta.,
17-dimethyl-14.beta.-[(3-phenyl- propyl)oxy]morphinan-6-one
[0058] 4,5.alpha.-epoxy-3-hydroxy-5.beta.,
17-dimethyl-14.beta.-[(3-phenyl- propyl)oxy)]morphinan-6-one
[0059]
17-propyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy)mo-
rphinan-6-one
[0060]
17-propyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenylpropyloxy)mo-
rphinan-6-one
[0061]
17-propyl-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-14.beta.-(3-phe-
nylpropyloxy)morphinan-6-one
[0062]
17-propyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.beta.-(3-phe-
nylpropyloxy)morphinan-6-one
[0063]
17-tetrahydrofurfuryl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenyl-
propyloxy)morphinan-6-one
[0064]
17-tetrahydrofurfuryl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenyl-
propyloxy)morphinan-6-one
[0065]
17-tetrahydrofurfuryl-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-14.-
beta.-(3-phenylpropyloxy)morphinan-6-one
[0066]
17-tetrahydrofurfuryl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.-
beta.-(3-phenylpropyloxy)morphinan-6-one
[0067]
17-(2-phenylethyl)-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpro-
pyloxy)morphinan-6-one
[0068]
17-(2-phenylethyl)-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenylpro-
pyloxy)morphinan-6-one
[0069]
17-(2-phenylethyl)-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-14.bet-
a.-(3-phenylpropyloxy)morphinan-6-one
[0070]
17-(2-phenylethyl)-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.bet-
a.-(3-phenylpropyloxy)morphinan-6-one
[0071]
17-ethyl-5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy)morph-
inan-6-one
[0072]
17-ethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenylpropyloxy)mor-
phinan-6-one
[0073]
17-ethyl-4,5.alpha.-epoxy-3-methoxy-5.beta.-methyl-14.beta.-(3-phen-
ylpropyloxy)morphinan-6-one
[0074]
17-ethyl-4,5.alpha.-epoxy-3-hydroxy-5.beta.-methyl-14.beta.-(3-phen-
ylpropyloxy)morphinan-6-one
[0075]
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(2-methyl-
benzyl)oxy]morphinan-6-one
[0076]
14.beta.-[(2-chlorobenzyl)oxy]-17-(cyclopropylmethyl)-4,5.alpha.-ep-
oxy-3-hydroxymorphinan-6-one
[0077]
14.beta.-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxym-
orphinan-6-one
[0078]
14.beta.-butoxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxymorp-
hinan-6-one
[0079]
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3-methyl-
butyl)oxy]morphinan-6-one
[0080] 4,5.alpha.-epoxy-5.beta.,
17-dimethyl-14.beta.-[(3-phenylpropyl)oxy-
]-3-[(prop-2-inyl)oxy]morphinan-6-one
[0081]
14.beta.-[(3-chlorobenzyl)oxy]4,5.alpha.-epoxy-17-methyl-3-[(prop-2-
-inyl)oxy]morphinan-one
[0082]
4,5.alpha.-epoxy-17-ethyl-3-methoxy-14.beta.-[(3-phenylpropyl)oxy]m-
orphinan-6-one
[0083]
4,5.alpha.-epoxy-17-ethyl-3-hydroxy-14.beta.-[(3-phenylpropyl)oxy]m-
orphinan-6-one
[0084]
4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3-methylbutyl)oxy]-17-propylm-
orphinan-6-one
[0085] 5.beta.-benzyl-14-methoxycodeinone
(=5-benzyl-7,8-didehydro-4,5.alp-
ha.-epoxy-3,14.beta.-dimethoxy-17-methyl-morphinan-6-one)
[0086]
5,3-benzyl-4,5.alpha.-epoxy-3,14.beta.-dimethoxy-17-methylmorphinan-
-6-one
[0087]
5.beta.-benzyl-4,5.alpha.-epoxy-3-hydoxy-14.beta.-methoxy-17-methyl-
morphinan-6-one
[0088]
4-hydroxy-3-methoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6--
one
[0089]
3,4-dimethoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one
[0090]
14.beta.-benzyloxy-4-hydroxy-3-methoxy-17-methylmorphinan-6-one
[0091]
14.beta.-benzyloxy-3,4-dimethoxy-17-methylmorphinanne-6-one
[0092]
4-hydroxy-3-methoxy-17-methyl-14.beta.-[(2-naphthylmethyl)oxy]morph-
inan-6-one
[0093]
3,4-dimethoxy-17-methyl-14.beta.-[(2-naphthylmethyl)oxy]morphinan-6-
-one
[0094]
4-hydroxy-3-methoxy-5.beta.,17-dimethyl-14.beta.-[(3-phenylpropyl)o-
xy]-morphinan-6-one
[0095] 3,4-dimethoxy-5.beta.,
17-dimethyl-14.beta.-[(3-phenylpropyl)oxy]-m- orphinan-6-one
[0096]
14.beta.-ethoxy-4-hydroxy-3-methoxy-5.beta.,17-dimethylmorphinan-6--
one
[0097] 14.beta.-ethoxy-3,4-dimethoxy-5.beta.,
17-dimethylmorphinan-6-one
[0098] 14.beta.-benzyloxy-3,4-dimethoxy-5.beta., 1
7-dimethylmorphinan-6-o- ne
[0099] In a preferred representation of the formula (IA) or (IAa),
when X is oxygen, R.sub.1 is C.sub.1-C.sub.6-alkyl,
C.sub.2-C.sub.6-alkenyl, C.sub.4-C.sub.16-Cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6,
C.sub.7-C.sub.16-arylalkyl, where aryl is C.sub.6-aryl and alkyl is
C.sub.1-C.sub.3-alkyl; R.sub.2 is C.sub.1-C.sub.6-alkyl,
C.sub.2-C.sub.6-alkenyl, C.sub.7-C.sub.16-arylalky- l, where aryl
is C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl; R.sub.3 is hydrogen or
methyl; R.sub.4 is hydroxy, methoxy or acetoxy.
[0100] In a particularly preferred representation of this invention
is the compound selected from:
[0101]
4,5.alpha.-epoxy-3-hydroxy-17,17-dimethyl-6-oxo-14.beta.-[(3-phenyl-
propyl)oxy]morphinanium-iodide
[0102]
(17S)-4,5.alpha.-epoxy-17-ethyl-3-hydroxy-17-methyl-6-oxo-14.beta.--
[(3-phenylpropyl)oxy]morphinanium-iodide
[0103]
(17R)-4,5.alpha.-epoxy-3-hydroxy-17-methyl-6-oxo-14.beta.-[(3-pheny-
lpropyl)oxy]-17-[(2-R,S-tetrahydrofurfuran-2-yl)methyl]morphinanium-iodide
[0104]
(17R)-17-allyl-4,5.alpha.-epoxy-14.beta.-ethoxy-3-hydroxy-17-methyl-
-6-oxomorphinanium-iodide
[0105] (17R)-17-allyl-4,5.alpha.-epoxy
3-hydroxy-14.beta.-methoxy-17-methy- l-6-oxomorphinanium-iodide
[0106]
(17S)-17-allyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17-methy-
l-6-oxomorphinanium-iodide
[0107]
4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17,17-dimethyl-6-oxo-mo-
rphinanium-iodide
[0108]
5.beta.-benzyl-14.beta.-(butyloxy)-4,5.alpha.-epoxy-3-hydroxy-17,17-
-dimethyl-6-oxomorphinanium-iodide
[0109]
(17S)-17-allyl-5.beta.-benzyl-14.beta.-butoxy-4,5.alpha.-epoxy-3-hy-
droxy-17-methyl-6-oxomorphinanium-iodide
[0110]
14.beta.-butoxy-4,5.alpha.-epoxy-3-hydroxy-17,17-dimethyl-6-oxomorp-
hinanium-iodide
[0111]
(17R)-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-17-methyl-6-o-
xo-14.beta.-[(3-phenylpropyl)oxy]morphinanium-iodide
[0112]
(17R)-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-methoxy-17-methyl-6-o-
xo-14.beta.-[(3-phenylpropyl)oxy]morphinanium-iodide
[0113]
(17R)-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-17-methyl-6-o-
xo-14.beta.-[(2-phenylbenzyl)oxy]morphinanium-iodide
[0114]
(17R)-14.beta.-[(4-chlorobenzyl)oxy]-17-cyclopropylmethyl-4,5.alpha-
.-epoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide
[0115]
17(R)-4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17-methyl-6-oxo-1-
7-(2-phenylethyl)morphinanium-iodide
[0116] It has now been found that the compounds of the objective
invention (morphinan compounds and their quaternary salts
substituted in Position 14) represent effective opioid receptor
ligands and exhibit a high therapeutic usage potential as
analgesics, narcotics, as immunomodulators with immunostimulating
or immunosuppressive effects, as cancer therapeutics, inflammation
inhibitors, as antirheumatics, for the suppression of organ
rejection after transplants, as diuretics, anorectics, as agents
against diarrhoea, obstipation, ileus, pruritis, as anaesthetics or
as neuroprotective active substances.
[0117] The compounds stated in the claims are therefore potentially
usable for the treatment of acute and chronic pain, of functional
intestinal diseases, such as diarrhoea, abdominal pain,
obstipation, ileus, for the treatment of inflammatory intestinal
diseases, for the treatment of mammals, especially human beings,
for the treatment of the Raynaud syndrome, for the treatment of
complaints caused by vasoconstriction, for the treatment of
dysmenorrhoea, angina pectoris, cardiac infarction, emphysema,
bronchial spasms, chronic obstructive bronchitis, rheumatic
complaints, oedemas, nephrosis, nephritis in conjunction with
rheumatic diseases, for the treatment of tumours,
phaeochromocytome, the Addison disease, hepatic cirrhosis, chronic
inflammations of the small and large intestines and rectum, for the
treatment of pruritis, psoriasis, neurodermatitis, for addition
withdrawal from for example opioids, cocaine or alcohol, for the
treatment of overweight, or for the treatment of psychic diseases
such as dysphoria, depression or schizophrenia.
[0118] Surprisingly it was also found that the compounds of this
objective invention were not capable of overcoming the blood-brain
barrier or only to a slight extent, and therefore a special
significance could be attributed to them with regard to their use
as peripherally effective therapeutics, for example as medicaments
for the treatment of pain, for the treatment or prevention of
obstipation caused by analgesics, for the treatment or prevention
of postoperative ileus, postpartum ileus, for rheumatic therapy,
for suppressing organ rejection after transplants with mammals,
especially human beings, also for the treatment of erection
problems. The limited access to the central nervous system goes
with a very reduced side-effect rate, which is relevant to central
side effects, such as for example nausea, vomiting, sedation,
dizziness, confusion, respiratory depression and mania.
[0119] Production of the Compounds
[0120] The compounds according to this invention, which are
represented by the formula (I) or (Ia), can be obtained with the
aid of the following methods:
[0121] Starting from thebaine of the formula (II), 1
[0122] this compound is reacted with dialkylsulphates,
fluorosulphonic acid alkylesters, alkylsulphonic acid alkylesters,
arylsulphonic acid alkylesters, alkylhalogenides,
aralkylhalogenides, alkylsulphonic acid aralkylesters,
arylsulphonic acid aralkylesters, arylalkenylhalogenides,
chloroformic acid esters or similar compounds in solvents such as
tetrahydrofuran, 1,2-dimethoxyethane, diethylether or similar
compounds in the presence of a strong base such as n-butyllithium,
lithium diethylamide, lithium diisopropylamide or similar compounds
at low temperatures (-20.degree. C. to -800C) (see Boden et al., J.
Org. Chem., Vol 47, pp. 1347-1349, 1982; Schmidhammer et al., Helv.
Chim. Acta, Vol. 71, pp. 642-647, 1988; Gates et al., J. Org.
Chem., Vol. 54, pp. 972-975, 1984) to obtain the compounds of
formula (III), where R.sub.3 is C.sub.1-C.sub.6-alkyl;
C.sub.2-C.sub.6-alkenyl; C.sub.7-C.sub.16-arylalky- l, where aryl
is C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl; alkoxyalkyl, where alkoxy
is C.sub.1-C.sub.6-alkoxy and alkyl is C.sub.1-C.sub.6-alkyl;
CO.sub.2(C.sub.1-C.sub.6-alkyl); CO.sub.2H; CH.sub.2OH. 2
[0123] The compounds of formula (III) or thebaine (formula (II))
can be converted into the corresponding 14-hydroxycodeinones of
formula (IV), 3
[0124] where R.sub.3 represents hydrogen, C.sub.1-C.sub.6-alkyl;
C.sub.2-C.sub.6-alkenyl; C.sub.7-C.sub.16-arylalkyl, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl; alkoxyalkyl, where alkoxy
is C.sub.1-C.sub.6-alkoxy and alkyl is C.sub.1-C.sub.6-alkyl;
CO.sub.2 (C.sub.1-C.sub.6-alkyl). This reaction is carried out with
performic acid (see H. Schmidhammer et al., Helv. Chim. Acta, Vol.
71, 1801-1804, 1988), m-chloroperbenzoic acid or similar at
temperatures between 0.degree. C. and 60.degree. C. The preferred
method is the reaction with performic acid at 0.degree. C. to
40.degree. C.
[0125] These 14-hydroxycodeinones of formula (IV) are reacted in
sequence with dialkylsulphates, alkylhalogenides,
alkenylhalogenides, alkinylhalogenides, arylalkylhalogenides,
arylalkenylhalogenides, arylalkinylhalogenides or chloroformates in
solvents such as N,N-dimethylformamide (DMF) or tetrahydrofuran
(THF) in the presence of a strong base such as sodium hydride,
potassium hydride or sodium amide in order to obtain the compounds
of formula (V), 4
[0126] where R.sub.3 is defined as above; and R.sub.2 represents
C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.4-C.sub.16-cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10-cycloalkyl and alkyl is
C.sub.1-C.sub.6-alkyl; C.sub.5-C.sub.16-cycloalkylalkenyl, where
cycloalkyl is C.sub.3-C.sub.10-cycloalkyl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.5-C.sub.16-cycloalkylalkinyl, where
cycloalkyl is C.sub.3-C.sub.10-cycloalkyl and alkinyl is
C.sub.2-C.sub.6-alkinyl; C.sub.7-C.sub.16-arylalkyl, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinyl is C.sub.2-C.sub.6-alkinyl; C.sub.1-C.sub.6-alkanoyl;
C.sub.3-C.sub.6-alkenoyl; C.sub.3-C.sub.6-alkinoyl;
C.sub.7-C.sub.16-arylalkanoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkanoyl is C.sub.1-C.sub.6-alkanoyl;
C.sub.9-C.sub.16-arylalkenoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenoyl is C.sub.3-C.sub.6-alkenoyl;
C.sub.9-C.sub.16-arylalkinoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinoyl is C.sub.3-C.sub.6-alkinoyl.
[0127] These compounds are then reduced to compounds of formula
(VI) using catalytic hydrogenation via a catalyst such as Pd/C,
PdO, Pd/Al.sub.2O.sub.3, Pt/C, PtO.sub.2, Pt/Al.sub.2O.sub.3 or
similar in solvents such as alcohols, alcohol/water mixtures,
glacial acetic acid or similar, 5
[0128] where R.sub.2 and R.sub.3 are defined as above.
[0129] The following N-demethylation is carried out with
chloroformates or bromocyanogens in solvents such as
1,2-dichloromethane, chloroform or similar, and compounds of the
formula (VII) are obtained, 6
[0130] where R.sub.1 represents CO.sub.2CH(Cl)CH.sub.3,
CO.sub.2CH.dbd.CH.sub.2, CO.sub.2CH.sub.2CCl.sub.3,
CO.sub.2CH.sub.2CH.sub.3, CO.sub.2Ph, CN or similar; and R.sub.2
and R.sub.3 are defined as above.
[0131] The carbamates of formula (VII) are split either by reflux
heating in alcohols (in the case of 1-chloroethylcarbamates) or by
the addition of hydrogen halogenides or halogens followed by reflux
x heating in alcohols (in the case of vinylcarbamates) and the
cyanamides of formula (VII) are obtained by acid or alkali
hydrolysis, whereby N-Nor compounds of formula (VIII) are obtained,
7
[0132] in which R.sub.2 and R.sub.3 are defined as above.
[0133] The N-alkylation of the compounds of formula (VIII) is
achieved with alkylhalogenides, dialkylsulphates,
alkenylhalogenides, alkinylhalogenides, cycloalkylalkylhalogenides,
cycloalkenylalkylhalogeni- des, arylalkyl halogenides, arylalkenyl
halogenides, arylalkinyl halogenides or similar in solvents such as
dichloromethane, chloroform or N,N-dimethylformamide in the
presence of a base such as sodium bicarbonate, potassium carbonate,
triethylamine or similar and therefore compounds of the formula
(IX) are obtained, 8
[0134] where R.sub.2 and R.sub.3 are defined as above; and R.sub.1
represents C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.4-C.sub.16-cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10-cycloalkyl and alkyl is
C.sub.1-C.sub.6-alkyl; C.sub.5-C.sub.16-cycloalkylalkenyl, where
cycloalkyl is C.sub.3-C.sub.10-cycloalkyl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.5-C.sub.16-cycloalkylalkinyl, where
cycloalkyl is C.sub.3-C.sub.10-cycloalkyl and alkinyl is
C.sub.2-C.sub.6-alkinyl; C.sub.7-C.sub.16-arylalkyl, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, whereby aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinyl is C.sub.2-C.sub.6-alkinyl.
[0135] Ether splitting of these compounds of the formula (IX) with
boron tribromide (in a solvent such as dichloromethane or
chloroform) at 0.degree. C., 48% hydrobromic acid (reflux heating),
with sodium alkanthiolates (in a solvent such as
N,N-dimethylformamide) or with other generally well-known ether
splitting reagents, gives phenolic compounds of the formula (X),
9
[0136] in which R.sub.1, R.sub.2 and R.sub.3 are defined as
above.
[0137] The 3-O alkylation of the compounds of formula (X) are
achieved with alkylhalogenides, dialkylsulphates,
alkenylhalogenides, alkinylhalogenides, cycloalkylalkylhalogenides,
cycloalkylalkenylhalogeni- des, arylalkylhalogenides,
arylalkenylhalogenides, arylalkinylhalogenides or similar in
solvents such as dichloromethane, chloroform, acetone or
N,N-dimethylformamide in the presence of a base such as sodium
bicarbonate, potassium carbonate, triethylamine or similar; 3-O
acylation of the compounds of the formula (X) is achieved with
carboxylic acid halogenides, carboxylic acid anhydrides or similar
in solvents such as dichloromethane, chloroform, acetone,
N,N-dimethylformamide, pyridine or similar and therefore compounds
of the formula (XI) are obtained; 10
[0138] where R.sub.1, R.sub.2 and R.sub.3 are as defined above;
R.sub.4 represents C.sub.1-C.sub.6-alkyl; C.sub.2-C.sub.6-alkenyl;
C.sub.2-C.sub.6-alkinyl; C.sub.4-C.sub.16-cycloalkylalkyl, where
cycloalkyl is C.sub.3-C.sub.10-Cycloalkyl and alkyl is
C.sub.1-C.sub.6-alkyl; C.sub.5-C.sub.16-cycloalkylalkenyl, where
cycloalkyl is C.sub.3-C.sub.10-cycloalkyl and alkenyl is
C.sub.2-C.sub.6-alkenyl; C.sub.5-C.sub.16-cycloalkylalkinyl, where
cycloalkyl is C.sub.3-C.sub.10-cycloalkyl and alkinyl is
C.sub.2-C.sub.6-alkinyl; C.sub.7-C.sub.16-arylalkyl, where aryl is
C.sub.6-C.sub.10-aryl and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinyl is C.sub.2-C.sub.6-alkinyl; C.sub.1-C.sub.6-alkanoyl;
C.sub.3-C.sub.6-alkenoyl; C.sub.3-C.sub.6-alkinoyl;
C.sub.7-C.sub.16-arylalkanoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkanoyl is C.sub.1-C.sub.6-alkyl;
C.sub.9-C.sub.16-arylalkenoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkenoyl is C.sub.3-C.sub.6-alkenoyl;
C.sub.9-C.sub.16-arylalkinoyl, where aryl is C.sub.6-C.sub.10-aryl
and alkinoyl is C.sub.3-C.sub.6-alkinoyl.
[0139] An alternative path starts with compounds of formula (XII),
in which R.sub.1 and R.sub.3 are defined as above (see Weiss et
al., J. Amer. Cheri. Soc., Vol. 77, p. 5891, 1955; Iijima et al.,
J. Med. Chem., Vol. 21, pp. 398400, 1978; Coop et-al., J. Org.
Chem., Vol. 63, pp. 43924396, 1998; Schmidhammer et al., Helv.
Chim. Acta, Vol. 71, pp. 1801-1804, 1988; Schmidhammer et al.,
Helv. Chim. Acta, Vol. 73, pp. 1986-1990, 1990). 11
[0140] The ketones of formula (XII) are reacted in the presence of
methane sulphonic acid or similar with ethylene glycol (as reagent
and solvent) to form the compounds of formula (XIII), 12
[0141] in which R.sub.1 and R.sub.3 are defined as above.
[0142] The introduction of a protective group such as for example
benzyl, trityl or silyl to the 3-hydroxy group is achieved by
3-O-benzylation, 3-O-tritylation or 3-O-silylation of the compounds
of the formula (XIII) with benzyl halogenides, trityl halogenides,
trialkyl halogen silanes in solvents such as dichloromethane,
chloroform, acetone or N,N-dimethylformamide in the presence of a
base such as sodium bicarbonate, potassium carbonate, triethylamine
or similar or by means of phase transfer catalysis and therefore
compounds of the formula (XIV) are obtained, 13
[0143] where R.sub.1 and R.sub.3 are defined as above; R.sub.4 is a
protective group such as benzyl, trityl,
tri-(C.sub.1-C.sub.6-alkyl)silyl or
tris-(C.sub.7-C.sub.6-arylalkyl)silyl or another easily split off
protective group.
[0144] These 14-hydroxy compounds are following reacted with
dialkylsulphates, alkylhalogenides, alkenylhalogenides,
alkinylhalogenides, arylalkylhalogenides, arylalkenylhalogenides,
arylalkinylhalogenides or chloroformates in solvents such as
N,N-dimethylformamide (DMF) or tetrahydrofuran (THF) in the
presence of a strong base such as sodium hydride, potassium hydride
or sodium amide to obtain the compounds of formula (XV), 14
[0145] where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined as
above. If R.sub.2 and R.sub.4 are benzyl, compounds of the formula
(XIII) can be directly reacted with two equivalents of benzyl
bromide in DMF in the presence of sodium hydride, forming
3,14-O-dibenzyl derivatives of the formula (XV), in which R.sub.2
and R.sub.4 are benzyl and R.sub.1 and R.sub.3 are defined as
above.
[0146] The acidic splitting of the 3-O protective group and the
ketal function of the compounds with the formula (XV) is carried
out in one step with an acid such as hydrochloric acid in methanol,
tetrafluoroboric acid in dichloromethane or trifluoroacetic acid
and compounds of the formula (X) are obtained (see 1 st route).
[0147] Alternatively to this, if R.sub.4 in compounds of formula
(XV) is benzyl, one can, through hydrogenolysis of the 3-O-benzyl
binding with hydrogen gas in the presence of a catalyst such as
Pd/C, PdO, Pd/Al.sub.2O.sub.3, Pt/C, PtO.sub.2, Pt/Al.sub.2O.sub.3
or similar in solvents such as alcohols, alcohol/water mixtures,
glacial acetic acid or similar compounds, followed by acid
hydrolysis of the ketal function in Position 6 with, for example,
methanol and concentrated hydrochloric acid obtain compounds of the
formula (X) (see 1.sup.st route). 15
[0148] in which R.sub.1, R.sub.2 and R.sub.3 are defined as
above.
[0149] The compounds of the formula (X) are reacted according to
the first scheme to form compounds according to the invention of
formula (1).
[0150] Compounds of the formula (I) can be converted to compounds
of the formula (Ia), in which R.sub.5 is hydrogen; hydroxy;
C.sub.1-C.sub.6-alkyloxy; C.sub.2-C.sub.10-alkyloxyalkoxy, where
alkyloxy is C.sub.1-C.sub.4 and alkoxy is C.sub.1-C.sub.6-alkyloxy
C.sub.1-C.sub.6-alkyloxy; C.sub.2-C.sub.6-alkenyloxy;
C.sub.2-C.sub.6-alkinyloxy; C.sub.4-C.sub.16-Cycloalkylalkyloxy,
where cycloalkyl is C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-Cycloalkylalkenyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-cycloal- kylalkinyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalkyloxy, where aryl is C.sub.6-C.sub.10-aryl
and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.1-C.sub.6-alkanoyloxy; C.sub.7-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.1-C.sub.6-alkylanoyloxy, as follows:
[0151] Compounds of the formula (I) can be converted to compounds
of the formula (XVI) in that first a reductive opening of the
4,5-ether bridge is carried out with for example zinc in an
alcohol, such as methanol or ethanol (preferred temperature
40-80.degree. C.) in the presence of ammonium chloride. 16
[0152] (R.sub.1, R.sub.2 and R.sub.3 are as stated above; for
R.sub.4 see formula (I))
[0153] Compounds of the formula (XVI) can be converted to the
compounds according to the invention of formula (Ia) in which
R.sub.5 is C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.10-alkyloxyalkoxy, where alkyloxy is C.sub.1-C.sub.4
and alkoxy is C.sub.1-C.sub.6-alkyloxy C.sub.1-C.sub.6-alkyloxy;
C.sub.2-C.sub.6-alkenyloxy; C.sub.2-C.sub.6-alkinyloxy;
C.sub.4-C.sub.16-cycloalkylalkyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkyl is C.sub.1-C.sub.6;
C.sub.5-C.sub.16-cycloalkylalkenyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkenyl is C.sub.2-C.sub.6;
C.sub.5-C.sub.16-cycloal- kylalkinyloxy, where cycloalkyl is
C.sub.3-C.sub.10 and alkinyl is C.sub.2-C.sub.6;
C.sub.7-C.sub.16-arylalkyloxy, where aryl is C.sub.6-C.sub.10-aryl
and alkyl is C.sub.1-C.sub.6-alkyl;
C.sub.8-C.sub.16-arylalkenyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkenyl is C.sub.2-C.sub.6-alkenyl;
C.sub.8-C.sub.16-arylalkinyloxy, where aryl is
C.sub.6-C.sub.10-aryl and alkinyl is C.sub.2-C.sub.6-alkinyl;
C.sub.1-C.sub.6-alkanoyloxy; C.sub.7-C.sub.16-arylalkanoyloxy,
where aryl is C.sub.6-C.sub.10-aryl and alkanoyloxy is
C.sub.1-C.sub.6-alkylanoyloxy, and R.sub.1, R.sub.2 and R.sub.3 are
as stated above and R.sub.4 is stated in formula (I), through
alkylation or acylation according to generally accepted methods.
Compounds of the formula (XVI) can be converted to the compounds
according to the invention of formula (I) in which R.sub.5 is
hydrogen by removing the hydroxyl group in Position 4. This can
occur for example by the formation of the corresponding
phenyltetrazolylether in the presence of a base such as potassium
carbonate in a solution such as N,N-dimethylformamide and then
catalytic hydration of the phenyltetrazolylether, for example over
a catalyst such as Pd/C in an alcohol or glacial acetic acid at
temperatures between 20.degree. C. and 100.degree. C. (see for
example Schmidhammer et al. J. Med. Chem. 1984, 27, pp.
1575-1579).
[0154] Compounds of the formula (I) or (Ia) can be converted into
quaternary ammonium salts of the formula (IA) or (IAa) by
alkylation with an appropriate alkyl halogenide or another
alkylation agent in solvents such as N,N-dimethylformamide,
acetonitrile, acetone, alcohols, tetrahydrofuran, ether, ethyl
acetate, etc. or in a solvent mixture. The arrangement of the
incoming substituents is preferably axial (see M. A. Iorio et al.,
Eur. J. Med. Chem.- Chim. Ther. 1984,19,301-303).
[0155] The following examples describe the production of the
compounds according to the invention in detail.
EXAMPLE 1
Synthesis of
17-allyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropylo-
xy)morphinan-6-one Hypochloride (compound 1 HCl (Verbindung 1))
[0156] 17
[0157] NaH (0.97 g, 40.4 mmol) (obtained from 1.62 g 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of 14-hydroxycodeinone (Iijima et al. J. Med. Chem. 1978,
21, pg. 398) (3.00 g, 9.6 mmol) in 100 ml of water-free
N,N-dimethylformamide und N.sub.2 at 0.degree. C. (bath
temperature) under stirring. After 20 min. cinnamyl bromide (2.28
g, 11.6 mmol) is added and the mixture then stirred for 30 min. at
0.degree. C. (bath temperature), then stirred further with reducing
cooling for 4.5 hours. To terminate the reaction pieces of ice were
added until no more hydrogen was produced and the mixture made up
to 100 ml of water. The precipitated product was extracted with
dichloromethane (3.times.100 ml), the combined organic phases
washed with 250 ml saturated sodium chloride solution and dried
over sodium sulphate. After removal of the solvent under reduced
pressure a brown oil was obtained. This was crystallised from
methanol. Yield: 2.49 g (60%) of colourless crystals of
14-cinnamyloxycodeinone (=7,8-dihydro-4,5.alpha.-e-
xpoxy-3-methoxy-17-methyl-14.beta.{[(E)-3-phenylprop-2-enyl]oxy}morphinan--
6-one. Fp. 216-219.degree. C.; .sup.1H-NMR (DMSO-d.sub.6, .delta.
in ppm): .delta. 7.46-7.17 (m, 5 arom. H), 7.19 (d, 1 olef. H,
CH-8, J=10.2 Hz), 6.74 (d, 1 arom. H, J=8.3 Hz), 6.65 (d, 1 arom.
H, J=8.3 Hz), 6.51-6.59 (m, 1 olef. H, --CH.dbd.CH-Ph), 6.34
(trans) and 6.26 (cis) (2 ps-d, 1 olef. H, --CH.dbd.CH-Ph), 6.18
(d, 1 olef. H, CH-7, J=10.2 Hz), 4.85 (s, CH-5), 4.26 and 4.11 (2
dxdxd, 2H, C-14-OCH.sub.2--), 3.73 (s, CH.sub.3O), 2,36 (s,
CH.sub.3N).
[0158] A mixture of 14-cinnamyloxycodeinone (6.27 g, 14.6 mmol) and
0.32 g Pd/C (10%) in 200 ml glacial acetic acid was hydrogenated
for 3 h at 30 psi and room temperature. The catalyst was filtered
off and washed with 50 ml of glacial acetic acid. The filtrate was
evaporated down, water added and alkalised with concentrated
ammonia and extracted with dichloromethane (3.times.50 ml). The
combined organic phases were washed with saturated sodium chloride
solution (3.times.70 ml), dried over sodium sulphate and evaporated
down. The oily residue (6.27 g) was crystallised from methanol.
Yield: 4.93 g (78%) of colourless crystals of
4.5.alpha.-epoxy-3-methoxy-17-methyl-14.beta.-(3-phenylpropyloxy)morphina-
n-6-one (=14-O-(3-phenylpropyl)oxycodon). Fp. 119-121.degree. C.;
.sup.1H-NMR (CDCl.sub.3, .delta. in ppm): .delta. 7.35-7.15 (m, 5
arom. H), 6.68 (d, 1 arom. H, J=8.2 Hz), 6.60 (d, 1 arom. H, J=8.2
Hz), 4.63 (s, CH-5), 3.89 (s, CH.sub.3O), 2.34 (s, CH.sub.3N).
[0159] A mixture of
4,5.alpha.-epoxy-3-methoxy-17-methyl-14.beta.-(3-pheny-
lpropyloxy)morphinan-6-one (=14.beta.-(3-phenylpropyl)oxycodon)
(5.00 g, 11.50 mmol), sodium bicarbonate (6.8 g, 80.91 mmol) and
chloroformic acid-1-chloroethylester (7.5 ml, 67.5 mmol) in 30 ml
1,2-dichloroethane was reflux heated with exclusion of moisture at
60.degree. C. (bath temperature) under stirring. After 17 h
filtration was carried out from the inorganic residue, washed with
dichloromethane and the filtrate evaporated down. The carbamate
produced was not isolated, but rather dissolved in 100 ml methanol
and reflux heated for one hour. The solution was evaporated down
and the evaporation residue, a colourless foamy resin (6.08 g) was
crystallised out of acetone. Yield: 4.91 g (93%)
4,5-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy)morphinan-6-one
hydrochloride as colourless crystals. Fp. 215-218.degree. C.; IR
(KBr): 1730 (CO) cm.sup.-1; .sup.1H-NMR (CDCl.sub.3): .delta. 10.55
and 8.67 (2 s, wide, 2H, .sup.+NH.sub.2), 7.28-7.10 (m, 5 arom. H),
6.75 (d, 1 arom. H, J=8.2 Hz), 6.71 (d, 1 arom. H, J=8.2 Hz), 4.41
(s, C5-H), 3.89 (s, CH.sub.3O); El-MS: m/z 419 (M.sup.+).
[0160] A mixture of
4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy-
)morphinan-6-one hydrochloride (2.00 g, 4.76 mmol), potassium
carbonate (4.00 g, 28.9 mmol) and allyl bromide (0.56 ml, 6.62
mmol) in water-free N,N-dimethylformamide (15 ml) was stirred for 7
h under exclusion of moisture and under nitrogen at 80.degree. C.
(bath temperature). After filtration from the inorganic residue,
which was washed three times each time with 50 ml dichloromethane,
the filtrate was evaporated down under reduced pressure. The oily
residue was dissolved in 300 ml dichloromethane, washed with water
(3.times.200 ml) and saturated sodium chloride solution
(4.times.200 ml), dried over sodium sulphate and evaporated down.
The obtained brown oil was purified by column chromatography
(silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:2:0.5), the
oily evaporation residue dissolved in 50 ml ether and precipitated
by the addition of etherial HCl up to the acid reaction. The
product was recrystallised from isopropanol. Yield: 1.50 g (69%) of
the compound 1.HCl as colourless crystals. Fp. 129-1300.degree. C.;
MS (Cl): 460 (M.sup.++1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1;
.sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): .delta. 8.98 (s, wide,
HN.sup.+), 7.30-7.18 (m, 5 arom. H), 6.89 (d, 1 arom. H, J=8.4 Hz),
6.83 (d, 1 arom. H, J=8.4 Hz), 5.89 (m, 1 olef. H), 5.69 (m, 2
olef. H), 4.94 (s, CH-5), 3.81 (s, CH.sub.3O).
EXAMPLE 2
Synthesis of
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-ph-
enylpropyloxy)morphinan-6-one Hydrochloride (Compound 2.HCl).
[0161] 18
[0162] A mixture of
4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy-
)morphinan-6-one hydrochloride (500 mg, 1.19 mmol), potassium
carbonate (1.00 g, 7.24 mmol) and cyclobutylmethylbromide (0.6 ml,
5.43 mmol) in water-free N,N-dimethylformamide (7 ml) was stirred
for 24 h under exclusion of moisture and under nitrogen at
80.degree. C. (bath temperature). After filtration from the
inorganic residue, which was washed three times each time with 20
ml dichloromethane, the filtrate was evaporated down under reduced
pressure. The oily residue was dissolved in 100 ml dichloromethane,
washed with water (3.times.100 ml) and saturated sodium chloride
solution (4.times.100 ml), dried over sodium sulphate and
evaporated down. The evaporation residue (520 mg of brown oil) was
purified by column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc- . NH.sub.4OH 250:2:0.5), the oily
evaporation residue dissolved in 10 ml ether and precipitated by
the addition of etherial HCl. Yield: 0.40 g (69%) of the compound
2.HCl as colourless crystals. Fp. 128-133.degree. C.; MS (Cl): 488
(M.sup.++1); IR (KBr): 1728 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, .delta. in ppm): .delta. 8.48 (s, wide, HN.sup.+),
7.30-7.15 (m, 5 arom. H), 6.87 (d, 1 arom. H, J=8.4 Hz), 6.77 (d, 1
arom. H, J=8.4 Hz), 4.93 (s, CH-5), 3.81 (s, CH.sub.3O).
EXAMPLE 3
Synthesis of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-p-
henylpropyloxy)morphinan-6-one Hydrochloride (Compound 3.HCl).
[0163] 19
[0164] A mixture of
4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy-
)morphinan-6-one hydrochloride (1.5 g, 3.57 mmol), potassium
carbonate (3.00 g, 21.7 mmol) and cyclopropylmethylbromide (1.0 ml,
6.62 mmol) in water-free N,N-dimethylformamide (10 ml) was stirred
for 4 h under exclusion of moisture and under nitrogen at
80.degree. C. (bath temperature). After filtration from the
inorganic residue, which was washed three times each time with 10
ml dichloromethane, the filtrate was evaporated down under reduced
pressure. The oily residue was dissolved in 50 ml dichloromethane,
washed with water (3.times.50 ml) and saturated sodium chloride
solution (4.times.50 ml), dried over sodium sulphate and evaporated
down. The evaporation residue (1.42 g of yellow oil) was purified
by column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc- .
NH.sub.4OH 250:2:0.5), the oily evaporation residue dissolved in 50
ml ether and precipitated by the addition of etherial HCl up to the
acidic reaction.
[0165] Yield: 0.60 g (53%) of the compound 3.HCl as colourless
crystals. Fp. 130-133.degree. C.; MS (EI): 473 (M.sup.+); IR (KBr):
1725 (C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in
ppm): .delta. 8.30 (s, wide, HN.sup.+), 7.31-7.18(m, 5 arom. H),
6.88 (d, 1 arom. H, J=8.4 Hz), 6.78 (d, 1 arom. H, J=8.4 Hz), 4.96
(s, CH-5), 3.81 (s, CH.sub.3O), 0.80-0-40 (m, 5 cyclopropyl H).
EXAMPLE 4
Synthesis of
4,5.alpha.-epoxy-3-methoxy-17-(2-phenylethlyl)-14.beta.-(3-ph-
enylpropyloxy)morphinan-6-one Hydrochloride (Compound 4.HCl).
[0166] 20
[0167] A mixture of
4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy-
)morphinan-6-one hydrochloride (1.0 g, 2.38 mmol), potassium
carbonate (3.00 g, 21.7 mmol) and 2-phenylethylbromide (1.19 ml,
8.8 mmol) in water-free N,N-dimethylformamide (10 ml) was stirred
for 12 h under exclusion of moisture and under nitrogen at
80.degree. C. (bath temperature). After filtration from the
inorganic residue, which was washed three times each time with 50
ml dichloromethane, the filtrate was evaporated down under reduced
pressure. The oily residue was dissolved in 300 ml dichloromethane,
washed with water (3.times.200 ml) and saturated sodium chloride
solution (4.times.200 ml), dried over sodium sulphate and
evaporated down. The evaporation residue (960 mg of brown oil) was
purified by column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc- . NH.sub.4OH 250:2:0.5), the oily
evaporation residue dissolved in 50 ml ether and precipitated by
the addition of etherial HCl up to the acidic reaction. Yield: 0.45
g (36%) of the compound 4.HCl as colourless crystals. Fp.
128-130.degree. C.; MS (Cl): 524 (M.sup.++1); IR (KBr): 1726
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm):
.delta. 8.84 (s, wide, HN.sup.+), 7.39-7.17 (m, 10 arom. H), 6.89
(d, 1 arom. H, J=8.2 Hz), 6.79 (d, 1 arom. H, J=8.2 Hz), 4.95 (s,
CH-5), 3.81 (s, CH.sub.3O).
EXAMPLE 5
Synthesis of
4,5.alpha.-epoxy-17-[2-((R,S)-tetrahydrofuran-2-yl)methyl]-3--
methoxy-14.beta.-(3-phenylpropyloxy)morphinan-6-one Hydrochloride
(Compound 5.HCl).
[0168] 21
[0169] A mixture of
4,5.alpha.-epoxy-3-methoxy-14.beta.-(3-phenylpropyloxy-
)morphinan-6-one hydrochloride (1.0 g, 2.38 mmol), potassium
carbonate (0.6 g, 4.34 mmol) and tetrahydrofurfurylchloride (0.5
ml, 4.59 mmol) in water-free N,N-dimethylformamide (10 ml) was
stirred for 15 h under exclusion of moisture and under nitrogen at
150.degree. C. (bath temperature). The mixture was cooled, 50 ml of
water added to it and it was extracted with dichloromethane
(3.times.30 ml). The combined organic phases were washed with water
(3.times.60 ml) and saturated sodium chloride solution (4.times.100
ml), dried over sodium sulphate and evaporated down. The residue
(1.3 g of brown oil) was purified by column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH
250:1.5:0.5->250:3.5:0.5), the oily evaporation residue
dissolved in 50 ml ether and precipitated by the addition of
etherial HCl up to the acidic reaction. Yield: 0.57 g (48%) of the
compound 5.HCl as colourless crystals. Fp. 121-123.degree. C.; MS
(Cl): 504 (M.sup.++1); IR (KBr): 1727 (C.dbd.O) cm.sup.1;
.sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): .delta. 8.18 and 7.64
(s, wide, HN.sup.+), 7.08-6.96 (m, 5 arom. H), 6.88-6.52 (d, 2
arom. H), 4.75 and 4.73 (2s, CH-5), 3.79 and 3.81 (2s,
CH.sub.3O).
EXAMPLE 6
Synthesis of
17-allyl-4,5.alpha.-epoxy-3-hydroxy-140-(3-phenylpropyloxy)mo-
rphinan-6-one Hydrochloride (Compound 6.HCl).
[0170] 22
[0171] A solution of compound 1.HCl (4.50 g, 3.02 mmol) in 5 ml 48%
HBr was reflux heated for 15 min. Then the solution was cooled,
poured onto approx. 50 ml of ice, alkalised with conc. NH.sub.4OH
and extracted with dichloromethane (3.times.80 ml). The combined
organic phases were washed with saturated sodium chloride solution
(4.times.50 ml), dried over sodium sulphate and evaporated down.
The residue (1.3 g of brown oil) was purified by column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc- .
NH.sub.4OH 250:2:0.5), the oily evaporation residue dissolved in 50
ml ether and precipitated by the addition of etherial HCl up to the
acidic reaction. Yield: 0.5 g (34%) of the compound 6.HCl as
colourless crystals. Fp. >250.degree. C. (decomp.); MS (Cl): 446
(M.sup.++1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, .delta. in ppm): g 9.51 (s, OH), 8.81 (s, wide,
HN.sup.+), 7.30-7.16 (m, 5 arom. H), 6.71 (d, 1 arom. H, J=8.0 Hz),
6.64 (d, 1 arom. H, J=8.0 Hz), 5.92 (m, 1 olef. H), 5.61 (m, 2
olef. H), 4.87 (s, CH-5).
EXAMPLE 7
Synthesis of
17-cyclobutylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-ph-
enylpropyloxy)morphinan-6-one Hydrochloride (Compound 7.HCl).
[0172] 23
[0173] A solution of compound 2.HCl (336 mg, 0.64 mmol) in 5 ml 48%
HBr was reflux heated for 15 min. Then the solution was cooled,
poured onto approx. 50 ml of ice, alkalised with conc. NH.sub.4OH
and extracted with dichloromethane (3.times.50 ml). The combined
organic phases were washed with saturated sodium chloride solution
(4.times.50 ml), dried over sodium sulphate and evaporated down.
The residue (210 mg of brown foamy resin) was purified by column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH
250:2:0.5), the oily evaporation residue dissolved in 50 ml ether
and precipitated by the addition of etherial HCl up to the acidic
reaction. Yield: 79 mg (34%) of the compound 7.HCl as colourless
crystals. Fp. >227.degree. C. (decomp.); MS (Cl): 474
(M.sup.++1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, .delta. in ppm): .delta. 9.51 (s, OH), 8.30 (s,
wide, HN.sup.+), 7.29-7.18 (m, 5 arom. H), 6.70 (d, 1 arom. H,
J=8.4 Hz), 6.63 (d, 1 arom. H, J=8.4 Hz), 4.86 (s, CH-0.5).
EXAMPLE 8
Synthesis of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-p-
henylpropyloxy)morphinan-6-one Hydrochloride (Compound 8.HCl).
[0174] 24
[0175] A solution of compound 3.HCl (600 mg, 1.26 mmol) in 5 ml 48%
HBr was reflux heated for 12 min. Then the solution was cooled,
poured onto approx. 50 ml of ice, alkalised with conc. NH.sub.4OH
and extracted with dichloromethane (3.times.50 ml). The combined
organic phases were washed with saturated sodium chloride solution
(4.times.50 ml), dried over sodium sulphate and evaporated down.
The brown oil obtained was purified by column chromatography
(silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:2:0.5), the
oily evaporation residue dissolved in 50 ml ether and precipitated
by the addition of etherial HCl up to the acidic reaction.
Recrystallisation out of isopropanol gave 206 mg (34%) of the pure
compound 8.HCl as colourless crystals. Fp. 175-178.degree. C.; MS
(Cl): 460 (M.sup.++1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1;
.sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): .delta. 9.52 (s, OH),
8.20 (s, wide, HN.sup.+), 7.30-7.18 (m, 5 arom. H), 6.71 (d, 1
arom. H, J=8.0 Hz), 6.64 (d, 1 arom. H, J=8.0 Hz), 4.89(s,
CH-5).
EXAMPLE 9
Synthesis of
4,5.alpha.-epoxy-3-hydroxy-17-(2-phenylethyl)-14.beta.-(3-phe-
nylpropyloxy)morphinan-6-one hydrochloride (compound 9.HCl).
[0176] 25
[0177] A solution of compound 4.HCl (1.79 g, 3.2 mmol) in 5 ml 48%
HBr was reflux heated for 15 min. Then the solution was cooled,
poured onto approx. 50 ml of ice, alkalised with conc. NH.sub.4OH
and extracted with dichloromethane (3.times.60 ml). The combined
organic phases were washed with saturated sodium chloride solution
(4.times.60 ml), dried over sodium sulphate and evaporated down.
The brown oil obtained (1.02 g) was purified by column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/ conc. NH.sub.4OH
250:2:0.5), the oily evaporation residue dissolved in 50 ml ether
and precipitated by the addition of etherial HCl up to the acidic
reaction. Yield: 247 mg (15%) of the pure compound 9.HCl as
colourless crystals. Fp. >218.degree. C. (decomp.); MS (Cl): 510
(M.sup.++1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, .delta. in ppm): .delta. 9.51 (s, OH), 8.84 (s,
wide, HN.sup.+), 7.39-7.17 (m, 10 arom. H), 6.72 (d, 1 arom. H,
J=8.4 Hz), 6.66 (d, 1 arom. H, J=8.4 Hz), 4.87 (s, CH-5).
EXAMPLE 10
Synthesis of
4,5.alpha.-epoxy-17-[2-((R,S)-tetrahydrofuran-2-yl)methyl]-3--
hydroxy-14.beta.-(3-phenylpropyloxy)morphinan-6-one Hydrochloride
(Compound 10.HCl).
[0178] 26
[0179] A solution of compound 5.HCl (600 mg, 1.11 mmol) in 5 ml
48%. HBr was reflux heated for 15 min. Then the solution was
cooled, poured onto approx. 50 ml of ice, alkalised with conc.
NH.sub.4OH and extracted with dichloromethane (3.times.60 ml). The
combined organic phases were washed with saturated sodium chloride
solution (4.times.60 ml), dried over sodium sulphate and evaporated
down. The brown oil obtained (0.52 g) was purified by column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc- .
NH.sub.4OH 250:2:0.5), the oily evaporation residue dissolved in 50
ml ether and precipitated by the addition of etherial HCl up to the
acidic reaction. Yield: 210 mg (36%) of the compound 10.HCl as
colourless crystals. Fp. 170-172.degree. C.; MS (Cl): 490
(M.sup.++1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, .delta. in ppm): .delta. 9.45 (s, OH), 8.45 and 7.85
(s, wide, HN.sup.+), 7.30-7.21 (m, 5 arom. H), 6.70-6.65 (m, 2
arom. H), 4.90 and 4.87 (2 s, CH-5).
EXAMPLE 11
Synthesis of
4,5.alpha.-epoxy-3-hydroxy-14.beta.-(3-phenylpropyloxyy-17-pr-
opylmorphinan-6-one Hydrochloride (Compound 11.HCl).
[0180] 27
[0181] A mixture of compound 6.HCl (308 mg, 0.64 mmol) and 35 mg
10% Pd/C catalyst in 50 ml methanol was hydrogenated for 3 h at 30
psi and room temperature. The catalyst was filtered off and washed
with 50 ml methanol. The filtrate was evaporated down. The
evaporation residue, a colourless foamy resin, was dissolved in 30
ml ether and precipitated as the hydrochloride by the addition of
etherial HCl up to the acid reaction. Yield: 295 mg (95%)
colourless crystals of the compound 11.HCl. Fp. 162-163.degree. C.;
MS (Cl): 460 (M.sup.++1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1;
.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): .delta. 9.51
(s, OH), 8.50 (s, wide, HN.sup.+), 7.30-7.18 (m, 5 arom. H), 6.75
(d, 1 arom. H, J=8.4 Hz), 6.64 (d, 1 arom. H, J=8.4 Hz), 4.86 (s,
CH-5), 0.94 (t, CH.sub.3CH.sub.2CH.sub.2, J=7 Hz).
EXAMPLE 12
Synthesis of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(2--
methylbenzyl)oxy]-morphinan-6-one Hydrochloride (Compound
12.HCl)
[0182] 28
[0183] A solution of tritylbromide (3.8 g, 11.86 mmol),
triethylamine (2.41 ml, 15.99 mmol), DMAP (14 mg, 0.21 mmol) and
17-cyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihydroxymorphinan-6-spi-
ro-2'-(1,3-dioxolane) (Schmidhammer et al., Heterocycles 1998, 49,
489497) (3.0 g, 7.78 mmol) in CH.sub.2Cl.sub.2 (80 ml) was reflux
heated for 24 h, cooled and washed with H.sub.2O (2.times.100 ml).
The combined organic phases were evaporated down and the residue
(7.11 g of yellow crystals) was recrystallised out of MeOH (15 ml).
Yield: 4.15 g (85%) of
17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-hydroxy-3-triphenylmethoxy-
morphinan-6-spiro-2'-(1,3-dioxolane). Fp. 203-205.degree. C.;
.sup.1H-NMR (CDCl.sub.3) .delta. 7.50-7.15 (m, 15 arom. H), 6.60
(d, 1 arom. H, J=8.2 Hz), 6.30 (d, 1 arom. H, J=8.2 Hz), 6.13 (s,
wide, OH), 4.37 (s, CH-5), 4.12-3.80 (m, 4H, OCH.sub.2CH.sub.2O);
Cl-MS: m/z 628 (M.sup.++1).
[0184] NaH (312 mg, 13.34 mmol) (obtained from 520 mg of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of
17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-hydroxy-3-trip-
henylmethoxymorphinan-6-spiro-2'-(1,3-dioxolane) (2.0 g, 3.18 mmol)
in water-free N,N-dimethylformamide (20 ml) under N.sub.2 at
0.degree. C. (bath temperature) under stirring. After 20 min.
2-methylbenzylbromide (0.64 ml, 5.4 mmol) was added and the
resulting mixture stirred for 20 h at room temperature. Excess NaH
was broken down by the addition of small pieces of ice and then the
mixture was diluted with H.sub.2O (80 ml) and extracted with
CH.sub.2Cl.sub.2 (1.times.40 ml, 2.times.30 ml). The combined
organic phases were washed with H.sub.2O (3.times.100 ml), dried
(Na.sub.2SO.sub.4) and evaporated down. The residue (1.8 g of
orange coloured oil) was purified using column chromatography
(silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:2:0.5). 480
mg of a yellow oil was obtained, which was crystallised out of
MeOH. Yield: 304 mg (13%) of pure
17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-[(2-methylbenzyl)oxy]-
-3-triphenylmethoxy)morphinan-6-spiro-2'-(1,3-dioxolane). Fp
180-182.degree. C.; .sup.1H-NMR (Me.sub.2SO-d.sub.6): .delta.
7.30-7.15 (m, 19 arom. H), 6.31 (d, 1 arom. H, J=8.2 Hz), 6.23 (d,
1 arom. H, J=8.2 Hz), 4.68 (d, 1H, OCH.sub.2Ar, J=10.2 Hz), 4.22
(d, 1H, OCH.sub.2Ar, J=10.2 Hz), 4.17 (s, CH-5), 4.05-3.50 (m, 4H,
OCH.sub.2CH.sub.2O), 2.33 (s, 3H, MePh); Cl-MS: m/z 733
(M.sup.++1).
[0185] A solution of
17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-[(2-me-
thylbenzyl)oxy]-3-triphenylmethoxy)morphinan-6-spiro-2'-(1,3-dioxolane)
(300 mg, 0.67 mmol) in MeOH (5 ml) and conc. HCl (0.5 ml) was
reflux heated for 10 h. After cooling with ice, the solution was
alkalised with conc. NH.sub.4OH and extracted with CH.sub.2Cl.sub.2
(1.times.30 ml, 2.times.20 ml). The combined organic phases were
washed with H.sub.2O, dried over Na.sub.2SO.sub.4 and evaporated
down. The residue (165 mg of yellow oil) was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH
250:2:0.5). 80 mg of a colourless oil was obtained, which was
dissolved in ether and precipitated as the hydrochloride by the
addition of etherial HCl up to the acidic reaction. Yield: 70 mg
(23%) of pure compound 12.HCl. Fp. 198-200.degree. C.; .sup.1H-NMR
(Me.sub.2SO-d.sub.6): .delta. 9.50 (s, OH), 8.60 (s, .sup.+NH),
7.67-7.22 (m, 4 arom. H), 6.74 (d, 1 arom. H, J=8 Hz), 6.69 (d, 1
arom. H, J=8 Hz), 5.16 (s, C-5H), 2.31 (s, 3H, MePh); Cl-MS: m/z
446 (M.sup.++1).
EXAMPLE 13
Synthesis of
14.beta.-[(2-chlorobenzyl)oxy]-17-(cyclopropylmethyl)-4,5.alp-
ha.-epoxy-3-hydroxymorphinan-6-one Hydrochloride (Compound
13.HCl).
[0186] 29
[0187] A mixture of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3,14.beta.-dihyd-
roxymorphinan-6-spiro-2'-(1,3-dioxolane) (Schmidhammer et al.
Heterocycles 1998, 49, 489497) (6.9 g, 17.9 mmol), K.sub.2CO.sub.3
(6.7 g, 48.48 mmol), benzylbromide (2.34 ml, 19.66 mmol) and
water-free N,N-dimethylformamide (70 ml) was stirred for 22 h under
N.sub.2 and at room temperature. The inorganic material was
filtered off and the filtrate evaporated down. The residue was
dissolved in CH.sub.2Cl.sub.2 (80 ml), washed with H.sub.2O
(7.times.50 ml), dried over Na.sub.2SO.sub.4 and evaporated down.
The residue (8.2 g of colourless crystals) was recrystallised out
of MeOH. Yield: 7.37 g (87%)
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-hydroxymorphin-
an-4-spiro-2'-(1,3-dioxolane). Fp. 130-131.degree. C.; .sup.1H-NMR
(CDCl.sub.3): .delta. 7.42-7.27 (m, 5 arom. H), 6.75 (d, 1 arom. H,
J=8.3 Hz), 6.54 (d, 1 arom. H, J=8.3 Hz), 5.17 (d, 1H, OCH.sub.2Ph,
J=11.7 Hz), 5.10 (d, 1H, OCH.sub.2Ph, J=11.7 Hz), 4.58 (s, C-5H),
4.19-3.73(m, 4H, OCH.sub.2CH.sub.2O); Cl-MS: m/z 476
(M.sup.++1).
[0188] A mixture of
3-(benzyloxy)-17-(cyclopropylmethyl)-4,5.alpha.-epoxy--
14.beta.-hydroxy-morphinan-6-spiro-2'-(1,3-dioxolane) (5.82 g, 12.2
mmol), NaH (1.47 g, 61.3 mmol; obtained from 2.45 g of a 60% NaH
dispersion in oil by washing with petroleum ether) and 100 ml
water-free N,N-dimethylformamide was stirred for 25 min. under
N.sub.2 at 0-5.degree. C. (bath temperature). 2-chlorobenzylbromide
(3.16 ml, 24.3 mmol) was added and the resulting mixture stirred
for 4 h (1 h at 0-5.degree. C., 3 h at room temperature). Excess
NaH was broken down by the addition of small pieces of ice, and
then the mixture diluted with H.sub.2O (350 ml) and extracted with
CH.sub.2Cl.sub.2 (1.times.250 ml, 3.times.100 ml). The combined
organic phases were washed with H.sub.2O (3.times.100 ml) and
saturated sodium chloride solution (2.times.50 ml), dried
(Na.sub.2SO.sub.4), and evaporated down. The residue (8.3 g of
yellowish oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:4:0.5). 4.75 g
(65%) of pure
3-(benzyloxy)-140-[(2-chlorobenzyl)oxy]-17-cyclopropylmethyl-4,5.alpha.-e-
poxymorphinan-6-spiro-2'-(1,3-dioxolane) was obtained as a
colourless oil, which was used for the next synthetic stage as
such. .sup.1H-NMR (Me.sub.2SO-d.sub.6) .delta. 7.71-7.31 (m, 9
arom. H), 6.79 (d, 1 arom. H, J=8.0 Hz), 6.57 (d, 1 arom. H, J=8.0
Hz), 5.14 (d, 1H, OCH.sub.2Ar, J=11.6 Hz), 5.07 (d, 1H,
OCH.sub.2Ar, J=11.6 Hz), 4.81 (d, 1H, OCH.sub.2Ar, J=12 Hz), 4.50
(s, C.sub.5--H), 4.46 (d, 1H, OCH.sub.2Ar, J=12 Hz), 4.01-3.74 (m,
4H, OCH.sub.2CH.sub.2O).
[0189] A solution of
3-benzyloxy-14.beta.-[(2-chlorobenzyl)oxy]-17-cyclopr-
opylmethyl-4,5.alpha.-epoxymorphinan-6-spiro-2'-(1,3-dioxolane)
(5.50 g, 9.16 mmol) in MeOH (52 ml) and conc. HCl (23 ml) was
reflux heated for 2.5 h. After cooling with ice, the solution was
alkalised with conc. NH.sub.4OH and extracted with CH.sub.2Cl.sub.2
(1.times.200 ml, 1.times.100 ml, 2.times.50 ml). The combined
organic phases were washed with H.sub.2O, dried over
Na.sub.2SO.sub.4 and evaporated down. The residue (5.54 g of
yellowish oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:3:0.5) and in this
way 2.69 g (63%) of pure 14.beta.-[(2-chlorobenzyl-
)oxy]-17-cyclopropylmethyl)-4,5.alpha.-epoxy-3-hydroxymorphinan-6-one
(compound 13) was obtained. A part was dissolved in ether and
etherial HCl added to it. Compound 13.HCl was isolated. Fp.
165-168.degree. C.; .sup.1H-NMR (Me.sub.2SO-d.sub.6) .delta. 8.63
(br. s, OH), 7.96 (s, 1H, .sup.+NH), 7.50-7.30 (m, 4 arom. H), 6.74
(d, 1 arom. H, J=8 Hz), 6.69 (d, 1 arom. H, J=8 Hz), 5.19(s,
C.sub.5--H), 4.87 (d, 1H, OCH.sub.2Ar, J=11.6 Hz), 4.81 (d, 1H,
OCH.sub.2Ar, J=11.6 Hz); Cl-MS: m/z 466 (M.sup.++1).
EXAMPLE 14
Synthesis of
14.beta.-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hy-
droxymorphinan-6-one (Compound 14.HBr).
[0190] 30
[0191] A solution of
3,114-dibenzyloxy-17-cyclopropylmethyl-4,5.alpha.-epo- xymorphinan
6-spiro-2'-(1,3-dioxolane) (Schmidhammer et al., Heterocycles
1998,49,489-497) (10.0 g, 17.68 mmol) in MeOH (200 ml)/H.sub.2O
(250 ml)/conc. HCl (50 ml) was reflux heated for 4 h. After cooling
with ice, the solution was alkalised with conc. NH.sub.4OH and
extracted with CH.sub.2Cl.sub.2 (1.times.100 ml, 2.times.25 ml).
The combined organic phases were washed with H.sub.2O, dried over
Na.sub.2SO.sub.4 and evaporated down. The residue (8.48 g of
slightly brown foamy resin) was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/c- onc.
NH.sub.4OH 90:9:1) and in this way 6.28 g of
3,14.beta.-dibenzyloxy-1-
7-cyclopropylmethyl-4,5.alpha.-epoxymorphinan-6-one (Schmidhammer
et al., Heterocycles 1998, 49, 489-497) was obtained as colourless
foamy resin and 1.14 g (18%) of the compound 14 as a slightly
yellow foamy resin. One part of the compound 14 was converted in
the usual way to the hydrobromide (compound 14.HBr) using 48% HBr.
Fp. >210.degree. C. (decomp.); .sup.1H-NMR (Me.sub.2SO-d.sub.6)
.delta. 9.48 (s, OH), 8.31 (s, .sup.+NH), 7.56-7.32 (m, 5 arom. H),
6.72 (d, 1 arom. H, J=8 Hz), 6.68 (d, 1 arom. H, J=8 Hz), 5.10 (s,
C-5H), 4.70 (d, 1H, OCH.sub.2Ph, J=10.4 Hz), 4.25 (d, 1H,
OCH.sub.2Ph, J=10.4 Hz); Cl-MS: m/z 432 (M.sup.++1).
EXAMPLE 15
Synthesis of
14.beta.-butoxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydro-
xymorphinan-6-one Hydrochloride (Compound 15.HCl).
[0192] 31
[0193] NaH (2.8 g, 118 mmol; obtained from 4.2 g of a 60% NaH
dispersion by washing with petroleum ether) was added to an
ice-cooled, stirred solution of
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-hy-
droxymorphinan-6-spiro-2'-(1,3-dioxolane) (see Example 13) (10.70
g, 22.5 mmol) in 200 ml water-free N,N-dimethylformamide under
N.sub.2. After 15 min. trans-crotylbromide (27 mmol, 3.2 ml of an
85% trans-crotylbromide solution) was added and stirred for 3.5 h
(1 h at 0-5.degree. C., 2.5 h at room temperature). After the
breakdown of excess NaH by the addition of small pieces of ice, the
mixture was poured onto 500 ml H.sub.2O and extracted with
CH.sub.2Cl.sub.2 (3.times.100 ml, 2.times.50 ml). The combined
organic phases were washed with H.sub.2O (3.times.200 ml) and
saturated NaCl solution, dried over Na.sub.2SO.sub.4 and evaporated
down. The residue from the evaporation (13.85 g of yellow oil) was
purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250/3/0.5)). The residue
from the evaporation (7.11 g of yellow oil) was dissolved in ether
and 3-benzyloxy-14.beta.-[(E)-(but-2en-
yl)oxy]-17-cyclopropylmethyl-4,5.alpha.-epoxymorphinan-6-spiro-2'-(1,3-dio-
xolane) was precipitated as the hydrochloride by the addition of
etherial HCl. Yield: 6.85 g (54%). Fp. 135-139.degree. C.;
.sup.1H-NMR (DMSO-d.sub.6): .delta. 8.11 (s, wide, .sup.+NH),
7.50-7.25 (m, 5 arom. H), 6.92 (d, 1 arom. H. J=8.4 Hz), 6.68 (d, 1
arom. H, J=8.4 Hz), 5.79 (m, 2 olefin. H), 5.14 (s, 2H,
C.sub.3OCH.sub.2), 4.59 (s, C.sub.5--H), 4.20-3.72 (m, 6H,
C.sub.6-(OCH.sub.2).sub.2, C.sub.14(OCH.sub.2), 1.72 (m, 3H,
CH.dbd.CHCLH.sub.3); MS (Cl): m/z 530 (M.sup.++1).
[0194] A mixture of
3-benzyloxy-14.beta.-[(E)-(but-2-enyl)oxy]-17-cyclopro-
pylmethyl-4,5.alpha.-epoxymorphinan-6-spiro-2'-(1,3-dioxolane)hydrochlorid-
e (6.27 g, 11 mmol), 630 mg of 10% Pd/C catalyst and 100 ml MeOH
was hydrogenated for 2 h at room temperature and 30 psi. Then the
catalyst was filtered off and the filtrate was evaporated down in a
vacuum. The evaporation residue (reddish crystals) was treated with
reflux boiling MeOH. Yield: 4.17 g (79%) of colourless crystals of
14.beta.-butoxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxymorphinan--
6-spiro-2'-(1,3-dioxolane)hydrochloride. Fp. 247-252.degree. C.;
.sup.1H-NMR (DMSO-d.sub.6): .delta. 9.23 (s, 1H, OH), 7.87 (s,
wide, 1H, .sup.+NH), 6.68 (d, 1 arom. H, J=8.2 Hz), 6.57 (d, 1
arom. H, J=8.2 Hz), 4.49 (s, C.sub.5--H), 4.11-3.55 (m, 4H,
C.sub.6(OCH.sub.2).sub.2), 0.95 (t, 3H, CH.sub.2CH.sub.3, J=7.4
Hz); MS (Cl): m/z 443 (M.sup.++1).
[0195] A solution of
14.beta.-butoxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-
-3-hydroxymorphinan-6-spiro-2'-(1,3-dioxolane)hydrochloride (4.07
g, 8.5 mmol) in 100 ml MeOH/H.sub.2O/conc. HCl (50:85:15) was
reflux heated for 4 h. After the addition of H.sub.2O (70 ml) and
alkalisation with conc. NH.sub.4OH extraction with CH.sub.2Cl.sub.2
(3.times.60 ml) occurred. The combined organic phases were washed
with H.sub.2O and saturated NaCl solution, dried over
Na.sub.2SO.sub.4 and evaporated down. The evaporation residue (3.63
g of brown oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:3.5:0.5)). One part
of the evaporation residue (2.71 g of colourless foamy resin, 80%)
was dissolved in ether and the compound 15' HCl (2.46 g) was
obtained as a pure substance by the addition of etherial HCl. Fp.
240.degree. C. (decomp.); IR (KBr): 1725 (CO) cm.sup.-1;
.sup.1H-NMR (DMSO-d.sub.6): .delta. 9.50 (s, OH), 8.15 (s, wide,
.sup.+NH), 6.71 (d, 1 arom. H, J=8.0 Hz), 6.65 (d, 1 arom. H, J=8.0
Hz), 4.93 (s, C.sub.5--H), 0.95 (t, 3H, CH.sub.2CH.sub.3, J=7.2
Hz); MS (Cl): m/z 399 (M.sup.++1).
EXAMPLE 16
Synthesis of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3--
methylbutyl)oxy]morphinan-6-one Hydrochloride (Compound
16.HCl).
[0196] 32
[0197] NaH (840 mg, 35 mmol; obtained from 1.4 g of a 60% NaH
dispersion by washing with petroleum ether) was added to an
ice-cooled, stirred solution of
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-hy-
droxymorphinan-6-spiro-2'-(1,3-dioxolane) (see Example 13) (4.0 g,
8.4 mmol) in 200 ml water-free N,N-dimethylformamide under N.sub.2.
After 15 min. 3,3-dimethylallylbromide (1.95 ml, 16.8 mmol) was
added and stirred for 19 h (1 h at 0-5.degree. C., 18 h at room
temperature). After the breakdown of excess NaH by the addition of
small pieces of ice, the mixture was poured onto 200 ml H.sub.2O
and extracted with CH.sub.2Cl.sub.2 (1.times.70 ml, 3.times.40 ml).
The combined organic phases were washed with H.sub.2O (3.times.150
ml) and saturated NaCl solution, dried over Na.sub.2SO.sub.4 and
evaporated down. The evaporation residue (4.8 g of yellow-brown
oil) was purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:3:0.5).
[0198] The oil obtained was dissolved in ether and
3-benzyloxy-17-cyclopro-
pylmethyl-4,5.alpha.-epoxy-14.beta.-[(3-methylbut-2-enyl)oxy]morphinan-6-s-
piro-2'-(1,3-dioxolane)hydrochloride was obtained as a pure
substance by the addition of etherial HCl. Yield: 3.81 g (78%). Fp.
126-129.degree. C.; .sup.1H-NMR (DMSO-d.sub.6): .delta. 8.15 (s,
wide, .sup.+NH), 7.45-7.25 (m, 5 arom. H), 6.92 (d, 1 arom. H,
J=8.0 Hz), 6.68 (d, 1 arom. H, J=8.0 Hz), 5.51 (m, 1 olefin. H),
5.14 (s, 2H, C.sub.3OCH.sub.2), 4.58 (s, C.sub.5--H), 3.92-3.44 (m,
4H, C.sub.6(OCH.sub.2).sub.2), 1.76 (s, 3H, CH.dbd.CCH.sub.3); 1.67
(s, 3H, CH.dbd.CCH.sub.3); MS (Cl): m/z 544 (M.sup.++1).
[0199] A mixture of
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-14.b-
eta.-[(3-methylbut-2-enyl)oxy]-morphinan-6-spiro-2'-(1,3-dioxolane)hydroch-
loride (4.01 g, 6.9 mmol), 400 mg of 10% Pd/C catalyst and 100 ml
MeOH was hydrogenated for 2.5 h at room temperature and 30 psi.
Then the catalyst was filtered off and the filtrate was evaporated
down. The evaporation residue was treated with ether, the insoluble
portion filtered off, and etherial HCl added to the filtrate and in
this way
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3-methylbutyl)-
oxy]morphinan-6-spiro-2'-(1,3-dioxolane)hydrochloride was obtained
as a pure substance. Yield: 2.24 g (66%). Fp. 191-193.degree. C.;
.sup.1H-NMR (DMSO-d.sub.6): 6.9.22 (s, OH), 7.83 (s, wide,
.sup.+NH), 6.69 (d, 1 arom. H, J=8.0 Hz), 6.58 (d, 1 arom. H, J=8.0
Hz), 4.47 (s, C.sub.5--H), 4.08-3.50 (m, 4H,
C.sub.6(OCH.sub.2).sub.2), 0.96 (d, 3H, CHCH.sub.3, J=4.8 Hz); 0.92
(d, 3H, CHCH.sub.3, J=4.8 Hz); MS (Cl): m/z 457 (M.sup.++1).
[0200] A solution of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.be-
ta.-[(3-methyl-butyl)oxy]morphinan-6-spiro-2'-(1,3-dioxolane)hydrochloride
(2.8 g, 5.7 mmol) in 110 ml MeOH/H.sub.2O/conc. HCl (4:5:1) was
reflux heated for 4.5 h. After the addition of H.sub.2O (80 ml) and
alkalisation with conc. NH.sub.4OH extraction with CH.sub.2Cl.sub.2
(1.times.80 ml, 3.times.50 ml) occurred. The combined organic
phases were washed with H.sub.2O and saturated NaCl solution, dried
over Na.sub.2SO.sub.4 and evaporated down. The evaporation residue
(2.5 g of brown oil) was purified using column chromatography
(silica gel; CH.sub.2Cl.sub.2/MeOH/c- onc. NH.sub.4OH 250:3:0.5)).
The evaporation residue (2.21 g of white foamy resin) was dissolved
in ether and the compound 16.HCl was obtained as a pure substance
by the addition of etherial HCl. Yield: 1.99 g (78%). Fp.
168-170.degree. C.; IR (KBr): 1725 (CO) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 9.50 (s, OH), 8.08 (s, wide, .sup.+NH),
6.72 (d, 1 arom. H, J=8.0 Hz), 6.66 (d, 1 arom. H, J=8.0 Hz), 4.92
(s, C.sub.5--H), 0.96 (d, 3H, CHCLH.sub.3, J=3.8 Hz); 0.93 (d, 3H,
CHCH3, J=3.8 Hz); MS (Cl): m/z 412 (M.sup.++1).
EXAMPLE 17
Synthesis of
4,5.alpha.-epoxy-5.beta.,17-dimethyl-14.beta.-[(3-phenylpropy-
l)oxy]-3-[(prop-2-inyl)oxy]morphinan-6-one Hydrochloride (Compound
17.HCl).
[0201] 33
[0202] NaH (0.72 g, 30.0 mmol; obtained from 1.2 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of 14-hydroxy-5-methlycodeinone (Schmidhammer et al.,
Helv. Chim. Acta, 1988, 73, p. 642) (5.00 g, 15.27 mmol) in 30 ml
water-free N,N-dimethylformamide under N.sub.2 at 0.degree. C.
(bath temperature) under stirring. After 25 min. a solution of
cinnamyl bromide (3.01 g, 15.27 mmol) in 20 ml
N,N-dimethylformamide was added drop by drop and the mixture
stirred for 1.5 h at 0.degree. C. (bath temperature). Small pieces
of ice were added until no more hydrogen was produced, the mixture
was poured onto 500 ml H.sub.2O and extracted with
dichloromethane/isopropanol (4:1) (1.times.150 ml, 3.times.50 ml).
The combined organic phases were washed with H.sub.2O (5.times.400
ml) and 1.times. with 250 ml saturated sodium chloride solution,
dried over sodium sulphate and evaporated down. The evaporation
residue (7.59 g of orange coloured oil) was crystallised out of
isopropanol/ether (1:1) (20 ml). Yield: 3.03 g (45%) of colourless
crystals of 14-cinnamyloxy-5-methylcodeinone
(=7,8-didehydro-4,5.alpha.-epoxy-3-metho-
xy-50,17-dimethyl-140{[(E/Z)-3-phenylprop-2-enyl]oxy}morphinan-6-one).
Fp. >150.degree. C. (decomp.); IR (KBr): 1675 (CO) cm.sup.-1;
.sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): .delta. 7.44-7.23 (m, 5
arom. H, 1 olef. H), 6.70 (d, 1 arom. H. J=8.2 Hz), 6.62 (d, 1
arom. H, J=8.2 Hz), 6.56 (d, 1 olefin. H, --CH.dbd.CH-Ph, J=15.7
Hz)), 6.33 (dt, 1 olef. H, --CH.dbd.CH-Ph, J=15.7 Hz), 6.10 (d, 1
olef. H, J=10.0 Hz), 4.26 and 4.11 (2 dd, 2H, C-14-OCH.sub.2--,
J=5.0 and 10.6 Hz), 3.70 (s, CH.sub.3O), 2.36 (s, CH.sub.3N), 1.61
(s, C5-CH.sub.3); Cl-MS: m/z 444 (M.sup.++1).
[0203] A mixture of 14-cinnamyloxy-5-methylcodeinone (3.44 g, 7.76
mmol), 10% Pd/C catalyst (350 mg) and 80 ml EtOH was hydrogenated
for 2 h at a temperature of 50.degree. C. and 50 psi. Then, the
catalyst was filtered off, the filtrate was evaporated down and the
residue (3.31 g of dark oil) was crystallised out of 10 ml EtOH.
Yield: 2.52 g (73%) of
4,5.alpha.-epoxy-3-methoxy-5,17-dimethyl-14.beta.-[(3-phenylpropyl)oxy]mo-
rphinan-6-one (compound 17a). Fp. 126-128.degree. C.; IR (KBr):
1720 (CO) cm.sup.-1; .sup.1H-NMR (CDCl.sub.3, .delta. in ppm):
.delta. 7.32-7.17 (m, 5 arom. H), 6.67 (d, 1 arom. H, J=8.2 Hz),
6.58 (d, 1 arom. H, J=8.2 Hz), 3.87 (s, CH.sub.3O), 2.34 (s,
CH.sub.3N), 1.65 (s, C5-CH.sub.3); Cl-MS: m/z 448 (M.sup.++1).
[0204] A solution of
4,5.alpha.-epoxy-3-methoxy-5,3,17-dimethyl-14.beta.-[-
(3-phenylpropyl)oxy]morphinan-6-one (2.23 g, 4.98 mmol) in 13 ml
48% HBr was reflux heated for 20 min, then cooled and evaporated
down. The evaporation residue was dissolved in 20 ml MeOH and
evaporated down. The process was repeated 1.times., whereby 2.48 g
of beige crystals were obtained, which were recrystallised out of
15 ml MeOH. Yield: 2.26 g (88%)
4,5.alpha.-epoxy-3-hydroxy-5.beta.,17-dimethyl-14.beta.-[(3-phenylp-
ropyl)oxy]morphinan-6-one hydrobromide (compound 17b.HBr). Fp.
>270.degree. C. (decomp.); IR (KBr): 1720 (CO) cm.sup.-1;
.sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): .delta. 9.42 (s, OH),
8.58 (s, .sup.+NH), 7.36-7.16 (m, 5 arom. H), 6.69 (d, 1 arom. H,
J=8.2 Hz), 6.64 (d, 1 arom. H, J=8.2 Hz), 2.97 (s, CH.sub.3N), 1.65
(s, C5-CH.sub.3); Cl-MS: m/z 434 (M.sup.++1).
[0205] A mixture of
4,5.alpha.-epoxy-3-hydroxy-5.beta.,17-dimethyl-14.beta-
.-[(3-phenylpropyl)oxy]morphinan-6-one hydrobromide (380 mg, 0.88
mmol), calcium carbonate (370 mg, 2.68 mmol), propargylbromide
(0.20 ml, 2.66 mmol) and 25 ml acetone was reflux heated under
N.sub.2 for 7 h. The inorganic material was filtered off, the
filtrate evaporated down and the residue (460 mg of orange coloured
oil) was purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:2:0.5). The evaporation
residue (350 mg of yellow oil) was dissolved in ether and etherial
HCl was added to it, whereby 220 mg (49%) of the compound 17.HCl
was obtained. Fp. >130-133.degree. C.; IR (KBr): 1727 (CO)
cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): .delta. 9.38
(s, .sup.+NH), 7.34-7.19 (m, 5 arom. H), 6.92 (d, 1 arom. H, J=8.4
Hz), 6.78 (d, 1 arom. H, J=8.4 Hz), 4.81 (d, 2H, HCCCH.sub.2O--C3,
J=1 Hz), 3.59 (d, 1H, HCCCH.sub.2O--C3, J=1 Hz), 2.94 (s,
CH.sub.3N), 1.53 (s, C5-CH.sub.3); Cl-MS: m/z 472 (M.sup.++1).
EXAMPLE 18
Synthesis of
14.beta.-[(3-chlorobenzyl)oxy]-4,5.alpha.-epoxy-17-methyl-3-[-
(prop-2-inyl)oxy]-morphinan-6-one Hydrochloride (18.HCl).
[0206] 34
[0207] NaH (1.60 g, 66.76 mmol; obtained from 2.67 g of a 60% NaH
dispersion by washing with petroleum ether) was added to a solution
of
4,5.alpha.-epoxy-14.beta.-hydroxy-3-methoxy-17-methylmorphinan-6-spiro-2'-
1,3-dioxolane) (Lester et al., Tetrahedron 1965, 21. pp. 771-778)
(6.00 g, 16.69 mmol) in 100 ml water-free N,N-dimethylformamide
under N.sub.2 at 0.degree. C. (bath temperature) under stirring.
After 15 min. 3-chlorobenzylbromide (4.4 ml, 33.38 mmol) was added
and stirred for 24 h (1 h at 0-5.degree. C., 23 h at room
temperature). After the breakdown of excess NaH by adding small
pieces of ice, the mixture was poured onto 300 ml H.sub.2O and
extracted with CH.sub.2Cl.sub.2 (1.times.100 ml, 3.times.40 ml).
The combined organic phases were washed with H.sub.2O (4.times.200
ml) and saturated NaCl solution, dried over Na.sub.2SO.sub.4 and
evaporated down. The evaporation residue (13.36 g of yellow oil)
was crystallised out of MeOH and recrystallised. Yield: 4.29 g
(53%) of
140-[(3-chlorobenzyl)oxy]4,5.alpha.-epoxy-3-methoxy-17-methylmorphinan-6--
spiro-2'-(1,3-dioxolane) as colourless crystals. Fp.
131-133.degree. C.; .sup.1H-NMR (DMSO-d.sub.6): .delta. 7.58-7.26
(m, 4 arom. H), 6.74 (d, 1 arom. H, J=8.1 Hz), 6.60 (d, 1 arom. H,
J=8.1 Hz), 4.55 (d, 1H, C.sub.14OCH.sub.2, J=11.8 Hz), 4.31 (d, 1H,
C.sub.140CH.sub.2, J=11.8 Hz), 4.42 (s, C.sub.5--H), 4.10-3.61 (m,
4H, C.sub.6(OCH.sub.2).sub.2), 3.78 (s, OCH.sub.3), 2.30 (s,
NCH.sub.3); MS (Cl): m/z 485 (M.sup.++1).
[0208] A mixture of
14.beta.-[(3-chlorobenzyl)oxy]-4,5.alpha.-epoxy-3-meth-
oxy-17-methylmorphinan-6-spiro-2'-(1,3-dioxolane) (3.00 g, 6.2
mmol), sodium ethane thiolate (2.32 g, 27.6 mmol) and 30 ml of
water-free N,N-dimethylformamide was stirred for 5 h under N.sub.2
at 130.degree. C. (bath temperature) and then poured onto 400 ml
H.sub.2O and extracted with CH.sub.2Cl.sub.2 (1.times.100 ml,
3.times.60 ml). The combined organic phases were washed with
H.sub.2O (4.times.200 ml) and saturated NaCl solution, dried over
Na.sub.2SO.sub.4 and evaporated down. The evaporation residue (3.36
g of dark brown oil 14.beta.-[(3-chlorobenzyl)o-
xy]4,5.alpha.-epoxy-3-hydroxy-17-methylmorphinan-6-spiro-2'-(1,3-dioxolane-
)) could not be crystallised. Therefore one part (2.8 g) was used
without further purification for representing
14.beta.-[(3-chlorobenzyl)oxy]4,5.a-
lpha.-epoxy-3-hydroxy-17-methylmorphinan-6-one. The remainder (414
mg) was purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/c- onc. NH.sub.4OH (250:2:0.5)). The
evaporation residue (352 mg of yellow oil) was dissolved in ether
and 14.beta.-[(3-chlorobenzyl)oxy]4,5.alpha.--
epoxy-3-hydroxy-17-methylmorphinan-6-spiro-2'-(1,3-dioxolane)hydrochloride
(250 mg) was precipitated as a pure substance by the addition of
etherial HCl. Fp. 202-205.degree. C.; .sup.1H-NMR (DMSO-d.sub.6):
.delta. 9.28 (s, OH), 8.92 (s, wide, .sup.+NH), 7.60-7.36 (m, 4
arom. H), 6.70 (d, 1 arom. H, J=8.2 Hz), 6.60 (d, 1 arom. H, J=8.2
Hz), 4.59 (s, C.sub.5--H), 4.76 (d, 1H, C.sub.14OCH.sub.2, J=11.9
Hz), 4.57 (d, 1H, C.sub.14OCH.sub.2, J=11.9 Hz), 4.11-3.61 (m, 4H,
C.sub.6(OCH.sub.2).sub.2), 2.88 (d, .sup.+NCH.sub.3, J=4.6 Hz); MS
(Cl): m/z 471 (M.sup.++1).
[0209] A solution of unpurified 14
.beta.-[(3-chlorobenzyl)oxy]-4,5.alpha.-
-epoxy-3-hydroxy-17-methylmorphinan-6-spiro-2'-(1,3-dioxolane) (2.8
g of dark brown oil) in 100 ml MeOH/H.sub.2O/conc. HCl (4:5:1) was
reflux heated for 7 h. After the addition of ice-water and
alkalisation with conc. NH.sub.4OH extraction took place with
CH.sub.2Cl.sub.2 (3.times.60 ml). The combined organic phases were
washed with H.sub.2O (3.times.100 ml) and saturated NaCl solution,
dried over Na.sub.2SO.sub.4 and evaporated down. From the
evaporation residue (1.94 g of brown foamy resin
14.beta.-[(3-chlorobenzyl)oxy]-4,5.alpha.-epoxy-3-hydroxy-17-methyl-
-morphinan-6-one) one part (1.50 g) was used for further syntheses
without further purification. The remainder (443 mg) was purified
using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250:4:0.5)). The
evaporation residue (353 mg of yellow foamy resin) was dissolved in
ether and 14.beta.-[(3-chlorobenzyl)oxy]4,5.alpha.-epoxy-3-h-
ydroxy-17-methylmorphinanne hydrochloride (335 mg) was precipitated
as a pure substance by the addition of etherial HCl. Fp.
205-210.degree. C.; IR (KBr): 1724 (CO) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 9.55 (s, OH), 9.15 (s, wide, .sup.+NH),
7.70-7.25 (m, 4 arom. H), 6.73 (d, 1 arom. H, J=8 Hz), 6.67 (d, 1
arom. H, J=8 Hz), 5.10 (s, C.sub.5--H), 4.87 (d, 1H, OCH.sub.2),
J=12.4 Hz), 4.68 (d, 1H, OCH.sub.2), J=12.4 Hz), 2.93 (d,
.sup.+NCH.sub.3, J=4.6 Hz); MS (Cl): m/z 427 (M.sup.++1).
[0210] A mixture of unpurified
140-[(3-chlorobenzyl)oxy]-4,5.alpha.-epoxy--
3-hydroxy-17-methylmorphinanne (500 mg of brown foamy resin),
K.sub.2CO.sub.3 (485 mg, 3.51 mmol) and propargylbromide (0.26 ml,
3.51 mmol) and 40 ml acetone (with 0.5% H.sub.2O) was reflux heated
under N.sub.2 for 3 h. After cooling the inorganic material was
filtered off, washed with CH.sub.2Cl.sub.2 and the filtrate
evaporated down. The evaporation residue (538 mg of brown oil) was
purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250:2:0.5)). The
evaporation residue (337 mg of yellow oil) was dissolved in ether
and 18 HCl was precipitated as a pure substance by the addition of
etherial HCl. Yield: 347 mg (74%). Fp. 145-150.degree. C.; IR
(KBr): 1717 (CO), 2118 (C.dbd.C) cm.sup.1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 9.21 (s, wide, .sup.+NH), 7.71-7.32 (m, 4
arom. H), 6.96 (d, 1 arom. H, J=8.4 Hz), 6.82 (d, 1 arom. H, J=8.4
Hz), 5.20 (s, C.sub.5--H), 4.89 (d, 1H, C.sub.14OCH.sub.2, J=12.1
Hz), 4.69 (d, 1H, C.sub.14OCH.sub.2, J=12.1 Hz), 4.84 (d, 2H,
C.sub.3OCH.sub.2, J=2.2 Hz), 3.58 (t, 1H, C.dbd.CH, J=2.2 Hz), 2.94
(d, .sup.+NCH.sub.3, J=4.4 Hz); MS (Cl): m/z 465 (M.sup.++1).
EXAMPLE 19
Synthesis of
4,5.alpha.-epoxy-17-ethyl-3-methoxy-14.beta.-[(3-phenylpropyl-
)oxy]morphinan-6-one (Compound 19)
[0211] 35
[0212] A mixture of
4,5.alpha.-epoxy-3-methoxy-14.beta.-[(3-phenylpropyl)o-
xy]morphinan-6-one hydrochloride (see Example 1) (4.0 g, 8.77
mmol), K.sub.2CO.sub.3 (8.0 g, 57.89 mmol), ethyl iodide (0.99 ml,
12.40 mmol) and 50 ml of water-free N,N-dimethylformamide was
stirred for 5 h under N.sub.2 at 80.degree. C. (bath temperature).
After filtration from the inorganic residue, the filtrate was
evaporated down and the residue (4.7 g of brown oil) was purified
using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH: 8 l: (250/2/0.5)); 0.5 l:
(250/3/0.5), (250/4/0.5), (250/6/0.5), (250/8/0.5), (250/10/0.5)).
The evaporation residue (1.3 g of bright yellow oil) was
crystallised out of MeOH. Yield: 1.2 g (30%) of compound 19. Fp.
95-101.degree. C.; IR (KBr): 1719 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSOd.sub.6): .delta. 7.30-7.13 (m, 5 arom. H), 6.73 (d, J=8.2 Hz,
1 arom. H), 6.64 (d, J=8.2 Hz, 1 arom. H), 4.76 (s, 1H,
C.sub.5--H), 3.78 (s, 3H, OCH.sub.3), 0.96 (t, 3H,
N--CH.sub.2--CH.sub.3), J=7 Hz); MS (Cl): m/z 448 (M.sup.++1).
EXAMPLE 20
Synthesis of
4,5.alpha.-epoxy-17-ethyl-3-hydroxy-14.beta.-[(3-phenylpropyl-
)oxy]morphinan-6-one Hydrochloride (Compound 20.HCl).
[0213] 36
[0214] A solution of compound 19 (1.0 g, 2.23 mmol) in 48% HBr (10
ml) was reflux heated for 13 minutes. After cooling it was diluted
with water (50 ml), ice was added, it was alkalised with conc.
NH.sub.4OH and extracted with CH.sub.2Cl.sub.2 (5.times.50 ml). The
combined organic phases were washed with water (3.times.50 ml) and
NaCl solution (1.times.50 ml), dried over Na.sub.2SO.sub.4 and
evaporated down. The evaporation residue (1.3 g of brown foamy
resin) was purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250:2:0.5)). The
evaporation residue (448 mg of yellow foamy resin) was dissolved in
ether, etherial HCl added and the compound 20.HCl isolated. Yield:
380 mg (36%). Fp. 178-180.degree. C.; IR (KBr): 1724 (C.dbd.O)
cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.14 (s, OH),
7.29-7.03 (m, 5 arom. H), 6.56 (d, 1 arom. H, J=8 Hz), 6.50 (d, 1
arom. H, J=8 Hz), 4.69 (sI C.sub.5--H), 0.96 (t, 3H,
N--CH.sub.2--CH.sub.3), J=7.2 Hz); MS (Cl): m/z 434
(M.sup.++1).
EXAMPLE 21
Synthesis of
4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3-methylbutyl)oxy]-17-p-
ropylmorphinan-6-one Hydrochloride (Compound 21.HCl).
[0215] 37
[0216] A solution of naloxone.HCl.2H.sub.2O (20.0 g, 50.0 mmol) and
methane sulphonic acid (3.9 ml, 60.0 mmol) in 150 ml ethylene
glycol was stirred for 18 h at a bath temperature of 80-90.degree.
C. under N.sub.2. After the addition of 200 ml of ice-water and
alkalising with conc. NH.sub.4OH extraction took place with
CH.sub.2Cl.sub.2 (2.times.100 ml, 2.times.50 ml). The combined
organic phases were washed with H.sub.2O (2.times.100 ml) and
saturated NaCl solution, dried over Na.sub.2SO.sub.4 and evaporated
down. The evaporation residue (beige crystals) was treated with
boiling MeOH, whereby 16.52 g (89%) of colourless crystals of
4,5.alpha.-epoxy-3,140-dihydroxy-17-(prop-2-enyl)morphinan-6-spiro-2'-(1,-
3-dioxolane) was obtained. Fp. 244-247.degree. C.; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 8.87 (s, C.sub.3--OH), 6.54 (d, 1 arom. H,
J=8 Hz), 6.44 (d, 1 arom. H, J=8 Hz), 5.93-5.70 (m, 1 olef. H),
5.27-5.04 (m, 2 olef. H), 4.79 (s, C.sub.14--OH), 4.33 (s,
C.sub.5--H), 4.11-3.61 (m, 4H, C.sub.6(OCH.sub.2).sub.2); MS (Cl):
m/z 372 (M.sup.++1).
[0217] A mixture, consisting of
4,5.alpha.-epoxy-3,14.beta.-dihydroxy-17-(-
prop-2-enyl)morphinan-6-spiro-2'-(1,3-dioxolane) (16.0 g, 43.1
mmol), K.sub.2CO.sub.3 (16.2 g, 117 mmol), benzyl bromide (5.63 ml,
47.4 mmol) and 80 ml of water-free N,N-dimethylfonmamide was
stirred for 24 h under N.sub.2 at room temperature. The inorganic
material was filtered off, rinsed with CH.sub.2Cl.sub.2 and the
filtrate was evaporated down. The evaporation residue (white
crystals) was treated for 1 h with reflux boiling ether to remove
the solvent and the benzylbromide. The cooled mixture was filtered
off, the remaining crystals washed again with a little cold ether
and then treated with reflux boiling MeOH. 12.53 g (63%) of
3-benzyloxy-4,5.alpha.-epoxy-14.beta.-hydroxy-17-(prop-2-enyl)mo-
rphinan-6-spiro-2'-(1,3-dioxolane) was obtained as colourless
crystals. Fp. 142-144.degree. C.; .sup.1H-NMR (DMSO-d.sub.6):
.delta. 7.50-7.22 (m, 5 arom. H), 6.77 (d, 1 arom. H, J=8.0 Hz),
6.56 (d, 1 arom. H, J=8.0 Hz), 5.95-5.68 (m, 1H, 1 olef. H),
5.30-5.01 (m, 4H, 2 olef. H, C.sub.3OCH.sub.2), 4.81 (s, OH), 4.40
(s, C.sub.5--H), 4.08-3.65 (m, 4H. C.sub.6(OCH.sub.2).sub.2); MS
(Cl): m/z 463 (M.sup.++1).
[0218] NaH (650 mg, 27 mmol) (obtained from 1.1 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of 3-benzyloxy-4,5.alpha.-epoxy-14
.mu.l-hydroxy-17-(prop-2-enyl)morphinan-6-
-spiro-2'-(1,3-dioxolane) (5.00 g, 10.83 mmol) in 40 ml water-free
N,N-dimethylformamide under N.sub.2 at 0.degree. C. (bath
temperature) under stirring. After 15 min. 3,3-dimethylallylbromide
(1.90 ml, 16.25 mmol) was added and the mixture first stirred for 1
h at 0.degree. C. (bath temperature) and then with reducing cooling
stirred further for 4 hours. To terminate the reaction pieces of
ice were added until no more hydrogen was produced. The mixture was
poured onto 100 ml water and extracted with dichloromethane
(3.times.100 ml). The combined organic phases were washed with
H.sub.2O (3.times.100 ml) and 250 ml of saturated sodium chloride
solution, dried over sodium sulphate and evaporated down. The
evaporation residue (6.02 g of yellow oil) was purified using
column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc.
NH.sub.4OH (250:2:0.5)). The evaporation residue (5.01 g of bright
yellow oil) was dissolved in ether and pure
3-benzyloxy-4,5.alpha.-epoxy-14.beta.-[(3-met-
hylbut-2-enyl)oxy-17-(prop-2-enyl)morphinan-6-spiro-2'-(1,3-dioxolane)
hydrochloride was precipitated by the addition of etherial HCl.
Yield: 4.83 g (79%); Fp. 122-124.degree. C.; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 8.61 (s, wide, .sup.+NH), 7.50-7.25 (m, 5
arom. H), 6.92 (d, J=8.4 Hz, 1 arom. H), 6.70 (d, .sup.3J=8.4 Hz, 1
arom. H), 5.99-5.41 (m, 4 olefin. H), 5.14 (s, C.sub.3--OCH.sub.2),
4.57 (s, C.sub.5--H), 1.75 (s, 3H, CH.dbd.CCH.sub.3), 1.66 (s, 3H,
CH.dbd.CCH.sub.3); MS (Cl): m/z 531 (M.sup.++1).
[0219] A mixture of
3-benzyloxy-4,5.alpha.-epoxy-14.beta.-[(3-methylbut-2--
enyl)oxy]-17-(prop-2-enyl)morphinan-6-spiro-2'-(1,3-dioxolane)hydrochlorid-
e (4.59 g, 8.11 mmol), 460 mg 10% Pd/C catalyst and 100 ml MeOH was
hydrogenated for 4 h at room temperature and 30 psi. Then the
catalyst was filtered off and the filtrate was evaporated down in a
vacuum. The evaporation residue (slightly grey crystals) was
recrystallised out of MeOH/Et.sub.2O. Yield: 3.54 g (91%) of pure
4,5.alpha.-epoxy-3-hydroxy-14-
.beta.-[(3-methylbutyl)oxy]-17-propylmorphinan-6-spiro-2'-(1,3-dioxolane)h-
ydrochloride. Fp. 176-185.degree. C.; .sup.1H-NMR (DMSO-d.sub.6):
.delta. 9.22 (s, OH), 8.12 (s, wide, 1H, .sup.+NH), 6.68 (d, J=8.0
Hz, 1 arom. H), 6.58 (d, J=8.0 Hz, 1 arom. H), 4.46 (s, 1H,
C.sub.5--H), 4.11-3.62 (m, 4H, C.sub.6(OCH.sub.2).sub.2), 0.99-0.85
(m, 9H, N.sup.+(CH.sub.2).sub.2CH3, CH(CH.sub.3).sub.2); MS (Cl):
m/z 445 (M.sup.++1).
[0220] A solution of
4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3-methylbutyl)o-
xy]-17-propylmorphinan-spiro-2'-(1,3-dioxolane)hydrochloride (3.40
g, 7.1 mmol) in 40 ml MeOH/H.sub.2O/conc. HCl (50:85:15) was reflux
heated for 4 h. After the addition of H.sub.2O (50 ml) and
alkalising with conc. NH.sub.4OH extraction was carried out with
CH.sub.2Cl.sub.2 (3.times.60 ml). The combined organic phases were
washed with H.sub.2O (2.times.100 ml) and saturated NaCl solution,
dried over Na.sub.2SO.sub.4 and evaporated down. The evaporation
residue (2.61 g of dark brown oil) was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/c- onc.
NH.sub.4OH (250:3:0.5)). From the evaporation residue (1.77 g of
white foamy resin, 62%) a part (1.39 g) was dissolved in ether and
21.HCl (1.42 g) precipitated as a pure substance by the addition of
etherial HCl. Fp. 175-185.degree. C. (decomp.); IR (KBr): 1725 (CO)
cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.52 (s, OH), 8.33
(s, wide, .sup.+NH), 6.70 (d, 1 arom. H, J=8.2 Hz), 6.65 (d, 1
arom. H, J=8.2 Hz), 4.91 (s, C.sub.5--H), 1.00-0.85 (m, 9H,
N.sup.+(CH.sub.2).sub.2CH.sub.3, CH(CH.sub.3).sub.2); MS (Cl): m/z
401 (M.sup.++1).
EXAMPLE 22
Synthesis of 5.beta.-benzyl-14-methoxycodeinone hydrochloride
(=5.beta.-benzyl-7,8-didehydro-4.5.alpha.-epoxy-3,14.beta.-dimethoxy-17-m-
ethyl-morphinan-6-one hydrochloride) (compound 22.HCl).
[0221] 38
[0222] NaH (1.2 g, 50 mmol) (obtained from 2.0 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of 5.beta.-benzyl-14-hydroxycodeinone (M. Gates et al., J.
Org. Chem. 1989, 54, pp. 972-974) (7.95 g, 19.7 mmol) in 100 ml
water-free N,N-dimethylformamide under N.sub.2 at 0.degree. C.
(bath temperature) under stirring. After 15 min. dimethylsulphate
(2.43 ml, 25.6 mmol) was added and the mixture stirred for 1 h at
0.degree. C. (bath temperature). To terminate the reaction pieces
of ice were added until no more hydrogen was produced. The mixture
was poured onto 250 ml water and extracted with dichloromethane
(3.times.100 ml). The combined organic phases were washed with
H.sub.2O (1.times.100 ml, 3.times.60 ml) and saturated sodium
chloride solution, dried over sodium sulphate and evaporated down.
From the evaporation residue (8.3 g of yellow-brown oil) a part was
used further unmodified and the remainder (500 mg) purified using
column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc.
NH.sub.4OH (250:2:0.5)). The evaporation residue (210 mg of yellow
oil) was dissolved in ether and pure compound 22.HCl was
precipitated by the addition of etherial HCl. Yield: 148 mg. Fp.
164-166.degree. C.; IR (KBr): 1680 (CO) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 9.47 (s, wide, .sup.+NH), 7.37-7.09 (m, 5
arom. H), 7.04 (d, 1H, C.sub.8H, J=10.0 Hz), 6.84 (d, 1 arom. H,
J=8.4 Hz), 6.74 (d, 1 arom. H, J=8.4 Hz), 6.29 (d, 1H, C.sub.7--H,
J=10.0 Hz), 3.76 (s, 3H, C.sub.3OCH.sub.3), 3.59 (d, 1H,
C.sub.5--CH.sub.2, J=15.1 Hz), 3.29 (d, 1H, C.sub.5---(CH.sub.2),
J=15.1 Hz), 2.98 (s, 3H, C.sub.14--OCH.sub.3), 2.88 (d, 3H,
.sup.+NCH.sub.3, J=4.6 Hz); MS (Cl): m/z 419 (M.sup.++1).
EXAMPLE 23
Synthesis of
5.beta.-benzyl-4,5.alpha.-epoxy-3,14.beta.-dimethoxy-17-methy-
lmorphinan-6-one (compound 23)
[0223] 39
[0224] A mixture of unpurified compound 22 (6.96 g, 16.7 mmol of
yellow-brown oil), 0.7 g 10% Pd/C catalyst and 150 ml MeOH was
hydrogenated for 3 h at room temperature and 30 psi. Then the
catalyst was filtered off and the filtrate was evaporated down in a
vacuum. The evaporation residue (light brown foamy resin) was
recrystallised out of isopropanol, whereby 3.14 g (45%) of pure
compound 23 was obtained. Fp. 136-138.degree. C.; IR (KBr): 1725
(CO) cm.sup.-1; .sup.1H-NMR (CDCl.sub.3): .delta. 7.35-7.18 (m, 5
arom. H), 6.66 (d, 1 arom. H, J=8.2 Hz), 6.57 (d, 1 arom. H, J=8.2
Hz), 3.90 (s, C.sub.3--OCH.sub.3), 3.48 (s, 2H,
C.sub.5---(CH.sub.2), 3.34 (s, C.sub.14--OCH.sub.3), 2.42 (s,
NCH.sub.3): MS (Cl): m/z 421 (M.sup.++1).
EXAMPLE 24
Synthesis of
50-benzyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17-meth-
ylmorphinan-6-one hydrochloride (compound 24.HCl).
[0225] 40
[0226] A solution of compound 23 (2.90 g, 6.9 mmol) in 40 ml of 48%
hydrobromic acid was reflux heated for 15 min. Then the solution
was cooled and evaporated down. The evaporation residue was
dissolved in MeOH and again evaporated down. The resulting foamy
resin (2.50 g) was converted to the base and purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH
(250: 3:0.5)). The evaporation residue (2.27 g of yellow oil) was
dissolved in ether and the pure compound 24.HCl precipitated with
etherial HCl. Yield: 2.30 g (75%); Fp. 222-224.degree. C.; IR
(KBr): 1725 (CO) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta.
9.45 (s, OH), 9.38 (s, wide, .sup.+NH), 7.37-7.09 (m, 5 arom. H),
6.70 (d, 1 arom. H, J=8.2 Hz), 6.62 (d, 1 arom. H, J=8.2 Hz), 3.41
(s, OCH.sub.3), 2.89 (d, 3H, .sup.+NCH.sub.3, J=3.4 HZ); MS (Cl):
m/z 407 (M.sup.++1).
EXAMPLE 25
Synthesis of
4-hydroxy-3-methoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphi-
nan-6-one (Compound 25)
[0227] 41
[0228] A mixture of
4,5.alpha.-epoxy-3-methoxy-17-methyl-14-[(3-phenylprop-
yl)oxy]-morphinan-6-one (=14-O-(3-phenylpropyl)oxycodon) (see
Example 1) (600 mg, 1.4 mmol), ammonium chloride (0.97 g, 18.0
mmol) and 30 ml MeOH was reflux heated under stirring. Then within
5 minutes activated zinc powder (0.94 g, 14.0 mmol) was added in
portions and the mixture reflux heated for 6 h. After filtration
from the inorganic residue, the filtrate was evaporated down,
alkalised with conc. NH.sub.4OH, extracted with CH.sub.2Cl.sub.2
(3.times.40 ml), washed with H.sub.2O, dried over Na.sub.2SO.sub.4
and evaporated down. The evaporation residue (605 mg) was
crystallised out of a little MeOH. Yield: 562 mg (86%) of compound
25. Fp. >258.degree. C. (decomp.); IR (KBr): 3145 (OH), 1734
(CO) cm.sup.-1; .sup.1H-NMR (CDCl.sub.3): .delta. 7.37-7.05 (m, 5
arom. H), 6.64 (d, 1 arom. H, J=8.3 Hz), 6.54 (d, 1 arom. H, J=8.3
Hz), 3.79 (s, OCH.sub.3), 2.30 (s, NCH.sub.3); MS (Cl): m/z 436
(M.sup.++1).
EXAMPLE 26
Synthesis of
3,4-dimethoxy-17-methyl-14-[(3-phenylpropyl)oxy]morphinan-6-o- ne
Salicylate (Compound 26, C.sub.7H.sub.6O.sub.3)
[0229] 42
[0230] A mixture of compound 25 (200 mg, 0.5 mmol), K.sub.2CO.sub.3
(420 mg, 3.0 mmol) and phenyltrimethyl ammonium chloride (254 mg,
1.5 mmol) and 50 ml water-free N,N-dimethylfonmamide was stirred
for 9 h at 80.degree. C. (bath temperature) under N.sub.2. After
filtration from the inorganic residue, the filtrate was evaporated
down, and the evaporation residue was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH
(93:7:1)). The evaporation residue (250 mg of foamy resin) was
dissolved in MeOH and salicylic acid added to it. 102 mg (41%) of
the compound 26.C.sub.7H.sub.6O.sub.3 was isolated. Fp.
110-115.degree. C.; IR (KBr): 1720 (CO)cm.sup.-1; .sup.1H-NMR
(CDCl.sub.3): .delta. 7.29-7.18 (m, 5 arom. H), 6.75 (s, 2 arom.
H), 3.93 (S, C.sub.4--OCH.sub.3), 3.80 (s, C.sub.3--OCH.sub.3),
2.31 (s, NCH.sub.3); MS (Cl): m/z 450 (M.sup.++1).
EXAMPLE 27
Synthesis of
14.beta.-benzyloxy-4-hydroxy-3-methoxy-17-methylmorphinan-6-o- ne
Hydrochloride (Compound 27.HCl).
[0231] 43
[0232] A mixture of
4,5.alpha.-epoxy-14.beta.-hydroxy-3-methoxy-17-methylm-
orphinan-6-spiro-2'-(1,3-dioxolane) (Lester et al. 1965, 21, p.
771) (6.0 g, 16.69 mmol), NaH (2.16 g, 90.0 mmol), obtained from
3.6 g of 60% dispersion by washing with petroleum ether) and 150 ml
water-free N,N-dimethylformamide was stirred for 20 min. at
0.degree. C. (bath temperature) under N.sub.2. After the addition
of benzylbromide (4.0 ml, 33.39 mmol) it was stirred further for 16
h at room temperature. Then pieces of ice were added until no more
H.sub.2 was given off, it was diluted with water (100 ml) and
extracted with CH.sub.2Cl.sub.2 (1.times.250 ml, 3.times.150 ml,
1.times.100 ml). The combined organic phases were washed with water
(4.times.250 ml) and NaCl solution (1.times.250 ml), dried over
Na.sub.2SO.sub.4 and evaporated down. The evaporation residue (7.47
g of red-brown oil) was crystallised out of MeOH (12 ml). 6.01 g of
colourless 4,5.alpha.-epoxy-14.beta.-benzyloxy-3--
methoxy-17-methylmorphinan-6-spiro-2'-(1,3-dioxolane) was isolated.
The mother liquor was evaporated down and purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH:
2 l: (250/2/0.5); each 11: (250/4/0.5), (250/6/0.5), (250/8/0.5),
(250/101/0.5)). The evaporation residue (551 mg, bright yellow oil)
was crystallised out of MeOH (1 ml). Total yield: 6.32 g (84%) of
4,5.alpha.-epoxy-14.beta.-benzyloxy-3-methoxy-17-methylmorphinan-6-spiro--
2'-(1,3-dioxolane). Fp. 121-124.degree. C.; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 7.44-7.26 (m, 5 arom. H), 6.74 (d, 1 arom.
H, J=8.2 Hz), 6.60 (d, 1 arom. H, J=8.2 Hz), 4.55 (d, 1 aliph. H,
14-O--CH.sub.2.C.sub.6H.sub.5, J=11.2 Hz), 4.41 (s, C.sub.5--H),
4.31 (d, 1 aliph. H, 14-O-CH.sub.2--C.sub.6H.sub.5, J=11.2 Hz),
4.02-3.67 (m, 4H, OCH.sub.2CH.sub.2O), 3.77 (s, OCH.sub.3); 2.31
(s, NCH.sub.3); MS (Cl): m/z 450 (M.sup.++1).
[0233] A solution of
4,5.alpha.-epoxy-141-benzyloxy-3-methoxy-17-methylmor-
phinan-6-spiro-2'-(1,3-dioxolane) (957 mg, 2.13 mmol) in MeOH (15
ml) and 2N HCl (22.5 ml) was reflux heated for 4 h. After cooling,
it was diluted with water (20 ml), alkalised with conc. NH.sub.4OH
and extracted with CH.sub.2Cl.sub.2 (1.times.100 ml, 1.times.50 ml,
3.times.25 ml). The combined organic phases were washed with water
(1.times.100 ml) and NaCl solution (1.times.100 ml), dried over
Na.sub.2SO.sub.4 and evaporated down. The evaporation residue (879
mg of dark yellow oil) was crystallised out of MeOH Yield: 801 mg
(89%) of 14.beta.-benzyloxy-4,5.al-
pha.-expoxy-3-methoxy-17-methylmorphinan-6-one. Fp. 136-138.degree.
C.; IR (KBr): 1721 (CO) cm.sup.-1; .sup.1H-NMR (CDCl.sub.3):
.delta. 7.45-7.24 (m, 5 arom. H), 6.68 (d, 1 arom. H, J=8.3 Hz),
6.62 (d, 1 arom. H, J=8.3 Hz), 4.77 (d, 1H, OCH.sub.2Ph, J=10.3
Hz), 4.64 (s, CH-5), 4.37 (d, 1H, OCH.sub.2Ph, J=10.3 Hz), 3.88 (s,
CH.sub.3O), 2;39 (s, CH.sub.3N); MS (Cl): m/z 406 (M.sup.++1).
[0234] Zinc powder was carefully added in portions (totalling 1.4
g, 21.45 mmol) to a reflux boiling mixture of
14.beta.-benzyloxy-4,5.alpha.-expoxy-
-3-methoxy-17-methylmorphinan-6-one (870 mg, 2.15 mmol), NH.sub.4Cl
(1.4 g, 26.21 mmol) and MeOH (40 ml) under stirring. The mixture
was reflux heated for 2 h. After filtration from the inorganic
material, the filtrate was evaporated down, water (40 ml) was added
to the evaporation residue, extracted with a mixture of
CH.sub.2Cl.sub.2 and isopropanol (3:1) (3.times.each with 40 ml),
the combined organic phases washed with water (1.times.20 ml) and
NaCl solution (1.times.20 ml), dried over Na.sub.2SO.sub.4 and
evaporated down. The evaporation residue (961 mg of white foamy
resin) was purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250:4:0.5)). The
evaporation residue (750 mg) was dissolved in ether and etherial
HCl added to it. Yield: 730 mg (77%) of compound 27.HCl. Fp.
>220-224.degree. C. (decomp.); IR (KBr): 1714 (C.dbd.O)
cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.26 (s, wide,
.sup.+NH), 8.84 (s, C4-OH), 7.55-7.31 (m, 5 arom. H), 6.91 (d, 1
arom. H, J=8.2 Hz), 6.68 (d, 1 arom. H, J=8.2 Hz), 4.87 (d, 1
aliph. H, OCH.sub.2C.sub.6H.sub.5, J=11.6 Hz), 4.66(d, 1 aliph. H,
OCH.sub.2C.sub.6H.sub.5, J=11.6 Hz), 3.76 (s, C.sub.3--OCH.sub.3),
2.88 (d, 3H, .sup.+N--CH.sub.3). MS (Cl): m/z 408 (M.sup.++1).
EXAMPLE 28
Synthesis of
14.beta.-benzyloxy-3,4-dimethoxy-17-methylmorphinan-6-one
Hydrochloride (Compound 28.HCl).
[0235] 44
[0236] A mixture of 27.HCl (343 mg, 0.84 mmol), K.sub.2CO.sub.3
(353 mg, 2.52 mmol) and phenyltrimethyl ammonium chloride (285 mg,
1.68 mmol) and N,N-dimethylformamide (25 ml) was stirred for 4 h at
80.degree. C. (bath temperature) under N.sub.2. After filtration
from the inorganic material, the filtrate was evaporated down, the
evaporation residue (red-brown oil) dissolved in CH.sub.2Cl.sub.2
(50 ml), washed with water (2.times.20 ml) and NaCl solution
(1.times.20 ml), dried over Na.sub.2SO.sub.4 and evaporated down.
The evaporation residue (470 mg of brown oil) was purified using
column chromatography (silica gel; CH.sub.2Cl.sub.2 MeOH conc.
NH.sub.4OH: each 1 l: (250/2/0.5), (250/3/0.5), (250/4/0.5),
(250/6/0.5), (250/8/0.5)). The evaporation residue (280 mg, yellow
oil) was dissolved in ether and precipitated as compound 28.HCl
using etherial HCl. Yield: 251 mg (66%); Fp. 140-145.degree. C.; IR
(KBr): 1710 (C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6):
.delta. 9.27 (s, wide, .sup.+NH), 7.53-7.30 (m, 5 arom. H), 7.02
(d, 1 arom. H, J=8.4 Hz), 6.91 (d, 1 arom. H, J=8.4 Hz), 4.84 (d, 1
aliph. H, OCH.sub.2C.sub.6H.sub.5) J=11 Hz), 4.64 (d, 1 aliph. H,
OCH.sub.2C.sub.6H.sub.5), J=11 Hz), 3.78 and 3.82 (2 s, 2
OCH.sub.3), 2.87 (s, .sup.+N--CH.sub.3); MS (Cl): m/z 422
(M.sup.++1).
EXAMPLE 29
Synthesis of
4-hydroxy-3-methoxy-17-methyl-140-[(2-naphthylmethyl)oxy]morp-
hinan-6-one Hydrochloride (Compound 29.HCl).
[0237] 45
[0238] A mixture of
4,5.alpha.-expoxy-14.beta.-hydroxy-3-methoxy-17-methyl-
morphinan-6-spiro-2'-(1,3-dioxolane) (Lester et al., 1965, 21, p.
771) (1.96 g, 5.45 mmol), NaH (682 mg, 28.43 mmol, obtained from
1.14 g of 60% dispersion by washing with petroleum ether) and 40 ml
of water-free N,N-dimethylformamide was stirred for 45 min. at
0.degree. C. (bath temperature) under N.sub.2. After the addition
of 2-bromomethylnaphthalin (96%, 2.31 g, 10.9 mmol) stirring
continued for 2 h at 0.degree. C. (bath temperature). Then small
ice pieces were added until no more H.sub.2 was given off, the
mixture was, diluted with water (50 ml) and extracted with
CH.sub.2Cl.sub.2 (3.times.50 ml, 2.times.25 ml). The combined
organic phases were washed with water (4.times.50 ml) and NaCl
solution (1.times.250 ml), dried over Na.sub.2SO.sub.4 and
evaporated down. The crystalline evaporation residue (1.26 g) was
treated twice each time with 10 ml of reflux boiling MeOH for
purification. Yield: 960 mg (35%) of
4,5-expoxy-3-methoxy-17-methyl-14.beta.-[(2-naphthylmethyl)oxy]morphinan--
6-spiro-2'-(1,3-dioxolane). Fp. 184-185.degree. C.; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 7.93-7.89 (m, 4 arom. H), 7.62-7.48 (m, 3
arom. H), 6.75 (d, 1 arom. H, J=8.2 Hz), 6.62 (d, 1 arom. H, J=8.2
Hz), 4.72 (d, 1 aliph. H, OCH.sub.2naphthyl, J=11.4 Hz), 4.47 (d, 1
aliph. H, OCH.sub.2naphthyl, J=11.4 Hz), 4.43 (s, C.sub.5--H),
4.06-3.68 (m, 4H, OCH2CH.sub.2O), 3.78 (s, OCH.sub.3), 2.34 (s,
N--CH.sub.3); MS (Cl): m/z 500 (M.sup.++1).
[0239] A solution of
4,5.alpha.-expoxy-3-methoxy-17-methyl-14.beta.-[(2-na-
phthylmethyl)oxy]-morphinan-6-spiro-2'-(1,3-dioxolane) (2,3 g, 4.60
mmol) in MeOH (30 ml) and 2N HCl (45 ml) was reflux heated for 4 h.
After cooling, it was diluted with water (40 ml), alkalised with
conc. NH.sub.4OH and extracted with CH.sub.2Cl.sub.2 (1.times.200
ml, 1.times.100, 3.times.50 ml). The combined organic phases were
washed with water (1.times.200 ml) and NaCl solution (1.times.200
ml), dried over Na.sub.2SO.sub.4 and evaporated down. The
evaporation residue (1.84 g of dark yellow oil) was crystallised
out of MeOH. Yield: 1.63 g (78%)
4,5.alpha.-expoxy-3-methoxy-17-methyl-14.beta.-[(2-naphthylmethyl)oxy]-mo-
rphinan-6-one. Fp. 195-199.degree. C.; IR (KBr): 1724 (vC.dbd.O)
cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 8.00-7.90 (m, 4
arom. H), 7.68-7.48 (m, 3 arom. H), 6.77 (d, 1 arom. H, J=8.2 Hz),
6.70 (d, 1 arom. H, J=8.2 Hz), 4.88 (s, C.sub.5--H), 4.84 (d,
aliph. H, 140CH.sub.2-naphthyl, J=11.2 Hz), 4.64 (d, 1 aliph. H,
14OCH.sub.2-naphthyl, J=11.2 Hz), 3.80 (s, 3OCH.sub.3), 2.37 (s,
N--CH.sub.3); MS (Cl): m/z 456 (M.sup.++1).
[0240] Zinc powder was added in portions (totalling 1.75 g, 26.76
mmol) to a reflux boiling mixture of
4,5.alpha.-expoxy-3-methoxy-17-methyl-14.beta-
.-[(2-naphthylmethyl)oxy]-morphinan-6-one (1.0 g, 2.20 mmol),
NH.sub.4Cl (1.75 g, 32.71 mmol) and MeOH (42 ml) under stirring.
The mixture was reflux heated for 3 h. After filtration from the
inorganic residue and washing with MeOH, the filtrate was
evaporated down, water (40 ml) added to the evaporation residue,
alkalised with conc. NH.sub.4OH and extracted with CH.sub.2Cl.sub.2
(1.times.70 ml, 2.times.50 ml). The combined organic phases were
washed with water (1.times.40 ml), 1.times.30 ml) and NaCl solution
(1.times.30 ml), dried over Na.sub.2SO.sub.4 and evaporated down.
The evaporation residue (1.09 g of light brown foamy resin) was
purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/c- onc. NH.sub.4OH: 1.51: (250/2/0.5); 0.5 l
each of: (250/3/0.5), (250/14/0.5), (250 /6/0.5). The evaporation
residue (836 mg of beige foamy resin) was dissolved in ether and
compound 29 was precipitated out as the hydrochloride (29.HCl) with
etherial HCl. Yield: 729 mg (68%); Fp. 195-197.degree. C.; IR
(KBr): 1710 (C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6):
.delta. 9.24 (s, wide, .sup.+NH), 8.86 (s, 4-OH), 8.02-7.91 (m, 4
arom. H, naphthyl), 7.70-7.48 (m, 3 arom. H, naphthyl), 6.91 (d, 1
arom. H, J=8.2 Hz), 6.69 (d, 1 arom. H, J=8.2 Hz), 5.01 (d, 1
aliph. H, 140CH.sub.2-naphthyl, J=12 Hz), 4.82 (d, 1 aliph. H,
14OCH.sub.2-naphthyl, J=12 Hz), 3.77 (s, 30CH.sub.3), 2.90 (ps-d,
.sup.+NCH.sub.3); MS (Cl): m/z 458 (M.sup.++1).
EXAMPLE 30
Synthesis of
3,4-dimethoxy-17-methyl-14.beta.-[(2-naphthylmethyl)oxy]morph-
inan-6-one Hydrochloride (Compound 30.HCl).
[0241] 46
[0242] A mixture of 29.HCl (316 mg, 0.64 mmol), K.sub.2CO.sub.3
(304 mg, 2.17 mmol), phenyltrimethyl ammonium chloride (280 mg,
1.53 mmol) and N,N-dimethylformamide (25 ml) was stirred at
80.degree. C. (bath temperature) under N.sub.2 for 2 h. After
filtration from the inorganic material, the filtrate was evaporated
down, the evaporation residue (red-brown oil) absorbed in
CH.sub.2Cl.sub.2 (50 ml), washed with water (2.times.20 ml) and
NaCl solution (1.times.20 ml), dried over Na.sub.2SO.sub.4 and
evaporated down. The evaporation residue (237 mg of brown oil) was
purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH: 1.5 l: (250/2/0.5); 0.5 l
each of: (250/3/0.5), (250/4/0.5), (250/6/0.5), (250/8/0.5). The
evaporation residue (265 mg of beige foamy resin) was dissolved in
ether and compound 30 was precipitated out as the hydrochloride
(30.HCl) with etherial HCl. Yield: 257 mg (80%): Fp.
165-170.degree. C.; IR (KBr): 1712 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 9.27 (s, wide, .sup.+NH), 8.03-7.91 (m, 4
arom. H), 7.70-7.51 (m, 3 arom. H), 7.05 (d, 1 arom. H, J=8.6 Hz),
6.97 (d, 1 arom. H, J=8.6 Hz), 5.01 (d, 1 aliph. H,
14OCH.sub.2-naphthyl, J=11.6 Hz), 4.83 (d, 1 aliph. H.
14OCH.sub.2-naphthyl, J=11.6 Hz), 3.84 and 3,79 (s, 2 OCH.sub.3),
2.90 (d, .sup.+NCH.sub.3); MS (Cl): m/z 472 (M.sup.++1).
EXAMPLE 31
Synthesis of
4-hydroxy-3-methoxy-5.beta.,17-dimethyl-14.beta.-[(3-phenylpr-
opyl)oxy]morphinan-6-one Hydrochloride (Compound 31.HCl).
[0243] 47
[0244] Zinc powder was added in portions (totalling 5.5 g, 84.12
mmol) to a reflux boiling mixture of
4,5.alpha.-expoxy-3-methoxy-5.beta.,
17-dimethyl-14.beta.-[(3-phenylpropyl)oxy]morphinan-6-one (see
Example 17) (3.7 g, 8.27 mmol), NH.sub.4Cl (4.5 g, 83.87 mmol) and
EtOH (50 ml) under stirring. The mixture was reflux heated for 47
h. After filtration from the inorganic residue and washing with
EtOH, the filtrate was evaporated down, water (200 ml) added to the
evaporation residue (6.35 g of white foamy resin), alkalised with
conc. NH.sub.4OH and extracted with CH.sub.2Cl.sub.2 (1.times.100
ml, 4.times.50 ml). The combined organic phases were washed with
water (4.times.200 ml) and NaCl solution (1.times.200 ml), dried
over Na.sub.2SO.sub.4 and evaporated down. The evaporation residue
(3.93 g of yellow oil) was purified using column chromatography
(silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250/2/0.5).
2.99 g (80%) of the pure compound 31 was obtained as a yellow oil.
500 mg of it was dissolved in ether and the compound 31 was
precipitated out as the hydrochloride (31.HCl) with etherial HCl.
Fp. >210.degree. C. (decomp.); IR (KBr): 1700 (C.dbd.O)
cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.64 (s, C4-OH),
8.88 (s, wide, .sup.+NH), 7.33-7.17 (m, 5 arom. H), 6.91 (d, 1
arom. H, J=8.2 Hz), 6.70 (d, 1 arom. H, J=8.2 Hz), 3.78 (s,
3OCH.sub.3), 2.80 (d, .sup.+NCH.sub.3, J=3.4 Hz), 1.28 (d,
C.sub.5--CH.sub.3, J=6.6 Hz); MS (Cl): m/z 450 (M.sup.++1).
EXAMPLE 32
Synthesis of
3,4-dimethoxy-5.beta.,17-dimethyl-14.beta.-[(3-phenylpropyl)o-
xy]morphinan-6-one Hydrochloride (Compound 32.HCl).
[0245] 48
[0246] Compound 31 (base) (1.55 g, 3.44 mmol) was dissolved in 20 g
of 40% tetrabutyl ammonium hydroxide solution at room temperature
under N.sub.2. Then a solution of dimethyl sulphate (0.48 g, 3.8
mmol) in 15 ml of dichloromethane was added. The mixture was
vigorously stirred for 12.5 h at room temperature under N.sub.2 and
then 300 ml water and 50 ml dichloromethane were added. The aqueous
phase was extracted with dichloromethane (2.times.50 ml). The
combined organic phases were washed with conc. ammonia (1.times.50
ml), water (6.times.200 ml) and saturated sodium chloride solution
(1.times.200 ml), dried over sodium sulphate and evaporated down.
The evaporation residue (1.25 g of yellow oil) was purified using
column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/c- onc.
NH.sub.4OH (250/2/0.5) 1.0 g (53%) of the pure compound 32 was
obtained as a yellow oil. 810 mg of it was dissolved in ether and
the compound 32 was precipitated out as the hydrochloride (32.HCl)
with etherial HCl. Fp. 135-138.degree. C.; IR (KBr): 1700 (C.dbd.O)
cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.36 (s, wide,
.sup.+NH), 7.31-7.21 (m, 5 arom. H), 7.05 (d, 1 arom. H, J=8.4 Hz),
6.95 (d, 1 arom. H, J=8.4 Hz), 3.80 and 3.79 (2 s, 2 OCH.sub.3),
2.81 (d, .sup.+NCH.sub.3, J=4.8 Hz), 1.25 (d, C.sub.5--CH.sub.3,
J=7 Hz); MS (Cl): m/z 464 (M.sup.++1).
EXAMPLE 33
Synthesis of
14.beta.-ethoxy-4-hydroxy-3-methoxy-5.beta.,17-dimethylmorphi-
nan-6-one (Compound 33)
[0247] 49
[0248] Zinc powder was added in portions (totalling 15.0 g, 229.4
mmol) to a reflux boiling mixture of
4,5.alpha.-expoxy-14.beta.-ethoxy-3-methoxy-5- .beta.,1
7-dimethylmorphinan-6-one (Schmidhammer et al., Helv. Chim. Acta
1990, 73, pp. 1784-1787) (3.0 g, 8.4 mmol), NH.sub.4Cl (15.0 g,
280.1 mmol) and MeOH (30 ml) under stirring. The mixture was reflux
heated for 24 h. After filtration from the inorganic residue and
washing with MeOH, the filtrate was evaporated down, the
evaporation residue alkalised with diluted NH.sub.4OH and extracted
with a mixture of CH.sub.2Cl.sub.2 and MeOH (2:1) (1.times.100 ml,
3.times.30 ml). The combined organic phases were dried over
Na.sub.2SO.sub.4 and evaporated down. The evaporation residue (2.82
g of brown foamy resin) was crystallised out of MeOH and in this
way 684 mg of pure compound. 33 was obtained. The mother liquor was
evaporated down and the evaporation residue (1.895 g of brown foamy
resin) was used for the production of the compound 34 without
further purification. Compound 33: Fp. 122-129.degree. C.; IR
(KBr): 3480 (OH), 1715 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(CDCl.sub.3): .delta. 6.67 (d, 1 arom. H, J=8.0 Hz), 6.57 (d, 1
arom. H, J=8.0 Hz), 3.82 (s, OCH.sub.3), 2.32 (s, NCH.sub.3), 1.54
(s, C.sub.5--CH.sub.3), 1.18 (t, CH.sub.3CH.sub.2, J=5.7 Hz); MS
(Cl): m/z 360 (M.sup.++1).
EXAMPLE 34
Synthesis of
14.beta.-ethoxy-3,4-dimethoxy-5.beta.,17-dimethylmorphinan-6-- one
salicylate (compound 34.C.sub.7H.sub.6O.sub.3)
[0249] 50
[0250] A mixture of the compound 33 (1,895 g, 5.3 mmol)
(evaporation residue of the mother liquor, see above),
K.sub.2CO.sub.3 (2.12 g, 15.3 mmol), phenyltrimethyl ammonium
chloride (1.8 g, 10.5 mmol) and water free N,N-dimethylformamide
(20 ml) was stirred at 80.degree. C. (bath temperature) under
N.sub.2 for 3 h. After filtration from the inorganic material and
washing with dichloromethane, the filtrate was evaporated down. The
evaporation residue was dissolved in dichloromethane, washed with
water (2.times.50 ml) and saturated NaCl solution (1.times.50 ml),
dried over sodium sulphate and evaporated down. The evaporation
residue (2.11 g of dark brown oil) was purified using column
chromatography (basic aluminium oxide, activity level III;
dichloromethane). The evaporation residue was crystallised as
compound 34.C.sub.7H.sub.6O.sub.3 with salicylic acid in
diisopropylether. Yield: 1.32 g (49%). Fp. 135-141.degree. C.; IR
(KBr): 3400 (.sup.+NH, OH), 1710 (C.dbd.O), 1630 (CO.sub.2)
cm.sup.-1; .sup.1H-NMR (CDCl.sub.3): .delta. 7.88 (m, .sup.+NH),
7.27 (m, 2 arom. H), 6.81 (m, 4 arom. H), 3.86 (s, OCH.sub.3), 3.83
(s, OCH.sub.3), 2.84 (s, .sup.+NCH.sub.3), 1.40 (d,
C.sub.5--CH.sub.3, 5.8 Hz), 1.17 (t, CH.sub.3CH.sub.2, J=5.3 Hz);
MS (Cl): m/z 374 (M.sup.++1).
EXAMPLE 35
Synthesis of
14.beta.-benzyloxy-3,4-dimethoxy-5.beta.,17-dimethylmorphinan-
-6-one (Compound 37)
[0251] 51
[0252] Zinc powder was added in portions (totalling 10.5 g, 160.6
mmol) to a reflux boiling mixture of
4,5.alpha.-expoxy-3-methoxy-5.beta.,17-dimeth-
yl-14.beta.-hydroxymorphinan-6-one (Schmidhammer et al., Helv.
Chim. Acta 1988, 71, pp. 1801-1804) (4.17 g, 12.6.6 mmol),
NH.sub.4Cl (7.0 g, 130.87 mmol) and EtOH (50 ml) under stirring.
The mixture was reflux heated for 68 h. After filtration from the
inorganic residue and washing with EtOH, the filtrate was
evaporated down, water (150 ml) was added to the evaporation
residue (7.65 g of white foamy resin), it was alkalised with conc.
NH.sub.4OH and extracted with CH.sub.2Cl.sub.2/isopropanol (3:1)
(2.times.80 ml, 1.times.60 ml, 1.times.40 ml). The combined organic
phases were washed with water (3.times.70 ml) and NaCl solution
(1.times.70 ml), dried over Na.sub.2SO.sub.4 and evaporated down.
The evaporation residue (5.02 g of brown oil) was crystallised out
of CH.sub.2Cl.sub.2/isopropanol (5:3) to form compound 35
(4,140-dihydroxy-3-methoxy-5.beta., 17-dimethylmorphinan-6-one)
(3.39 g, (81%). 200 mg of it was dissolved in acetone and 135 mg
was precipitated with etherial HCl to give the compound 35.HCl: Fp.
>185.degree. C. (decomp.); IR (KBr): 3200 (OH), 1700 (C.dbd.O)
cm.sup.-1; Analytical data of the base compound 35: .sup.1H-NMR
(DMSO-d.sub.6): .delta. 8.43 (s, C.sub.4--OH), 6.77 (d, 1 arom. H,
J=8.2 Hz), 6.57 (d, 1 arom. H, J=8.2 Hz), 4,49 (s, C.sub.14--OH),
3.74 (s, C.sub.3--OCH.sub.3), 2.25 (s, NCH.sub.3), 1.30 (d,
C.sub.5--CH.sub.3, J=7.4 Hz); MS (Cl): m/z 332 (M.sup.++1). 52
[0253] Compound 35 (base) (9.5 g, 28.67 mmol) was dissolved in 45 g
of 40% tetrabutyl ammonium hydroxide solution at room temperature
under N.sub.2. Then a solution of dimethyl sulphate (2.75 ml (=3.67
g), 29.06 mmol) in 50 ml of dichloromethane was added. The mixture
was vigorously stirred at room temperature for 5 h under N.sub.2
and then 100 ml of water was added. The aqueous phase was extracted
with dichloromethane (3.times.50 ml). The combined organic phases
were washed with 2 M am monia solution (1.times.70 ml), water
(12.times.100 ml) and saturated sodium chloride solution
(1.times.100) ml, dried over sodium sulphate and evaporated down.
The evaporation residue (8.16 g of light coloured oil) was
crystallised out of 4 ml MeOH. Yield: 5.06 g (51%)
14.beta.-hydroxy-3,4-dimethoxy-50-17-dimethylmorphinan-6-one
(compound 36). Fp. 122-124.degree. C.; IR (KBr): 1704 (C.dbd.O)
cm.sup.-1; .sup.1H-NMR (CDCl.sub.3): .delta. 6.78 (s, 2 arom. H),
4.31 (s, C14-OH), 3.87 and 3.82 (2.s, 2 OCH.sub.3), 2.32 (s,
NCH.sub.3); 1.28 (d, C.sub.5--CH.sub.3, J=6.8 Hz); MS (Cl): m/z 346
(M.sup.++1). 53
[0254] A mixture of compound 36 (7.42 g, 21.48 mmol), 2.20 ml
methane sulphonic acid (3.26 g, 33.93 mmol) and 100 ml diethylene
glycol was stirred for 1 h under N.sub.2 and at a bath temperature
of 80.degree. C. Then the mixture was poured onto 600 ml of
ice-water, alkalised with concentrated ammonia and extracted with
dichloromethane (1.times.200 ml, 4.times.50 ml). The combined
organic phases were washed with water (5.times.200 ml) and
saturated sodium chloride solution (1.times.200 ml), dried over
sodium sulphate and evaporated down. The evaporation residue (8.13
g of reddish crystals) was recrystallised out of 8 ml methanol.
Yield: 4.91 g (59%) of
14.beta.-hydroxy-3,4-dimethoxy-5.beta.,17-dimethyl-
morphinan-6-spiro-2'-(1,3-dioxolane). Fp. 155-157.degree. C.;
.sup.1H-NMR (CDCl.sub.3): .delta. 6.76 (s, 2 arom. H), 4.36 (s,
C14-OH), 3.91-3.57 (m, 4H, OCH.sub.2CH.sub.2O--C), 3.83 and 3.74 (2
s, 2 CH.sub.3O), 2.30 (s, CH.sub.3N), 1.35 (d, C5-CH.sub.3, J=5.2
Hz); MS (Cl): m/z 390 (M.sup.++1).
[0255] NaH (0.13 g, 5.41 mmol) (obtained from 0.21 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of
14.beta.-hydroxy-3,4-dimethoxy-5.beta.,17-dimethylmorphinan-6-
-spiro-2'-(1,3-dioxolane) (1.00 g, 2.57 mmol) in 100 ml water-free
N,N-dimethylformamide under N.sub.2 at 0.degree. C. (bath
temperature) under stirring. After 15 min. benzyl bromide (0.88 g,
5.14 mmol) was added and the mixture stirred for 3 h at room
temperature. Then the excess sodium hydride was broken down with
pieces of ice, the reaction mixture was poured onto 300 ml water
and extracted with dichloromethane/isopropanol (5:2) (3.times.70
ml). The combined organic phases were washed with H.sub.2O
(5.times.200 ml) and a saturated sodium chloride solution
(1.times.200 ml), dried over sodium sulphate and evaporated down.
The evaporation residue (1.65 g of yellowish crystals) was
crystallised but of 2 ml ethanol. Yield: 0.65 g (53%)
14.beta.-benzyloxy-3,4-dimethoxy-5.beta.,17-dimethylmorphinan-6-spiro-2'--
(1,3-dioxolane). Fp. 201-202.degree. C.; .sup.1H-NMR. (CDCl.sub.3):
.delta. 7.49-7.23 (m, 5 arom. H), 6.77 (s, 2 arom. H), 4.61 (d, 1H,
PhCH.sub.2O, J=10.5 Hz), 4.29 (d, 1H, PhCH.sub.2O, J=10.5 Hz),
3.88-3.56 (m, 4H, OCH.sub.2CH.sub.2O), 3.83 and 3.76 (2 s, 2
CH.sub.3O), 2.30 (s, CH.sub.3N), 1.25 (d, C5-CH.sub.3, J=7.4 Hz);
MS (Cl): m/z480 (M.sup.++1).
[0256] A solution of
14.beta.-benzyloxy-3,4-dimethoxy-5.beta.,17-dimethylm-
orphinan-6-spiro-2'-(1,3-dioxolane) (0.50 g, 1.04 mmol) in 10 ml of
a mixture of 5 ml methanol, 4 ml water and 1 ml conc. HCl was
reflux heated for 30 minutes. Then the mixture was poured onto 150
ml of ice-water, alkalised with concentrated ammonia and extracted
with dichloromethane/isopropanol (4:1) (2.times.50 ml, 2.times.25
ml). The combined organic phases were washed with water
(2.times.100 ml) and a saturated sodium chloride solution
(1.times.100 ml), dried over sodium sulphate and evaporated down.
The evaporation residue (0.51 g of light coloured oil) was
crystallised out of 1 ml methanol. Yield: 0.34 g (76%) of compound
37. Fp. 166-167.degree. C.; IR (KBr): 1695 (CO) cm.sup.-1;
.sup.1H-NMR (CDCl.sub.3): .delta. 7.34-7.21 (m, 5 arom. H), 6.83
(d, 1 arom. H, J=8.6 Hz), 6,78 (d, 1 arom. H, J=8.6 Hz), 4.63 (d,
1H, PhCH.sub.2O, J=10.8 Hz), 4.32 (d, 1H, PhCH.sub.2O, J=10.8 Hz),
3.86 and 3 83 (2s, 2CH.sub.3O), 2.30 (s, CH.sub.3N), 1.43 (d,
C5-CH.sub.3, J=7.0 Hz); MS (Cl): m/z 436 (M.sup.++1).
EXAMPLE 36
Synthesis of
4,5.alpha.-epoxy-3-hydroxy-17,17-dimethyl-6-oxo-14.beta.-[(3--
phenylpropyl)oxy]morphinanium-iodide (compound 38)
[0257] 54
[0258] A solution of
4,5.alpha.-epoxy-3-methoxy-17-methyl-14-[(3-phenylpro-
pyl)oxy]morphinan-6-one (=14-O-(3-phenylpropyl)oxycodon; see
Example 1) (3.0 g, 6.90 mmol) in 48% HBr (30 ml) was reflux heated
for 15 minutes. After the reaction had finished, the solution was
cooled with ice, alkalised with conc. NH.sub.4OH and extracted with
CH.sub.2Cl.sub.2 (5.times.50 ml). The combined organic phases were
washed with water (3.times.50 ml) and a saturated NaCl solution
(1.times.50 ml), dried over Na.sub.2SO.sub.4 and evaporated down.
The evaporation residue (3.5 g of brown oil) was purified using
column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc.
NH.sub.4OH: 6 l: (250/2/0.5): each 0.5 l: (250/3/0.5), (250/4/0.5),
(250 /6/0.5), (250/8/0.5)). The evaporation residue
(4,5.alpha.-epoxy-3-hydroxy-17-methyl-14.beta.-[(3-phenylpropyl)o-
xy]morphinan-6-one, 1.36 g of yellow oil, 47%) could not be
crystallised. Therefore one part was passed as oil to the next
reaction and the remainder converted as usual to the hydrochloride
(4,5.alpha.-epoxy-3-hyd-
roxy-17-methyl-14.beta.-[(3-phenylpropyl)oxy]morphinan-6-one
hydrochloride). Analytical data of the hydrochloride: Fp.
185-189.degree. C.; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.50 (s,
C.sub.3--OH), 8.68 (s, wide, .sup.+NH), 7.34-7.16 (m, 5 arom. H),
6.70 (d, 1 arom. H, =8.0 Hz), 6.65 (d, 1 arom. H, J=8.0 Hz), 4.87
(s, C.sub.5--H), 2.92 (d, .sup.+NCH.sub.3).
[0259] A solution of
4,5.alpha.-epoxy-3-hydroxy-17-methyl-14.beta.-[(3-phe-
nylpropyl)oxy]morphinan-6-one (oil, 257 mg, 0.61 mmol) and methyl
iodide (0.38 ml, 6.11 mmol) in acetonitrile (10 ml) was stirred for
2 days at 50.degree. C. (bath temperature) under N.sub.2. A DC
examination showed that the reaction was not concluded. Therefore
further methyl iodide (0.38 ml, 6.11 mmol) was added and the
solution stirred further for 3 days under the same conditions. Then
the solvent was evaporated off and the evaporation residue (367 mg
of yellow foamy resin) was purified using column chromatography
(silica gel; CH.sub.2Cl.sub.2/MeOH (10:1)). Evaporation residue 240
mg (71%) amorphous compound 38. Fp. 164-170.degree. C.; IR (KBr):
1723 (C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.57
(s, C3-OH), 7.3-7.16 (m, 5 arom. H), 6.67 (s, 2 arom. H,
C.sub.1--H, C.sub.2--H), 4.88 (s, C.sub.5--H), 3.56 (s,
N.sup.+CH.sub.3, axial), 3.21 (s, .sup.+NCH.sub.3, equatorial); MS
(Cl): m/z 434 (M.sup.+).
EXAMPLE 37
Synthesis of
(17S)-4,5.alpha.-epoxy-17-ethyl-3-hydroxy-17-methyl-6-oxo-14.-
beta.-[(3-phenylpropyl)oxy]morphinanium-iodide (Compound 39)
[0260] 55
[0261] A solution of compound 20 (see Example 20) (250 mg, 0.58
mmol) and methyl iodide (0.36 ml, 5.80 mmol) in acetonitrile (10
ml) was stirred for 6 days at 50.degree. C. (bath temperature)
under N.sub.2. The solution was evaporated down and the evaporation
residue (320 mg of bright beige foamy resin) was purified using
column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH: each 1 l
: (95/5), (92.5/7.5)). Evaporation residue (240 mg, 72%) of
amorphous compound 39. Fp. 171-176.degree. C.; IR (KBr): 1723
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.55(s,
C3-OH), 7.31-7.16 (m, 5 arom. H), 6.68 (s, 2 arom. H, C.sub.1--H,
C.sub.2--H), 4.87 (s, C.sub.5--H), 3.44 (3H, N.sup.+CH.sub.3,
axial), 1.34 (t, 3H, .sup.+NCH.sub.2CH.sub.3, J=7 Hz); MS (Cl): m/z
448 (M.sup.+).
EXAMPLE 38
Synthesis of
(17R)-4,5.alpha.-epoxy-3-hydroxy-17-methyl-6-oxo-14.beta.-[(3-
-phenylpropyl)oxy]-17-[(2-R,S-tetrahydrofurfuran-2-yl)methyl]morphinanium--
iodide (Compound 40)
[0262] 56
[0263] A solution of the compound 10 (see Example 10) (190 mg, 0.39
mmol) and methyl iodide (0.24 ml, 3.9 mmol) in acetonitrile (8 ml)
was stirred for 10 days at 40-50.degree. C. (bath temperature)
under N.sub.2. The solution was evaporated down and the evaporation
residue (248 mg of beige foamy resin) was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH: 2 l: (250/5); 1
l: (250/7.5)). The resulting evaporation residue (70 mg of yellow
foamy resin, 28%) was pure compound 40. Fp. 156-159.degree. C.; IR
(KBr): 1724 (C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6):
.delta. 9.53 (s, C3-OH), 7.30-7.16 (m, 5 arom. H), 6.68 (s, 2 arom.
H, C.sub.1--H, C.sub.2--H), 4.85 (s, 1H, C.sub.5--H), 3.58 (s,
.sup.+NCH.sub.3, axial); MS (Cl): m/z 504 (M.sup.+).
EXAMPLE 39
Synthesis of
(17R)-17-allyl-4,5.alpha.-epoxy-14.beta.-ethoxy-3-hydroxy-17--
methylxomorphinanium-iodide (Compound 41)
[0264] 57
[0265] A solution of 14-O-ethylnaloxone (Kobylecki et al., J. Med.
Chem. 1982, 25, p. 116) (300 mg, 0.84 mmol) and methyl iodide (0.25
ml, 4.2 mmol) was stirred in 8 ml acetonitrile for 7 days at
30.degree. C. (bath temperature) and then evaporated down. The
evaporation residue (450 mg of light brown oil) was purified using
column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH (250:4)).
Evaporation residue (110 mg, 35%) of amorphous compound 41. Fp.
130-134.degree. C.; IR (KBr): 1724 (CO) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 9.54 (s, C3-OH), 6.70 (s, 2 arom. H),
6.32-6.07 (m, 1 olef. H), 5.84-5.63 (m, 2 olef. H), 4.92 (s, C5-H),
3.49 (s, .sup.+NCH.sub.3, axial), 1.24 (t, 3H, OCH.sub.2CH.sub.3,
J=6.8 Hz); MS (Cl): m/z 370 (M.sup.+).
EXAMPLE 40
Synthesis of
(17R)-17-allyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17-
-methyl-6-oxomorphinanium-iodide (Compound 42)
[0266] 58
[0267] A solution of 14-O-methylnaloxone (Kobylecki et al., J. Med.
Chem. 1982, 25, p. 116) (230 mg, 0.67 mmol) and methyl iodide (0.21
ml, 3.37 mmol) was stirred in 10 ml acetonitrile for 7 days at
40.degree. C. (bath temperature) and then evaporated down. The
evaporation residue (341 mg of light brown oil) was purified using
column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH
(250:4.5->250:9)). Evaporation residue (202 mg, 62%) of
amorphous compound 42. Fp. 178-181.degree. C.; IR (KBr): 1722 (CO)
cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 9.55 (s, C3-OH),
6.70 (s, 2 arom. H), 6.28-6.06 (m, 1 olef. H), 5.82-5.64 (m, 2
olef. H), 4.94 (s, C5-H), 3.45 (s, .sup.+NCH.sub.3, axial), 3.38
(s, CH.sub.3O); MS (Cl): m/z 356 (M.sup.+).
EXAMPLE 41
Synthesis of
(17S)-17-allyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17-
-methylxomorphinanium-iodide (Compound 43)
[0268] 59
[0269] A solution of 14-O-methyloxymorphone (Schmidhammer et al.,
J. Med. Chem. 1984, 27, pp. 1575-1579) (210 mg, 0.67 mmol) and
allyl iodide (0.28 ml, 3.35 mmol) was stirred in 5 ml
N,N-dimethylformamide for 7 days at 40.degree. C. (bath
temperature) and then evaporated down. The evaporation residue (484
mg of brown oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2 MeOH (250:5->250:12)). The evaporation
residue (134 mg) was again purified using column chromatography
(silica gel; CH.sub.2Cl.sub.2/MeOH (250:4.5)). Evaporation residue
77 mg (27%) of amorphous compound 43. Fp. >140.degree. C.; IR
(KBr): 1724 (CO) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta.
9.57 (s, C3-OH), 6.68 (s, 2 arom. H), 6.28-6.08 (m, 1 olef. H),
5.75-5.63 (m, 2 olef. H), 4.95 (s, C5-H), 3.42 (s, CH.sub.3O), 3.05
(s, .sup.+NCH.sub.3, equatorial); MS (Cl): m/z 356 (M+).
EXAMPLE 42
Synthesis of
4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17,17-dimethyl-6--
oxomorphinanium-iodide (Compound 44)
[0270] 60
[0271] A solution of 14-O-methyloxymorphone (Schmidhammer et al.,
J. Med. Chem. 1984, 27, pp. 1575-1579) (200 mg, 0.63 mmol) and
methyl iodide (0.32 ml, 5.07 mmol) in acetonitrile (10 ml) was
stirred for 21 hours under N.sub.2 at 50.degree. C. (bath
temperature). Then methyl iodide (0.2 ml, 3.17 mmol) was again
added, stirred further for 24 h under the same conditions and
evaporated down. The evaporation residue (324 mg of brown foamy
resin) was crystallised out of MeOH (0.5 ml) and purified by
recrystallisation out of MeOH. Yield: 244 mg (84%) of compound 44.
Fp. 225-240.degree. C.; IR(KBr): 1725 (C.dbd.O) cm.sup.-1;
.sup.1H-NMR (DMSO-d.sub.6): .delta. 9.55 (s, C.sub.3--OH), 6.69 (s,
2 arom. H, C, --H, C.sub.2--H), 4.94 (s, C.sub.5--H), 3.55 (s,
.sup.+NCH.sub.3, axial), 3.38 (s, OCH.sub.3), 3,22 (s,
.sup.+NCH.sub.3, equatorial); MS (Cl): m/z 330 (M.sup.+).
EXAMPLE 43
Synthesis of
5.beta.-benzyl-14.beta.-(butyloxy)-4,5.alpha.-epoxy-3-hydroxy-
-17,17-dimethyl-6-oxomorphinanium-iodide (Compound 45)
[0272] 61
[0273] NaH (0.52 g, 21.6 mmol) (obtained from 0.86 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of 5.beta.-benzyl-14-hydroxycodeinone (M. Gates et al., J,
Org. Chem. 1989, 54, pp. 972-974) (2.90 g, 7.2 mmol) in 40 ml
water-free N,N-dimethylformamide under N.sub.2 at 0.degree. C.
(bath temperature) under stirring. After 20 min.
trans-crotylbromide (1.26 g, 9.3 mmol) was added and the mixture
first stirred for 40 min at 0.degree. C. (bath temperature), then
for 2 h at room temperature. Then small pieces of ice were added
until no more hydrogen was given off, the reaction mixture was
poured onto 100 ml water and extracted with dichloromethane
(1.times.100 ml, 5.times.50 ml). The combined organic phases were
washed with saturated sodium chloride solution (6.times.250 ml),
dried over sodium sulphate and the evaporation residue (3.25 g of
brown oil) purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:6:0.5). From the
resulting yellowish oil (1.86 g, 56%) 0.1 g was dissolved in 5 ml
ether and etherial HCl added. 0.1 g of colourless crystals of
5.beta.-benzyl-14.beta.-{[(E)(but-2-enyl]oxy}-7,8.alpha.-dide-
hydro-4,5.alpha.-epoxy-3-methoxy-17-methylmorphinan-6-one
hydrochloride was isolated. Fp. 125-130.degree. C.; MS (Cl): 458
(M.sup.++1); IR (KBr): 1684 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, in ppm): 9.22 (s, wide HN.sup.+), 7.28-7.13 (m, 5
arom. H; 1 olefin. H, CH-8), 6.84 (d, 1 arom. H, J=8.4 Hz), 6.74
(d, 1 arom. H, J=8.4 Hz), 6.23 (d, 1 olefin. H, CH-7, J=10.2 Hz),
5.69-5.34 (m, 2 olefin. H), 3.75 (s, CH.sub.3O), 2.91 (d,
CH.sub.3N.sup.+), 1.69-1.65 (d, 3H, C14-OCH.sub.2CHCHCH.sub.3,
J=7.4 Hz).
[0274] A mixture of
5.beta.-benzyl-14.beta.{[(E)-(but-2-enyl]oxy}-7,8-dide-
hydro-4,5.alpha.-epoxy-3-methoxy-17-methylmorphinan-6-one (1.75 g,
3.8 mmol) and 0.24 g Pd/C (10%) in 60 ml methanol was hydrogenated
for 1.5 hours at 35 psi and room temperature. The catalyst was
filtered off and washed with 20 ml methanol. The filtrate was
evaporated down. Yield: 1.43 g (81%) of bright yellow oil of which
0.1 g was dissolved in 5 ml ether and the hydrochloride was
precipitated by the addition of etherial HCl. 0.1 g of colourless
crystals of 5.beta.3-benzyl-14.beta.-(butoxy)-4,5.alp-
ha.-epoxy-3-methoxy-17-methylmorphinan-6-one hydrochloride was
isolated. Fp. 148-152.degree. C.; MS (Cl): 462 (M.sup.++1); IR
(KBr): 1729 (C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta.
in ppm): 9.00 (s, wide HN.sup.+), 7.29-7.16 (m, 5 arom. H); 6.85
(d, 1 arom. H, J=8.4 Hz), 6.75 (d, 1 arom. H, J=8.4 Hz), 3.80 (s,
CH.sub.3O), 2.94 (d, CH.sub.3N.sup.+, J=4.4 Hz), 1.02 (t, 3H,
C14-O(CH.sub.2).sub.3CH.sub.3, J=7.2 Hz).
[0275] A solution of
5.beta.-benzyl-14.beta.-butoxy-4,5.alpha.-epoxy-3-met-
hoxy-17-methylmorphinan-6-one (1.30 g, 2.82 mmol) in 10 ml 48% HBr
was reflux heated for 20 min. Then the solution was cooled, poured
onto 100 ml of ice, alkalised With conc. NH.sub.4OH and extracted
with dichloromethane (5.times.50 ml). The combined organic phases
were washed with saturated sodium chloride solution (3.times.150
ml), dried over sodium sulphate and evaporated down. The residue
(0.97 g of grey-black foamy resin) was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH
250:6:0.5). Yield: 0.82 g (65%) of dark yellow oil of which 0.06 g
was dissolved in 5 ml ether and the hydrochloride precipitated by
the addition of etherial HCl. 0.06 g of beige crystals of
5.beta.-benzyl-14.beta.-butoxy-4,5.alpha.-epoxy-3-hydro-
xy-17-methylmorphinan-6-one hydrochloride was isolated. Fp.
200-204.degree. C.; MS (Cl): 448 (M.sup.++1); IR (KBr): 1729
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, o in ppm): 9.45 (s,
OH), 8.72 (s, wide HN.sup.+), 7.25-7.22 (m, 5 arom. H); 6.67-6.63
(s, 2 arom. H, CH-1 and CH-2), 2.93 (d, CH.sub.3N.sup.+), 1.02 (t,
3H, C14-O(CH.sub.23CH.sub.3, J=7.3 Hz).
[0276] A solution of
5.beta.-benzyl-14.beta.-butoxy-4,5.alpha.-epoxy-3-hyd-
roxy-17-methylmorphinan-6-one (0.32 g, 0.72 mmol) and methyl iodide
(0.51 g, 3.58 mmol) in 10 ml of water-free acetonitrile was stirred
under N.sub.2 at 40.degree. C. (bath temperature) for 2 days and
then evaporated down. The evaporation residue (0.41 g of brown oil)
was purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH 250:6). Yield: 0.22 g (54%) slightly beige
crystals of the compound 45. Fp. 188-195.degree. C.; MS (Cl): 462
(M+); IR (KBr): 1729 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, .delta. in ppm): 9.49 (s, OH), 7.28-7.20 (m, 5 arom.
H), 6.69 (d, 1 arom. H, J=8.2 Hz), 6.62 (d, 1 arom. H, J=8.2 Hz),
3.61 (s, CH.sub.3N.sup.+, axial), 3.23 (s, CH.sub.3N.sup.+,
equatorial), 1.01 (t, 3H, C14-0(CH.sub.2).sub.3CH.sub.3, J=7.0
Hz).
EXAMPLE 44
Synthesis of
(17S)-17-allyl-5.beta.-benzyl-14.beta.-butoxy-4,5.alpha.-epox-
y-3-hydroxy-17-methyl-6-oxomorphinanium-iodide (Compound 46)
[0277] 62
[0278] A solution of
5.beta.-benzyl-14.beta.-butoxy-4,5.alpha.-epoxy-3-hyd-
roxy-17-methylmorphinan-6-one (see Example 45) (0.31 g, 0.69 mmol)
and allyl bromide (0.94 g, 5.59 mmol) in 10 ml of water-free
acetonitrile was stirred under N.sub.2 at 40.degree. C. (bath
temperature) for one day and then evaporated down. The evaporation
residue (0.45 g of brown oil) was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH 250:5). Yield:
0.11 g (26%) of beige crystals of the compound 46. Fp.
200-205.degree. C.; MS (Cl): 488.2 (M.sup.+); IR (KBr): 1728
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm):
9.49 (s, OH), 7.26-7.23 (m, 5 arom. H), 6.67 (s, 2 arom. H, CH-1
and CH-2), 6.22-6.13 (m, 1 olefin. H), 5.80-5.66 (m, 2 olefin. H),
3.50 (s, CH.sub.3N.sup.+, equatorial), 1.02 (t,
C14-O(CH.sub.2).sub.3CH.sub.3, J=7.4 Hz).
EXAMPLE 45
Synthesis of
14.beta.-butoxy-4,5.alpha.-epoxy-3-hydroxy-17,17-dimethyl-6-o-
xomorphinanium-iodide (Compound 47)
[0279] 63
[0280] NaH (0.92 kg, 38.3 mmol) (obtained from 1.53 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
suspension of 14-hydroxycodeinone (Iijima et al., J. Med. Chem.
1978, 21, p. 398) (4.0 g, 12.8 mmol) in 50 ml water-free
N,N-dimethylformamide under N.sub.2 at 0.degree. C. (bath
temperature) under stirring. After 20 min. trans-crotylbromide
(2.24 g; 16.6 mmol), dissolved in 20 ml DMF, was added drop by drop
and the mixture stirred further for 40 min at 0.degree. C. (bath
temperature), then for 3 h at room temperature. Then small pieces
of ice were added until no more hydrogen was given off, the mixture
was poured onto 100 ml water and extracted with dichloromethane
(1.times.100 ml, 5.times.50 ml), the combined organic phases were
washed with saturated sodium chloride solution (6.times.250 ml) and
dried over sodium sulphate. The evaporation residue (5.2 g of
yellow-brown oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/c- onc. NH.sub.4OH (250:5:0.5)). A
yellowish oil (2.20 g) was produced which was crystallised out of
methanol. Yield: 1.75 g (36%) of yellowish crystals of
14.beta.-{[(E)-(but-2-enyl]oxy}-7,8-didehydro-4,5.alpha.-epox-
y-3-methoxy-17-methylmorphinan-6-one. Fp. 113-117.degree. C.; MS
(Cl): 368.2 (M.sup.++1); IR (KBr): 1679 (C.dbd.O) cm.sup.-;
.sup.1H-NMR (DMSO-d.sub.6, 5 in ppm): 7.13 (d, 1 olefin. H; CH-8,
J=10.0 Hz), 6.73 (d, 1 atom. H, J=8.0 Hz), 6.64 (d, 1 arom. H,
J=8.0 Hz), 6.14 (d, 1 olefin. H, CH-7, J=9.8 Hz), 5.69-5.43 (m, 2
olefin. H), 4.78 (s, CH-5), 4.03-3.80 (m, 2H, C14-OCH.sub.2--),
3.72 (s, CH.sub.3O), 2.34 (s, CH.sub.3N.sup.+), 1.64 (d,
OCH.sub.2CHCHCH.sub.3, J=6.0 Hz).
[0281] A mixture of
14.beta.-{[(Ebut-2-enyl]oxy}-7,8.alpha.-didehydro-4,5.-
alpha.-epoxy-3-methoxy-17-methylmorphinan-6-one (0.82 g, 2.23 mmol)
and 0.82 g Pd/C (10%) in 50 ml methanol was hydrogenated for 45
min. at 30 psi and at room temperature. The catalyst was filtered
off, washed with 20 ml methanol and the filtrate evaporated down.
Yield: 1.02 g of bright yellow oil, which was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH
(250:2:0.5)). This gave a yellowish oil which was crystallised out
of methanol. Yield: 0.52 g (63%) of colourless crystals of
14.beta.-butoxy-4,5.alpha.-epoxy-3-methoxy-17-m-
ethylmorphinan-6-one was isolated. Fp. 112-117.degree. C.; MS (Cl):
371.1 (M.sup.++1); IR (KBr): 1722 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, .delta. in ppm): 6.74 (d, 1 arom. H, J=8.0 Hz), 6.65
(d, 1 arom. H, J=8.2 Hz), 4.75 (s, CH-5), 3.78 (s, CH.sub.3O), 2.29
(s, CH.sub.3N), 0.93 (t, OCH.sub.2CH.sub.2CH.sub.2CH.sub.3, J=7.2
Hz).
[0282] A solution of
14.beta.-butoxy-4,5.alpha.-epoxy-3-methoxy-17-methylm-
orphinan-6-one (0.30 g, 0.81 mmol) in 3.2 ml 48% HBr was reflux
heated for 8 min. Then the solution was cooled, poured onto 20 ml
of ice, alkalised with conc. NH.sub.4OH and extracted with
dichloromethane (5.times.30 ml). The combined organic phases were
washed with saturated sodium chloride solution (3.times.100 ml),
dried over sodium sulphate and evaporated down. The residue (0.29 g
of brown oil) was purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:5:0.5). Yield: 0.06 g
(21%) of dark yellow oil which was dissolved in 5 ml ether and
converted into the hydrochloride with etherial HCl. 0.06 g of light
brown crystals of 14.beta.-butoxy-4,5.alpha.-epoxy-3-hydroxy-17--
methylmorphinan-6-one hydrochloride was isolated. Fp.
168-172.degree. C.; MS (Cl): 358.2 (M.sup.++1); IR (KBr): 1725
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm):
9.51 (s, OH), 8.75 (s, wide, HN.sup.+), 6.71 (d, 1 arom. H, J=8.2
Hz), 6.65 (d, 1 arom. H, J=8.0 Hz), 4.92 (s, CH-5), 2.82 (d,
CH.sub.3N+, J=4.4 Hz), 0.95 (t, O(CH.sub.2)CH.sub.3, J=7.4 Hz).
[0283] A solution of
14.beta.-butoxy-4,5.alpha.-epoxy-3-hydroxy-17-methylm-
orphinan-6-one (0.53 g, 1.49 mmol) and methyl iodide (1.06 g, 7.44
mmol) in 10 ml of water-free acetonitrile was stirred under N.sub.2
at 40.degree. C. (bath temperature) for 2 days and then evaporated
down. The evaporation residue (0.70 g of brown oil) was purified
using column chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH
250:4). Yield: 0.31 g (42%) of colourless crystals of the compound
47. Fp. 180-185.degree. C.; MS (Cl): 372.2 (M.sup.+); IR (KBr):
1726 (C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in
ppm): 9.55 (s, OH), 6.68 (s, 2 arom. H), 4.95 (s, CH-5), 3.57 (s,
CH.sub.3N.sup.+, axial), 3.21 (s, CH.sub.3N.sup.+, equatorial),
0.94 (t, O(CH.sub.2).sub.3CH.sub.3, J=7.3 Hz).
EXAMPLE 46
Synthesis of
(17R)-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-17-meth- yl
6-oxo-14.beta.-[(3-phenylpropyl)oxy]morphinanium-iodide (Compound
48) and of
(17R)-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-methoxy-17-methyl-6--
oxo-14.beta.-[(3-phenylpropyl)oxy]morphinanium-iodide (Compound
49)
[0284] 64
[0285] A mixture of
17-cyclopropylmethyl-4,5.alpha.-epoxymorphinan-6-spiro-
-2'-(1,3-dioxolane)-3,14.beta.]-diol. (Schmidhammer et al.,
Heterocycles 1998, 49, 1, pp. 489-498) (7.92 g, 20.55 mmol),
K.sub.2CO.sub.3 (7.67 g, 55.49 mmol), benzyl bromide (4.57 g, 26.72
mmol) and 80 ml of water-free N,N-dimethylformamide was stirred for
12 h under N.sub.2 at room temperature. The inorganic material was
filtered off, washed with dichloromethane and the filtrate
evaporated down. The crystalline evaporation residue (10.97 g) was
recrystallised out of methanol. Yield: 8.80 g (90%) of colourless
crystals of 3-benzyloxy-17-cyclopropylmethyl-4-
,5.alpha.-epoxy-14.beta.-hydroxymorphinan-6-spiro-2'-(1,3-dioxolane).
Fp. 130-131.degree. C.; MS (Cl): 476 (M.sup.++1); IR (KBr): 3352
(OH) cm.sup.-1; .sup.1H-NMR (CDCl.sub.3, .delta. in ppm): 7.42-7.27
(m, 5 arom. H), 6.75 (d, 1 arom. H, J=8.3 Hz), 6.54 (d, 1 arom. H,
J=8.3 Hz), 5.17 (d, 1H, J=11.7 Hz, OCH.sub.2Ph), 5.10 (d, 1H,
J=11.7 Hz, OCH.sub.2Ph), 4.58 (s, CH-5), 4.19-3.73 (m, 4H,
OCH.sub.2CH.sub.2O).
[0286] NaH (2.24 g, 93.6 mmol) (obtained from 3.75 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-hy-
droxymorphinan-6-spiro-2'-(1,3-dioxolane) (14.8 g, 31.2 mmol) in
100 ml water-free N,N-dimethylformamide under N.sub.2 at 0.degree.
C. (bath temperature) under stirring. After 20 min. cinnamyl
bromide (7.99 g, 40.6 mmol), dissolved in 20 ml DMF, was added drop
by drop and the mixture stirred further for 25 min at 0.degree. C.
(bath temperature), then for 3.5 h at room temperature. Then small
pieces of ice were added until no more hydrogen was given off. The
mixture was poured onto 200 ml water and extracted with
dichloromethane (4.times.100 ml), the combined organic phases were
washed with saturated sodium chloride solution (5.times.250 ml),
dried over sodium sulphate and evaporated down. The evaporation
residue (18.2 g of yellow-brown oil) was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH
250:3:0.5). A yellowish oil (6.1 g, 33%) was produced of which 0.2
g was dissolved in 5 ml ether and converted into the hydrochloride
with etherial HCl. 0.1 g of beige crystals of
3-benzyloxy-17-cyclopropylmethyl-
-4,5.alpha.-epoxy-14.beta.-{[(E)-3-phenylprop-2-enyl]oxy}morphinan-6-spiro-
-2'-(1,3-dioxolane)hydrochloride was isolated. Fp. 133-136.degree.
C.; MS (Cl): 592 (M.sup.++1); .sup.1H-NMR (DMSO-d.sub.6): .delta.
8.23 (s, wide, HN.sup.+), 7.63-7.24 (m, 10 arom. H), 6.93 (d, 1
arom. H, J=8.4 Hz), 6.70 (d, 1 arom. H, J=8.4 Hz), 6.70 (m, 2
olefin. H), 5.15 (s, 2H, C3-OCH.sub.2Ph), 4.65 (s, CH-5), 4.33-4.20
(m, 2H, OCH.sub.2CHCHPh), 4.04-3.74 (m, 4H, OCH.sub.2CH.sub.2).
[0287] A mixture of
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-14.b-
eta.-{[(E)-3-phenylprop-2-enyl]oxy}morphinan-6-spiro-2'-(1,3-dioxolane)
(6.08 g, 10.3 mmol) and 0.60 g of Pd/C (10%) in a mixture of 100 ml
methanol and 50 ml tetrahydrofuran was hydrogenated for 2.5 hours
at 30 psi and at room temperature. The catalyst was filtered off,
washed with 20 ml each of methanol and tetrahydrofuran and the
filtrate evaporated down. Evaporation residue 4.02 g of bright
yellow oil, which was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:5: 0.5). This gave
a yellowish oil (2.75 g, 53%) of which 0.07 g was dissolved in 5 ml
ether and converted into the hydrochloride with etherial HCl. 0.06
g of colourless crystals of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3-phenylpropyl-
)oxy]morphinan-6-spiro-2'-(1,3-dioxolane)hydrochloride was
isolated. Fp. 158-162.degree. C.; MS (Cl): 504 (M.sup.++1);
.sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): 9.24 (s, OH), 7.79 (5,
wide, HN.sup.+), 7.35-7.18 (m, 5 arom. H), 6.68 (d, 1 arom. H,
J=8.0 Hz), 6.57 (d, 1 arom. H, J=8.0 Hz), 4.51 (s, CH-5), 4.09-3.71
(m, 4H, OCH.sub.2CH.sub.2O).
[0288] A solution of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-140-[-
(3-phenylpropyl)oxy]morphinan-6-spiro-2'-(1,3-dioxolane) (0.22 g,
0.44 mmol) was reflux heated for 1 h in 5 ml of a mixture of conc.
HCl/MeOH (4:9). After cooling the resulting crystals were filtered
off, the filtrate evaporated down and the residue crystallised out
of ether. Yield: 0.122 g (61%) of colourless needle-shaped crystals
of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.beta.-[(3-phenylpropyl-
)oxy]morphinan-6-one hydrochloride. Fp. 200-230.degree. C.; MS
(Cl): 460.3 (M.sup.++1); JR (KBr): 1725 (C.dbd.O) cm.sup.-1;
.sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm): 9.52 (s, OH), 8.20 (s,
wide, HN.sup.+), 7.30-7.18 (m, 5 arom. H), 6.71 (d, 1 arom. H,
J=8.0 Hz), 6.64 (d, 1 arom. H, J=8.0 Hz), 4.89 (s, CH-5).
[0289] A solution of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14.be-
ta.-[(3-phenylpropyl)oxy]morphinan-6-one (0.54 g, 1.17 mmol) and
methyl iodide (0.83 g, 5.84 mmol) in 10 ml of water-free
acetonitrile was stirred under N.sub.2 at 40.degree. C. (bath
temperature) for 5 days and then evaporated down. The residue (0.72
g of brown oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH 250:4). Two different products were
isolated:
[0290] Compound 48: Yield: 0.21 g (30%) of colourless crystals. Fp.
175-176.degree. C.; MS (Cl): 474 (M.sup.+); IR (KBr): 1726
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm):
9.53 (s, wide, OH), 7.31-7.17 (m, 5 arom. H), 6.69 (s, 2 arom. H),
4.87 (s, CH-5), 3.53 (s, CH.sub.3N.sup.+, axial).
[0291] Compound 49: Yield: 0.03 g (4%) of bright orange crystals.
Fp. 133-136.degree. C.; MS (Cl): 488 (M.sup.+); IR (KBr): 1725
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6, .delta. in ppm):
7.31-7.19 (m, 5 arom. H), 6.89 (d, 1 arom. H, J=8.4 Hz), 6.82 (d, 1
arom. H, J=8.4 Hz), 4.94 (s, CH-5), 3.81 (s, C3-OCH.sub.3), 3.55
(s, CH.sub.3N.sup.+, axial).
EXAMPLE 47
Synthesis of
(17R)-17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-17-meth-
yl-6-oxo-14.beta.-[(2-phenylbenzyl)oxy]morphinanium-iodide
(Compound 50)
[0292] 65
[0293] NaH (1.51 g, 62.9 mmol) (obtained from 2.51 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-14.beta.-hy-
droxymorphinan-6-spiro-2'-(1,3-dioxolane) (see Example 46) (5.99 g,
12.6 mmol) in 75 ml water-free N,N-dimethylformamide under N.sub.2
at 0.degree. C. (bath temperature) under stirring. After 20 min.
2-phenylbenzyl bromide (4.04 g, 16.4 mmol) was added and the
mixture stirred for 20 min at 0.degree. C. (bath temperature), then
for 2 h at room temperature. Then small pieces of ice were added
until no more hydrogen was given off, the mixture was poured onto
200 ml water and extracted with dichloromethane (1.times.100 ml,
2.times.75 ml), the combined organic phases were washed with water
(5.times.300 ml) and saturated sodium chloride solution
(1.times.100 ml), dried over sodium sulphate and evaporated down.
From the evaporation residue (7.90 g of brown oil) 3.52 g were
purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:2.5:0.5). A yellowish
oil (2.83 g) was produced which was dissolved in 15 ml ether and
converted into the hydrochloride with etherial. HCl. In this way
2.20 g of colourless crystals of
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy--
14.beta.-[(2-phenylbenzyl)oxy]morphinan-6-spiro-2'-(1,3-dioxolane),
hydrochloride was obtained. Fp. 142-144.degree. C.; MS (Cl): 642
(M.sup.++1); .sup.1H-NMR of the purified base (DMSO-d.sub.6):
.delta. 7.70-7.25 (m, 14 arom. H), 6.76 (d, 1 arom. H, J=8.4 Hz),
6.53 (d, 1 arom. H, J=8.4 Hz), 5.10 (s, 2H, C3-OCH.sub.2Ph), 4.63
(d, 1H, C14-OCH.sub.2, J=10.6 Hz), 4.46 (s, CH-5), 4.34 (d, 1H,
C14-OCH.sub.2, J=10.6 Hz), 4.10-3.69 (m, 4H,
OCH.sub.2CH.sub.2O).
[0294] A solution of
3-benzyloxy-17-cyclopropylmethyl-4,5.alpha.-epoxy-14.-
beta.-[(2-phenylbenzyl)oxy]morphinan-6-spiro-2'-(1,3-dioxolane)hydrochlori-
de (2.10 g, 3.10 mmol) in 40 ml of a mixture of conc. HCl/MeOH.
(4:9) was reflux heated for 1.5 h. After cooling the mixture was
poured onto 100 ml of ice, alkalised with conc. NH.sub.4OH and
extracted with dichloromethane (1.times.100 ml, 4.times.75 ml), the
combined organic phases washed with water (2.times.150 ml) and a
saturated sodium chloride solution (1.times.100 ml), dried over
sodium sulphate and evaporated down. A yellow oil (1.90 g) was
obtained, which was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250:3:0.5)). This gave
a yellowish oil (0.7 g, 42%) of which 0.16 g was dissolved in 5 ml
ether and converted to the hydrochloride with etherial HCl. 0.12 g
of colourless crystals of 17-cyclopropylmethyl-4,5.alpha.-epo-
xy-3-hydroxy-14,.beta.-[(2-phenylbenzyl)oxy]morphinan-6-one
hydrochloride was isolated. Fp. 181-186.degree. C.; MS (Cl): 508
(M.sup.++1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, o in ppm): 9.58 (s, OH), 8.33 (s, wide, HN.sup.+),
7.95-7.25 (m, 9 arom. H), 6.72 (d, 1 arom. H, J=8.0 Hz), 6.64 (d, 1
arom. H, J=8.0 Hz), 5.14 (s, CH-5), 4.84 (d, 1H, C14-OCH.sub.2--R,
J=12.4 Hz), 4.56 (d, 1H, C14-OCH.sub.2R, J=12.4 Hz).
[0295] A solution of
17-cyclopropylmethyl-4,5.alpha.-epoxy-3-hydroxy-14,3--
[(2-phenylbenzyl)oxy]morphinan-6-one (0.39 g, 0.76 mmol) and methyl
iodide (0.54 g, 3.79 mmol) in 6 ml of water-free acetonitrile was
stirred under N.sub.2 at 40.degree. C. (bath temperature) for 2
days and then evaporated down. The residue (0.5 g of brown oil) was
purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH 250:4). Yield: 0.02 g (4%) of beige crystals
of the compound 50. Fp. 219-221.degree. C.; MS (Cl): 522 (M.sup.+);
IR (KBr): 1725 (C.dbd.O) cm.sup.1; .sup.1H-NMR (DMSO-d.sub.6):
.delta. 9.53 (s, OH), 7.68-7.25 (m, 9 arom. H), 6.67 (s, 2 arom.
H), 4.73 (d, C14-OCH.sub.2), 4.61 (s, CH-5), 3.26 (s,
CH.sub.3N.sup.+, axial).
EXAMPLE 48
Synthesis of
(17R)-14.beta.-[(4-chlorobenzyl)oxy]-17-cyclopropylmethyl-4,5-
.alpha.-epoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide
(compound 51)
[0296] 66
[0297] NaH (1.28 g, 53.3 mmol) (obtained from 2.139 g of a 60% NaH
dispersion in oil by washing with petroleum ether) was added to a
solution of
3-(benzyloxy)-17-(cyclopropylmethyl)-4,5.alpha.-epoxy-14.beta-
.-hydroxymorphinan-6-spiro-2'-(1,3-dioxolane) (see Example 48)
(5.00 g, 10.6 mmol) in 75 ml water-free N,N-dimethylformamide under
N.sub.2 at 0.degree. C. (bath temperature) under stirring. After 20
min. 4-chlorobenzyl bromide (2.95 g, 14.3 mmol) was added and the
mixture first stirred for 30 min at 0.degree. C. (bath
temperature), then for 1.5 h at room temperature. Then small pieces
of ice were added until no more hydrogen was given off, the mixture
was poured onto 400 ml water and extracted with dichloromethane
(3.times.100 ml), the combined organic phases were washed with
water (5.times.400 ml) and saturated sodium chloride solution
(1.times.100 ml), dried over sodium sulphate and evaporated down.
The evaporation residue (6.45 g of yellow oil) was crystallised out
of methanol. Yield: 4.72 g (75%) of colourless crystals of
3-benzyloxy-14.beta.-[(4-chlorobenzyl)oxy]-17-cyclopropylmethyl-4,5.al-
pha.-epoxymorphinan-6-spiro-2'-(1,3-dioxolane). Fp. 122-125.degree.
C.; MS (Cl): 600 (M.sup.++1); .sup.1H-NMR (DMSOd.sub.6 .delta. in
ppm): 7.53-7.35 (m, 9 arom. H), 6.78 (d, 1 arom. H, J=8.4 Hz), 6.57
(d, 1 arom. H, J=8.4 Hz), 5.11 (d, 2H, C.sub.3--OCH.sub.2Ph), 4.65
(d, 1H, C.sub.14--OCH.sub.2, J=11.2 Hz), 4.23 (s, CH-5), 4.30 (d,
1H, C14-OCH.sub.2, J=11.2 Hz), 4.10-3.70 (m, 4H,
OCH.sub.2CH.sub.2O).
[0298] A solution of
3-benzyloxy-14.beta.-[(4-chlorobenzyl)oxy]-17-cyclopr-
opylmethyl-4,5.alpha.-epoxymorphinan-6-spiro-2'-(1,3-dioxolane)
(4.60 g, 7.66 mmol) in 100 ml of a mixture of conc. HCl/MeOH (4:9)
was reflux heated for 1.5 h. After cooling the reaction mixture was
poured onto 300 ml of ice, alkalised with conc. NH.sub.4OH,
extracted with dichloromethane (3.times.150 ml), the combined
organic phases were washed with water (2.times.150 ml) and a
saturated sodium chloride solution (1.times.100 ml), dried over
sodium sulphate and evaporated down. The evaporation residue (4.86
g of yellow oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:3:0.5). This gave a
yellowish oil (1.18 g, 33%) of which 0.26 g was dissolved in 5 ml
ether and converted to the hydrochloride with etherial HCl. 0.23 g
of colourless crystals of 14.beta.-[(4-chlorobenzyl)oxy]-17-c-
yclopropylmethyl-4,5.alpha.-epoxy-3-hydroxymorphinan-6-one
hydrochloride was isolated. Fp. 195-200.degree. C.; MS (Cl): 466.1
(M.sup.30 +1); IR (KBr): 1725 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6, .delta. in ppm): 9.59 (s, OH), 8.63 (s, wide,
HN.sup.+), 7.61 (d, 2 arom. H, C14-OCH Ph-Cl, J=8.4 Hz), 7.47 (d, 2
arom. H, C14-OCH2Ph-Cl, J=8.4 Hz), 6.73 (d, 1 arom. H, J=8.2 Hz),
6.68 (d, 1 arom. H, J=8.0 Hz), 5.08 (s, CH-5), 4.80 (d, 1H,
C14-OCH.sub.2, J-=12 Hz), 4.72 (d, 1H, C14-OCH.sub.2, J=12 Hz).
[0299] A solution of
14.beta.-[(4-chlorobenzyl)oxy]-17-cyclopropylmethyl-4-
,5.alpha.-epoxy-3-hydroxymorphinan-6-one (0.50 g, 1.07 mmol) and
methyl iodide (0.76 g, 5.37 mmol) in 8 ml of water-free
acetonitrile was stirred under N.sub.2 at 40.degree. C. (bath
temperature) for 6 days and then evaporated down. The residue (0.56
g of brown oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH250:4). Yield: 0.07 g (11%) of beige
crystals of the compound 51. Fp. 214-219.degree. C.; MS (Cl): 480
(M.sup.+); IR (KBr): 1733 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6 6 in ppm): 9.57 (s, OH), 7.57 (d, 2 arom. H,
C14-OCH.sub.2Ph-Cl, J=8.6 Hz), 7.48 (d, 2 arom. H, C14-OCH2Ph-Cl,
J=8.6 Hz), 6.71 (s, 2 arom. H), 5.10 (s, CH-5), 4.86 (d, 1H,
C14-OCH.sub.2, J=11.4 Hz), 4.75-4.66 (m, 3H, C14-OCH.sub.1 and
CH-9), 3.44 (s, CH.sub.3N.sup.+, axial).
EXAMPLE 49
Synthesis of
17(R)-4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17-methyl-6-
-oxo-17-(2-phenylethyl)morphinanium-iodide (Compound 52)
[0300] 67
[0301] A mixture of
4,5.alpha.-epoxy-3,14.beta.-dimethoxymorphinan-6-ne (Kobylecki et
al., J. Med. Chem., 198 25, 2, pp. 116-120) (1.44 g, 4.57 mmol),
potassium carbonate (4.11 g, 29.7 mmol), 2-phenylethyl bromide (1.1
g, 5.94 mmol) and 20 ml of N,N-dimethylformamide was stirred for
5.5 h at 80.degree. C. (b temperature) under N.sub.2. Then 200 ml
of water was added to it and extraction took place with
dichloromethane (4.times.50 ml). The combined organic phases were
washed with water (6.times.130 ml dried over sodium sulphate and
evaporated down. Yield: 1.95 g of yellowish oil of
4,5.alpha.-epoxy-3,1-dimethoxy-17-(2-phenyleth- yl)morphinan-6-one,
which was used unmodified for the next synthesis step. Analytical
data: .sup.1H-NMR (CDCl.sub.3, 6 in ppm): 7.30-7.18 (m, 5 arom. H),
6.69 (d, 1 arom. H, J=8.0 Hz), 6.60 (d, 1 arom. H, J=8.0 Hz), 4.64
(s, CH-5), 3.89 (s, C3-OCH.sub.3), 3.18 (s, C14-OCH.sub.3).
[0302] A solution of
4,5.alpha.-epoxy-3,140-dimethoxy-17-(2-phenylethyl)mo-
rphinan-6-one (2.4 g, 5.72 mmol 25 ml of 48% HBr was reflux heated
for 13 min. Then the solution was cooled, poured onto 100 n ice,
alkalised with conc. NH.sub.4OH and extracted with dichloromethane
(5.times.50 ml). The combined organic phases were washed with a
saturated sodium chloride solution (3.times.150 ml), dried over
sodium sulphate and evaporated down. The evaporation residue (2.40
g of brown oil) was purified using column chromatography (silica
gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH 250:2:0.5). Yield: 0.4
(17%) of dark yellow oil of which 0.04 g was dissolved in 5 ml
ether and the hydrochloride obtainwith etherial HCl. 0.02 g of
colourless crystals of 4,5.alpha.-epoxy-3-hydroxy-14.beta.-meth-
oxy-17-(2-phenylethyl)morphinanne-6-one hydrochloride was isolated.
Fp. 259-262.degree. C.; MS (Cl): 406 (M.sup.++1); If (KBr): 1731
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6 .delta. in ppm):
9.52 (s, OH), 9.28 (s, wide, HN.sup.+), 7.38-7.(m, 5 arom. H), 6.70
(s, 2 arom. H, CH-1 and CH-2), 4.96 (s, CH-5), 3.40 (s,
C14-OCH.sub.3).
[0303] A solution of
4,5.alpha.-epoxy-3-hydroxy-14.beta.-methoxy-17-(2-phe-
nylethyl)morphinan-6-one (0.32 g, 0.7 mmol) and methyl iodide (0.56
g, 3.92 mmol) in 6 ml of water-free acetonitrile was stirred under
N 40.degree. C. (bath temperature) for 2 days and then evaporated
down. The residue (0.32 g of brown oil) was purified using column
chromatography (silica gel; CH.sub.2Cl.sub.2/MeOH 250:2). Yield:
0.07 g (16% of colourless crystals of the compound 52. Fp.
180-181.degree. C.; MS (Cl): 420 (M.sup.++1); IR (KBr): 1727
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (D.sub.2O, 6 in ppm): 7.17-7.14
(m, 5 arom. H), 6.56 (s, 2 arom. H), 5.18 (s, CH-5), 3.64 (s,
CH.sub.3N.sup.+, axial), 3.44 (s, OCH.sub.3).
EXAMPLE 50
4,5.alpha.-epoxy-17-methyl-14.beta.-[(3-phenylpropyl)oxy]morphinan-6-one
(Compound 53)
[0304] 68
[0305] Water-free K.sub.2CO.sub.3 (5.67 g, 41.06 mmol) and
5-chloro-1-phenyl-1H-tetrazol (3.02 g, 16.73 mmol) were added to a
solution of
4,5.alpha.-epoxy-3-hydroxy-17-methyl-140-[(3-phenylpropyl)oxy-
]morphinan-6-one (see Example 36) (6.38 g, 15.20 ml) in 40 ml of
water-free dimethylformamide and this mixture stirred for 23 h at
room temperature. After the addition of 300 ml H.sub.2O, extraction
took place with CH.sub.2Cl.sub.2 (3.times.75 ml). The combined
organic phases were washed with H.sub.2O (2.times.200 ml) and
saturated NaCl solution (3.times.250 ml), dried over
Na.sub.2SO.sub.4 and evaporated down. The evaporation residue (7.48
g of yellowish oil) was purified using column chromatography
(silica gel; CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250:2:0.5)).
The appropriate fractions were evaporated down. This gave 6.41 g of
yellow oil (4,5.alpha.-epoxy-17-methyl-14.beta.-[(3-phenylpropy-
l)oxy]-3-[(1-phenyl-1H-tetrazol-5-yl)oxy]morphinan-6-one; 75%),
which was used for the next reaction step without further
purification. For analytical purposes a small quantity was
crystallised out of ether and in this way
4,5.alpha.-epoxy-17-methyl-14.beta.-[(3-phenylpropyl)oxy]-3-[(1--
phenyl-1H-tetrazol-5-yl)oxy]morphinan-6-one was obtained as
colourless crystals. Fp. 117-119.degree. C.; MS (Cl): 564
(M.sup.++1); IR (KBr): 1723 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 7.88-7.837 (m, 2 arom. H), 7.73-7.62 (m, 3
arom. H), 7.30-7.16 (m, 6 arom. H), 6.85 (d, J=8.4 Hz, 1 arom. H),
4.93 (s, CH-5), 2.29 (s, 3H, N17-CH.sub.3).
[0306] A mixture of
4,5.alpha.-epoxy-17-methyl-14.beta.-[(3-phenylpropyl)o-
xy]-3-[(1-phenyl-1H-tetrazol-5-yl)oxy]morphinan-6-one (6.20 g,
11.00 mmol), 10% Pd/C catalyst (2.48 g) and 100 ml glacial acetic
acid was hydrogenated at 50 psi and 40.degree. C. for 17 h. After
filtering off the catalyst, the filtrate was reduced down to a
volume of 30 ml, 150 ml of ice/water mixture was added to it and
after alkalising with conc. NH.sub.4OH it was extracted with
CH.sub.2Cl.sub.2 (1.times.100 ml, 3.times.75 ml). The combined
organic phases were washed with saturated NaCl solution
(4.times.200 ml), dried over Na.sub.2SO.sub.4 and evaporated down.
The evaporation residue (4.15 g of yellowish oil, DC pure) was
crystallised out of a little methanol and in this way 3.26 g (72%)
of the compound 53 was obtained as colourless crystals. Fp.
105-109.degree. C.; MS (Cl): 404 (M.sup.++1); IR (KBr): 1721
(C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 7.29-7.16
(m, 5 arom. H), 7.04 (t, J=8.0 Hz, 1 arom. H), 6.73 (d, J=8.0 Hz, 1
arom. H), 6.64 (d, J=8.0 Hz, 1 arom. H), 4.75 (s, 1H, C5-H), 2.28
(s, 3H, N17-CLH.sub.3).
EXAMPLE 51
17-(cyclopropylmethyl)-4,5.alpha.-epoxy-14.beta.-[(3-phenylpropyl)oxy]morp-
hinan-6-one hydrochloride (Compound 54.HCl).
[0307] 69
[0308] NaHCO.sub.3 (3.33 g, 39.65 mmol) and 1-chloroethyl
chloroformate (4.32 ml, 39.65 mmol) were added to a solution of 53
(3.20 g, 7.93 mmol) in 40 ml of ethanol-free 1,2-dichloroethane.
This mixture was stirred for 13.5 h at 60.degree. C. (oil bath
temperature) under N.sub.2. Then filtration took place from the
inorganic residue, the residue was washed with ethanol-free
1,2-dichloroethane and the filtrate evaporated down. The
evaporation residue (3.7 g of yellow-brown oil, DC-pure)
was--without further purification and characterisation--reflux
heated in a mixture of 15 ml conc. HCl and 35 ml MeOH for 1 h. The
reaction solution was evaporated down and the evaporation residue
crystallised out of MeOH/Et.sub.2O. 2.77 g (82%) of
4,5.alpha.-epoxy-140-[(3-phenylpropyl)oxy- ]morphinan-6-one
hydrochloride was isolated. Fp. >225.degree. C. (decomposition);
MS (Cl): m/z 390 (M.sup.++1); IR (KBr): 1729 (C.dbd.O) cm.sup.-1;
.sup.1H-NMR (DMSO-d.sub.6): .delta. 9.25 (s, wide, 1H, .sup.+HN),
8.11 (s, wide, 1H, .sup.+HN), 7.34-7.12 (m, 5 arom. H), 7.16 (t,
j=8.0 Hz, 1 arom. H), 6.85 (d, J=8.0 Hz, 1 arom. H), 6.77 (d, J=8.0
Hz, 1 arom. H), 4.96 (s, 1H, C5-H), 4.28 (ps-d, C9-H).
[0309] Water-free K.sub.2CO.sub.3 (2.13 g, 15.40 mmol) and
cyclopropylmethyl bromide (0.64 ml, 6.67 mmol) were added to a
solution of
4,5.alpha.-epoxy-14.beta.-[(3-phenylpropyl)oxy]morphinan-6-ne
hydrochloride (2.36 g, 5.55 mmol) in 20 ml of water-free
dimethylformamide under N.sub.2. This mixture was stirred at a bath
temperature of 80.degree. C. under N.sub.2. Since a DC check after
7 h showed that the reaction had not yet completely finished, a
further 0.50 ml of cyclopropylmethyl bromide (5.24 mmol) was added.
After a further hour the reaction had finished and after cooling
filtration from the inorganic material took place, the residue was
washed with CH.sub.2Cl.sub.2 and the filtrate evaporated down. The
evaporation residue was dissolved in 150 ml CH.sub.2Cl.sub.2,
washed with H.sub.2O (5.times.150 ml) and saturated NaCl solution
(150 ml), dried over Na.sub.2SO.sub.4 and evaporated down. This
gave 2.43 g (99%) of
17-(cyclopropylmethyl)-4,5.alpha.-epoxy-14.beta.-[(3-phenylpropyl)oxy]mor-
phinan-6-one (54) as a yellowish oil which was used for the next
reaction without further purification. 0.30 g of the oil was
dissolved in ether and after the addition of etherial HCl 0.23 g of
17-(cyclopropylmethyl)-4-
,5.alpha.-epoxy-14.beta.-[(3-phenylpropyl)oxy]morphinan-6-one
hydrochloride (compound 54.HCl) was isolated as a colourless
powder. Fp. 145-150.degree. C.; MS (Cl): m/z 444 (M.sup.++1); IR
(KBr): 1726 (C.dbd.O) cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6):
.delta. 8.26 (s, wide, 1H), 7.31-7.14 (m, 5 arom. H), 7.18 (t,
J=8.0 Hz, 1 arom. H), 6.85 (d, J=8.0 Hz, 1 arom. H), 6.78 (d, J=8.0
Hz, 1 arom. H), 4.96 (s, 1H, C5-H), 4.55 (ps-d, C9-H), 1.09-1.06
(m, 1H, N17-CH.sub.2CH(CH.sub.2).sub.2), 0.75-0.69 (m, 2H,
N--CH.sub.2CH(CH.sub.2).sub.2), 0.55-0.42 (m, 2H.
N--CH.sub.2CH(CH.sub.2).sub.2).
EXAMPLE 52
17-(cyclopropylmethyl).sub.4-hydroxy-14.beta.-[(3-phenylpropyl)oxy]morphin-
an-6-one hydrochloride (Compound 55.HCl).
[0310] 70
[0311] NH.sub.4Cl (0.72 g, 13.46 mmol) was added to a reflux
boiling solution of 54 (1.2 g, 2.71 mmol) in 50 ml MeOH under
stirring. 0.88 g (13,46 mmol) activated zinc powder was added in
small portions to this mixture. This mixture was stirred under
reflux for 80 min., then cooled to room temperature and filtered
off from the inorganic residue. The inorganic residue was washed
with hot methanol and the filtrate evaporated down. 50 ml H.sub.2O
was added to the evaporation residue which was then alkalised with
conc. NH.sub.4OH. This mixture was extracted with CH.sub.2Cl.sub.2
(3.times.80 ml), the combined organic phases washed with saturated
NaCl solution (5.times.100 ml), dried over Na.sub.2SO.sub.4 and
evaporated down. 1.20 g (99%) of
17-(cyclopropylmethyl)-4-hydroxy-140-[(3-phenylpropyl)oxy]morphinan-6-one
(55) was obtained as a yellowish oil which was used for the next
reaction step without further purification. For analytical purposes
0.08 g of the oil was dissolved in ether and after the addition of
etherial HCl 0.059 g of
17-(cyclopropylmethyl)-4-hydroxy-14.beta.-[(3-phenylpropyl)oxy]morphin-
an-6-one hydrochloride (55.HCl) was isolated as a colourless
powder. Fp. >170.degree. C. (decomposition); MS (Cl): m/z 446
(M.sup.++1); IR (KBr): 1709 (C.dbd.O) cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 9.82 (s, 1H, C4-OH), 8.43 (s, wide, 1H,
.sup.+N17-H), 7.30-7.20 (m, 5 arom. H, C14-0(CH.sub.2).sub.3Ph),
7.03 (t, J=8.0 Hz, 1 arom. H, C2-H), 6.66 (m, 2 arom. H), 4.40
(ps-d, C9-H), 1.09 (m, 1H, N17-CH.sub.2CH(CH.sub.2).sub.2)- ,
0.70-0.67 (m, 2H, N17-CH.sub.2CH(CH.sub.2).sub.2), 0.52-0.40 (m,
2H, N17-CH.sub.2CH(CH.sub.2).sub.2).
EXAMPLE 53
17-(cyclopropylmethyl)-4-methoxy-14.beta.-[(3-phenylpropyl)oxy]morphinan-6-
-one hydrochloride (56.HCl).
[0312] 71
[0313] Water-free K.sub.2CO.sub.3 (0.37 g, 2.69 mmol) and 0.46 g
(2.69 mmol) of phenyltrimethyl ammonium chloride were added to
absolution of 55 (0.40 g, 0.90 mmol) in 6 ml of water-free
dimethylformamide under N.sub.2. This mixture was stirred for 3.5 h
at a bath temperature of 80.degree. C. under N.sub.2. After cooling
filtration from the inorganic material took place, the residue was
washed with CH.sub.2Cl.sub.2 and the filtrate evaporated down. The
evaporation residue was dissolved in 100 ml CH.sub.2Cl.sub.2,
washed with saturated NaCl solution (4.times.150 ml), dried with
Na.sub.2SO.sub.4 and evaporated down. The evaporation residue (0.30
g) was purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/conc. NH.sub.4OH (250/4/0.5)) and the
appropriate fractions evaporated down. The evaporation residue
(0.23 g) was dissolved in ether and after the addition of etherial
HCl, 0.22 g (48%) of the compound 56.HCl was isolated as a
colourless powder. Fp. 121-126.degree. C.; MS (Cl): m/z460
(M.sup.++1); IR (KBr): (C.dbd.O) 1710 cm.sup.-1; .sup.1H-NMR
(DMSO-d.sub.6): .delta. 8.34 (s, wide, 1H, .sup.+N--H), 7.30-7.16
(m, 5 arom. H), 7.22 (t, J=8.0 Hz, 1 arom. H), 6.88 (d, J=8.0 Hz, 1
arom. H), 6.82 (d, J=8.0 Hz, 1 arom. H), 4.42 (ps-d, C9-H), 3.77
(s, 3H, C4-OCH.sub.3), 1.08 (m, 1H, N--CH.sub.2CH(CH.sub.2).sub.2),
0.70-0.42 (m, 4H, N--CH.sub.2CH(CH.sub.2).sub.2).
EXAMPLE 54
4-(n-butoxy)-17-(cyclopropylmethyl)-14.beta.-[(3-phenylpropyl)oxy]morphina-
n-6-one hydrochloride (57.HCl).
[0314] 72
[0315] Water-free K.sub.2CO.sub.3 (0.55 g, 4.01 mmol) and
iodo-butane (0.31 ml, 2.67 mmol) were added to a solution of 55
(0.60 g, 1.34 mmol) in 5 ml of water free dimethylformamide under
N.sub.2. This mixture was stirred for 7 h at a bath temperature of
90.degree. C. under N.sub.2. Then filtration from the inorganic
material took place, the residue was washed with CH.sub.2Cl.sub.2
and the filtrate evaporated down. The evaporation residue was
dissolved in 100 ml CH.sub.2Cl.sub.2, washed with saturated NaCl
solution (3.times.150 ml), dried over Na.sub.2SO.sub.4 and
evaporated down. The evaporation residue (0.43 g of brown oil) was
purified using column chromatography (silica gel;
CH.sub.2Cl.sub.2/MeOH/c- onc. NH.sub.4OH (250:4:0.5)) and the
appropriate fractions evaporated down. The evaporation residue
(0.26 g) was dissolved in ether and after the addition of etherial
HCl, 0.19 g (26%) 57.HCl was isolated as a colourless powder. Fp.
172-177.degree. C.; MS (Cl): m/z 502 (M.sup.++1); IR (KBr):
(C.dbd.O) 1711 cm.sup.-1; .sup.1H-NMR (DMSO-d.sub.6): .delta. 8.52
(s, wide, 1H, .sup.+N--H), 7.30-7.15 (m, 6 arom. H), 6.86 (d, J=8.0
Hz, 1 arom. H), 6.80 (d, J=8.0 Hz, 1 arom. H), 4.42 (ps-d, C9-H),
3.95 (t, 2H, J=6.4 Hz, C4-OCH.sub.2(CH.sub.2).sub.2CH.sub.3),
1.13-1.06 (m, 1H, N--CH.sub.2CH(CH.sub.2).sub.2), 0.95 (t, 3H,
J=7.3 Hz, C4-O(CH.sub.2).sub.3CH.sub.3), 0.69-0.40 (m, 4H,
N--CH.sub.2CH(CH.sub.2).- sub.2).
EXAMPLE 55
[0316] Opioid Receptor Binding Studies
[0317] Opioid receptor binding studies were carried out on rat's
brain homogenisates using [.sup.3H]DAMGO (.mu.-receptor agonist) as
radio-ligand and under strict conformance to an earlier published
specification (M. Spetea et al., Neurochemical Research 1998, Vol.
23, pp. 1213-1218).
[0318] The compounds 8, 17, 17a 17b, 38, 40-43, 48, 49, and 54-56
show very high affinity to .mu.-opioid receptors which are
primarily responsible for analgesia (Table 1). All have a clearly
higher affinity than the antagonist cyprodime (see H. Schmidhammer
et al., J. Med. Chem. 1995, 38, 3071-3077), which is selective to
.mu.-opioid receptors. The compounds 8, 17, 17a 17b, 40, 48, and
54-56 show extremely high affinity to .mu.-opioid receptors (in the
subnanomolar range). Morphine and the opioid antagonist
3-hydroxycyprodime (see H. Schmidhammer et al., J. Med. Chem. 1995,
38, 3071-3077) show in comparison to these two compounds clearly
lower affinity to .mu.-opioid receptors, whereas 14-methoxymetopon
exhibits similar affinity.
1TABLE 1 Opioid receptor binding studies of the compounds 8, 17,
17a 17b, 38, 40-43, 48, 49, and 54-56, morphine, 14-methoxymetopon,
cyprodime and 3-hydroxycyprodime. Compound K.sub.i (nM)
(.mu.-receptors) 8 0.34 17 0.73 17a 0.62 17b 0.20 38 4.11 40 0.37
41 2.32 42 5.93 43 1.33 48 0.93 49 1.78 54 0.84 55 0.40 56 0.34
Morphine 6.55 14-methoxymetopon 0.55 Cyprodime 23.7
3-hydroxycyprodime 6.15
EXAMPLE 56
Analgesia Tests
[0319] a) "Hot-Plate Test"
[0320] A test on mice ("hot-plate test") was carried out as
described earlier (E. L. May et al., J. Med. Chem.; 2000; 43,
5030-5036).
[0321] All tested substances show substantially higher analgesic
activity than morphine. The compounds 6-11, 17a, 17b and 53 show
extremely high analgesic activity which is significantly higher
than that of the reference substance 14-methoxymetopdn (see Zs.
Furst et al., Eur. J. Pharmacol. 1993; 236: 209-215). Compounds 4
and 32 show in comparison to the compounds 6-11 somewhat lower
analgesic activity, because these compounds exhibit an ether
function (methoxy group) in Position 3, from which it is known that
it reduces the analgesic activity in comparison to the 3-hydroxy
analogues. However, the analgesic activity of the compounds 4 and
32 is still surprisingly high. Also, the analgesic activity of the
compound 17 with a different ether function (propargyloxy group) in
Position 3 is surprisingly high.
2TABLE 2 "Hot-plate Test" of compounds 4, 6-11, 17, 17a, 17b, 32,
53, morphine and 14-methoxymetopon. Compound ED.sub.50 (.mu.g/kg,
sc.sup.a) 4 60 6 5.9 7 3.7 8 2.3 9 11.7 10 1.3 11 1.7 17 38 17a 2.6
17b 0.10 32 22 53 3.0 Morphine 850 14-methoxymetopon 30 .sup.asc =
subcutaneous application
[0322] b) "Mouse Tail Flick Test"
[0323] To determine the analgesic activity of non-quaternised
compounds, the "Mouse Tail Flick Test" was carried out as earlier
described (E. L. May et al., J. Med. Chem. 2000; 43,
5030-5036).
[0324] All tested substances show substantially higher analgesic
activity than morphine. The compounds 6-8, 10, 11, 17a, 17b and 53
show extremely high analgesic activity which is significantly
higher than that of the reference substance 14-methoxymetopon (see
Zs. Furst et al., Eur. J. Pharmacol. 1993; 236:209-215)., Compound
4 shows in comparison to the compounds 6-8, 10, 11, 17a, 17b and 53
a somewhat lower analgesic activity, because this compound exhibits
a methoxy group in Position 3, from which it is known that it
reduces the analgesic activity in comparison to the 3-hydroxy
analogues. However, the analgesic activity of compound 4 is
surprisingly high. Similarly, compounds 17a and 32, which
surprisingly have a very high analgesic activity, have a methoxy
group in Position 3. The most active compound in this series,
compound 17b, with an ED.sub.50 (.mu.g/kg, sc) of 0.08, is more
active than the most active analgesically effective substances
recognized, etorphine and dihydroetorphine (M. D. Aceto et al.,
Eur. J. Pharmacol 1997; 338, 215-223).
3TABLE 3 "Mouse Tail Flick Test" of compounds 4, 6-8, 10, 11, 17,
17a, 17b, 32, 53, morphine and 14-methoxymetopon. Compound
ED.sub.50 (.mu.g/kg, sc.sup.a) 4 84 6 5.6 7 8.2 8 3.2 10 7.0 11 1.6
17 21 17a 4.4 17b 0.08 32 14 53 0.4 Morphine 1920 14-methoxymetopon
30 .sup.asc = subcutaneous application
[0325] c) "Rat Tail Flick Test"
[0326] To determine the analgesic activity of quaternised
compounds, a test on rats, the "Rat Tail Flick Test", was used. The
test was carried out as described earlier (Zs. Furst et al., Eur.
J. Pharmacol.; 236: 209-215).
[0327] As quatemary ammonium salts, compounds 38 and 42 show a very
high analgesic effect--both are substantially more active than
morphine after subcutaneous application (Table 3). Compound 42 is
somewhat less active than 14-methoxymetopon after subcutaneous
application. After ubtracerebroventricular application, compound 42
is extremely active, which is an indication that it can overcome
the blood-brain barrier only to a limited degree and shows its
effectiveness therefore primarily in the periphery (outside of the
central nervous system). This goes with a very reduced side-effect
rate which is relevant to central side effects such as nausea,
vomiting, sedation, dizziness, confusion, respiratory-depression
and mania.
4TABLE 4 "Rat Tail Flick Test" of compounds 38, 42, morphine and
14-methoxymetopon. Compound ED.sub.50 (.mu.g/kg, sc.sup.a)
ED.sub.50 (.mu.g/rat.sup.b, icv.sup.c) 38 120 12 42 16 0.22
Morphine 1900 -- 14-methoxymetopon 7.2 -- .sup.asc = subcutaneous
application .sup.bThe weight of the rats used was 120 g in each
case .sup.cicv = intracerebroventricular application
EXAMPLE 57
[0328] Determination of the Antagonistic Activity
[0329] Vas Deferens Preparation of the Mouse
[0330] This test was carried out as earlier described using DAMGO
(.mu.-receptor agonist) (S. Garadnay et al., Curr. Med. Chem. 2001,
8, 621-626).
[0331] Compound 48 shows surprisingly very high antagonistic
activity to .mu.-opioid receptors, which is unusual for quaternised
morphinans (Table 4).
[0332] Normally quaternised morphinans have a substantially lower
activity in comparison to the non-quaternised morphinans. It has
substantially higher antagonistic activity than the .mu.-selective
opioid receptor antagonist cyprodime. In comparison to naloxone it
has a somewhat lower activity, whereas in comparison to
3-hydroxycyprodime it exhibits a somewhat higher activity. Due to
its structure as a quaternary ammonium salt, it can only overcome
the blood-brain barrier with difficulty and produces its effect
mainly in the periphery. Because of this, it can, for example, be
used to counter or prevent obstipation or ileus caused by opioids
without the analgesia of the administered opioid being cancelled.
In comparison to it, naloxone, cyprodime and 3-hydroxycyprodime
pass through the blood-brain barrier relatively easily and
therefore also cancel the analgesic effect of opioids.
5TABLE 5 Antagonistic K.sub.e values of compounds 48, naloxone,
cyprodime and 3-hydroxycyprodime in the Vas Deferens preparation of
the mouse. Compound K.sub.e (vM) (.mu.-receptors) 48 2.94 Naloxone
1.4 Cyprodime 55.4 3-hydroxycyprodime 5.62
* * * * *